false
--12-31
Semper Paratus Acquisition Corp
0001860871
0001860871
2024-02-14
2024-02-14
0001860871
LGSTU:CommonStockParValue0.0001PerShareMember
2024-02-14
2024-02-14
0001860871
LGSTU:WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember
2024-02-14
2024-02-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 14, 2024
Tevogen
Bio Holdings Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41002 |
|
85-1284695 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
15
Independence Boulevard, Suite #410 |
|
|
Warren,
New Jersey |
|
07059 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (877) 838-6436
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
|
|
|
|
Common
Stock, par value $0.0001 per share |
|
LGST |
|
The
Nasdaq Stock Market LLC |
|
|
|
|
|
Warrants,
each exercisable for one share of Common Stock for $11.50 per share |
|
LGSTW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Introductory
Note
As
previously disclosed, on June 28, 2023, Semper Paratus Acquisition Corporation, a Cayman Islands exempted company (“Semper Paratus”),
entered into an Agreement and Plan of Merger by and among Semper Paratus, Semper Merger Sub, Inc., a Delaware corporation and a wholly
owned subsidiary of Semper Paratus (“Merger Sub”), SSVK Associates, LLC, Semper Paratus’s sponsor (the “Sponsor”),
in its capacity as purchaser representative, Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), and Dr. Ryan
Saadi, in his capacity as seller representative (the “Merger Agreement”). On February 14, 2024 (the “Closing
Date”), pursuant to the Merger Agreement, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving
company and a wholly owned subsidiary of Semper Paratus (the “Merger,” and together with the other transactions contemplated
by the Merger Agreement, the “Business Combination”).
Prior
to the effective time of the Merger (the “Effective Time”), pursuant to the Merger Agreement, Semper Paratus changed
its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation
incorporated under the laws of the State of Delaware (the “Domestication”). In connection with the Domestication,
Semper Paratus changed its name to “Tevogen Bio Holdings Inc.” We refer to Semper Paratus after giving effect to the Domestication
as “Tevogen” or the “Company.” Also in connection with the Domestication, the governing documents
of Semper Paratus were amended and restated as set forth in Semper Paratus’s definitive proxy statement filed with the Securities
and Exchange Commission (the “SEC”) on January 10, 2024 (the “Definitive Proxy Statement”).
At
the Effective Time, in accordance with the terms and subject to the conditions of the Merger Agreement, each share of the common stock
of Tevogen Bio issued and outstanding immediately prior to the Effective Time was converted into the right to receive the number of shares
of duly authorized, validly issued, fully paid, and nonassessable shares of the common stock of the Company, par value $0.0001 (the “Common
Stock”), equal to the quotient obtained by dividing (x) the quotient obtained by dividing (i) $1,200,000,000 by (ii) ten dollars
($10.00) by (y) the aggregate number of shares of the common stock of Tevogen Bio that were issued and outstanding immediately prior
to the Effective Time (the “Exchange Ratio”). In addition, for a period of 36 months following the Closing Date, the
Company may issue up to 20,000,000 shares of Common Stock in the aggregate to the former stockholders of Tevogen Bio and up to 4,500,000
shares of Common Stock in the aggregate to the Sponsor (the “Earnout Shares”), in each case in three equal tranches
upon the occurrence of certain triggering events.
See
the section titled “Business Combination Proposal” in the Definitive Proxy Statement for additional information and
a summary of certain terms of the Merger Agreement. The foregoing description of the Merger Agreement is a summary only and is qualified
in its entirety by reference to the full text of the Merger Agreement, which is incorporated by reference as Exhibit 2.1 to this Current
Report on Form 8-K (this “Report”) and incorporated herein by reference.
Item
1.01 Entry into a Material Definitive Agreement.
Amended
and Restated Registration Rights Agreement
On
February 14, 2024, in connection with the consummation of the Business Combination, the Company, the Sponsor, Semper Paratus Sponsor
LLC (the “Original Sponsor”), Dr. Saadi, the Company’s Chief Executive Officer, Kirti Desai, the Company’s
Chief Financial Officer, Dr. Neal Flomenberg, the Company’s Chief Scientific Officer and Global R&D Lead (the “Company
Holders”), the Sponsor Holders (as defined therein) (together with the Sponsor, the Original Sponsor, and the Company Holders,
the “Special Holders”), and Cantor Fitzgerald & Co. (“Cantor” and, together with the Special
Holders, the “RRA Holders”) entered into an Amended and Restated Registration Rights Agreement (the “A&R
Registration Rights Agreement”). Pursuant to the A&R Registration Rights Agreement, the Company agreed to use commercially
reasonable efforts to file, as soon as reasonably practical, but in no event later than 60 days after the Closing Date, a shelf registration
statement registering the resale of certain shares of Common Stock and warrants (the “Registrable Securities”). In
addition, at any time (after the expiration of any lock-up period) and from time to time after the shelf registration statement has been
declared effective, the Special Holders holding at least a majority in interest of Registrable Securities may request to sell all or
any portion of their Registrable Securities in an underwritten offering that is registered pursuant to the shelf registration statement
(each, an “Underwritten Shelf Takedown”); provided that such Underwritten Shelf Takedown meets certain requirements
and that the Company shall not be obligated to effect more than one Underwritten Shelf Takedown during any twelve-month period.
A
more complete summary of the terms and obligations under the A&R Registration Rights Agreement, which summary is incorporated herein
by reference, is set forth in the Definitive Proxy Statement in the section titled “Business Combination Proposal.”
Such summary and the foregoing description of the A&R Registration Rights Agreement are qualified in their entirety by reference
to the full text of the A&R Registration Rights Agreement, a copy of which is filed as Exhibit 10.4 to this Report and incorporated
herein by reference.
Lock-Up
Agreement
On
February 14, 2024, in connection with the consummation of the Business Combination, the Company, the Sponsor, and Dr. Saadi (the “Significant
Company Holder” and, together with the Sponsor, the “Locked-Up Parties”) entered into a Lock-Up Agreement
(the “Lock-Up Agreement”) with respect to certain securities of the Company held by the Locked-Up Parties immediately
following the Closing Date (the “Lock-Up Securities”), pursuant to which each Locked-Up Party agreed subject to specified
exceptions not to transfer any Lock-Up Securities until the earlier of (A) six months after the Closing Date and (B) subsequent to the
Business Combination, (x) if the closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for share subdivisions,
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing
at least 150 days after the Business Combination, or (y) the date on which Tevogen completes a liquidation, merger, share exchange, or
other similar transaction that results in all of its stockholders having the right to exchange their Common Stock for cash, securities,
or other property.
The
foregoing description of the Lock-Up Agreement is qualified in its entirety by reference to the full text of the Lock-Up Agreement, a
copy of which is filed as Exhibit 10.5 to this Report and incorporated herein by reference.
Non-Competition
and Non-Solicitation Agreement
Effective
as of the Closing Date, the Company entered into a Non-Competition and Non-Solicitation Agreement (the “Non-Competition Agreement”)
with Dr. Saadi, pursuant to which Dr. Saadi agreed for a term of five years after the closing of the Business Combination (the “Closing”)
not to compete with the Company or solicit certain personnel of the Company, subject to certain requirements and customary conditions.
The foregoing description of the Non-Competition Agreement is qualified in its entirety by reference to the full text of the Non-Competition
Agreement, a copy of which is filed as Exhibit 10.6 to this Report and incorporated herein by reference.
Note
Assumption Agreement
On
February 14, 2024, in connection with the consummation of the Business Combination, the Company and Tevogen Bio entered into an Assignment
and Assumption Agreement (the “Note Assumption Agreement”), pursuant to which the Company has assumed all obligations
of Tevogen Bio under seven convertible promissory notes that were outstanding as of the Closing Date (the “Assumed Notes”),
with an aggregate principal amount totaling approximately $24.0 million. The foregoing description of the Note Assumption Agreement is
qualified in its entirety by reference to the full text of the Note Assumption Agreement, a copy of which is filed as Exhibit 10.7 to
this Report and incorporated herein by reference. The Assumed Notes were automatically converted immediately following Closing in accordance
with their terms into an aggregate of 10,337,419 shares of Common Stock. The Assumed Notes and the shares of Common Stock issued upon
conversion thereof were issued pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act.
Indemnification
Agreements
On
February 14, 2024, in connection with the consummation of the Business Combination, Tevogen entered into indemnification agreements with
each of its directors and executive officers. Each indemnification agreement provides for indemnification and advancement by Tevogen
of certain expenses and costs relating to claims, suits, or proceedings arising from service to Tevogen or, at its request, service to
other entities to the fullest extent permitted by applicable law.
The
foregoing description of the indemnification agreements is a summary only and is qualified in its entirety by reference to the full text
of the form of indemnification agreement, a copy of which is filed as Exhibit 10.10 to this Report and incorporated herein by reference.
Item
2.01. Completion of Acquisition of Disposition of Assets.
The
disclosure set forth in the “Introductory Note” above is incorporated by reference into this Item 2.01.
FORM
10 INFORMATION
Item
2.01(f) of Form 8-K states that if the predecessor registrant was a shell company, as Semper Paratus was immediately prior to the Business
Combination, then the registrant must disclose the information that would be required if the registrant were filing a general form for
registration of securities on Form 10. Accordingly, the Company is providing the information below that would be included in a Form 10
if the Company were to file a Form 10. Please note that the information provided below relates to the Company following the consummation
of the Business Combination, unless otherwise specifically indicated or the context otherwise requires.
Forward-Looking
Statements
Statements
made in this Report regarding Tevogen or its subsidiaries that are not historical facts are forward-looking statements based on current
expectations, assumptions, estimates, and projections about Tevogen and the industry in which Tevogen operates. In some cases, forward-looking
statements can be identified by words such as “anticipate,” “believe,” “seek,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “should,” “will,”
“would,” and similar words or their opposites. Forward-looking statements include, without limitation, statements regarding
the Company’s operations, cash flows, financial position, business strategy, and plans and objectives of management for future
operations.
Forward-looking
statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied
by such statements. Such risks and uncertainties include, but are not limited to, the following:
|
● |
We
have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to
continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability. We have never generated
revenue from product sales and may never be profitable. |
|
|
|
|
● |
We
will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms,
or at all. |
|
|
|
|
● |
The
regulatory landscape that applies to cellular therapy product candidates is rigorous, complex, uncertain, and subject to change. |
|
|
|
|
● |
As
an organization, we have limited experience designing and implementing clinical trials, and we have never conducted pivotal clinical
trials. |
|
|
|
|
● |
We
may encounter substantial delays and disruptions in completing the development of our product candidates. |
|
|
|
|
● |
The
FDA regulatory approval process is lengthy and time-consuming, and may lead to significant delays in the clinical development and
regulatory approval of our product candidates. |
|
|
|
|
● |
Our
business is highly dependent on our first product candidate, TVGN 489, and we must complete clinical testing before we can seek regulatory
approval and begin commercialization of any of our product candidates. |
|
|
|
|
● |
Preclinical
studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. |
|
|
|
|
● |
Interim
and preliminary results from our clinical trials that we announce or publish from time to time may change. |
|
|
|
|
● |
The
results of earlier preclinical and clinical trials may not be predictive of future clinical trial results. |
|
|
|
|
● |
Our
approach to the development of product candidates using our ExacTcell platform is unproven and may not result in marketable products. |
|
|
|
|
● |
We
may depend on third-party collaborators for the development and commercialization of certain of our current and future product candidates.
If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. |
|
|
|
|
● |
The
manufacture of cell therapies is subject to a multitude of manufacturing risks, any of which could substantially increase our costs
and limit supply of our product candidates. |
|
● |
Our
efforts to establish manufacturing capabilities, either on our own or through a contract relationship, will involve significant time
and expense and may not be successful. |
|
|
|
|
● |
If
we are unable to obtain and maintain patent protection for our product candidates or ExacTcell, or if the scope of the patent protection
obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar or identical to ours,
and our ability to successfully commercialize our product candidates may be adversely affected. |
|
|
|
|
● |
We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful. |
|
|
|
|
● |
We
are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified
personnel, we may not be able to successfully implement our business strategy. |
|
|
|
|
● |
We
may face competition, which may result in others discovering, developing, or commercializing products before or more successfully
than we do. |
|
|
|
|
● |
The
price of the Common Stock and warrants may fluctuate significantly and you could lose all or part of your investment as a result. |
|
|
|
|
● |
An
active, liquid trading market for Tevogen’s securities may not develop, which may limit your ability to sell such securities. |
|
|
|
|
● |
Tevogen’s
management team has no experience managing a public company. |
The
foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the various risks described in the
“Risk Factors” section and elsewhere in the Definitive Proxy Statement. You should not place undue reliance on any
forward-looking statements. Tevogen undertakes no obligation to update publicly any forward-looking statements for any reason, unless
required by law, even if new information becomes available or other events occur in the future. You should, however, review the factors
and risks that the Company describes in the reports it will file from time to time with the SEC after the date of this Report.
In
addition, statements that “the Company believes” and similar statements reflect the Company’s beliefs and opinions
on the relevant subject. These statements are based on information available to the Company as of the date of this Report. While the
Company believes that information provides a reasonable basis for these statements, that information may be limited or incomplete. The
Company’s statements should not be read to indicate that it has conducted an exhaustive inquiry into, or review of, all relevant
information. These statements are inherently uncertain, and you are cautioned not to unduly rely on these statements.
Although
the Company believes the expectations reflected in the forward-looking statements were reasonable at the time made, it cannot guarantee
future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility
for the accuracy or completeness of any of these forward-looking statements. You should carefully consider the cautionary statements
contained or referred to in this section in connection with the forward-looking statements contained in this Report and any subsequent
written or oral forward-looking statements that may be issued by the Company or persons acting on the Company’s behalf.
Business
The
business of the Company is described in the Definitive Proxy Statement in the section titled “Information About Tevogen”
and that information is incorporated herein by reference.
Properties
The
principal physical properties of the Company are described in the Definitive Proxy Statement in the section titled “Information
About Tevogen—Facilities” and that information is incorporated herein by reference.
Risk
Factors
The
risks associated with the Company’s business are described in the Definitive Proxy Statement in the section titled “Risk
Factors” and are incorporated herein by reference. A summary of such risks is also included in the section titled “Summary
of the Proxy Statement/Prospectus—Summary of Risk Factors.”
Financial
Information
The
(i) audited financial statements of Tevogen Bio as of and for the years ended December 31, 2022 and 2021 included in the Definitive Proxy
Statement beginning on page F-43; (ii) unaudited financial statements of Tevogen Bio as of and for the nine months ended September 30,
2023 and 2022 included in the Definitive Proxy Statement beginning on page F-57; and (iii) the unaudited pro forma condensed combined
financial information of Tevogen Bio and Semper Paratus as of and for the nine months ended September 30, 2023 and as of and for the
year ended December 31, 2022 included in the Definitive Proxy Statement beginning on page 215 are incorporated herein by reference.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
The
disclosure contained in the Definitive Proxy Statement in the section titled “Tevogen’s Management’s Discussion
and Analysis of Financial Condition and Results of Operations” is incorporated herein by reference.
Beneficial
Ownership of Securities
The
following table sets forth information regarding the beneficial ownership of Common Stock upon consummation of the Business Combination
by:
|
● |
each
person known by the Company to be the beneficial owner of more than 5% of the outstanding shares of Common Stock; |
|
|
|
|
● |
each
of the Company’s named executive officers and directors; and |
|
|
|
|
● |
all
of the Company’s executive officers and directors as a group. |
Beneficial
ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security
if they possess sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities
that the individual or entity has the right to acquire, such as through the exercise of warrants or the vesting of restricted stock units
(“RSUs”), within 60 days of February 14, 2024. Shares subject to warrants that are currently exercisable or
exercisable within 60 days of February 14, 2024 or subject to RSUs that vest within 60 days of February 14, 2024 are considered
outstanding and beneficially owned by the person holding such warrants or RSUs for the purpose of computing the percentage ownership
of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as
noted by footnote, and subject to community property laws where applicable, based on the information provided to the Company, the Company
believes that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown
as beneficially owned by them.
The
beneficial ownership of the Common Stock is based on 163,754,418 shares issued and outstanding as of February 14, 2024.
Name
and Address of Beneficial Owner |
|
Number
of
Shares of
Tevogen
Common
Stock |
|
|
% |
|
5%
Holders |
|
|
|
|
|
|
|
|
SSVK
Associates, LLC |
|
|
9,488,889 |
(1) |
|
|
5.8 |
% |
Manmohan
Patel, MD |
|
|
9,274,489 |
(2) |
|
|
5.6 |
% |
Tevogen
Directors and Named Executive Officers(3) |
|
|
|
|
|
|
|
|
Dr.
Ryan Saadi |
|
|
118,350,228 |
(4) |
|
|
72.3 |
% |
Kirti
Desai |
|
|
9,696,186 |
|
|
|
5.9 |
% |
Dr.
Neal Flomenberg |
|
|
3,636,070 |
(5) |
|
|
2.2 |
% |
Surendra
Ajjarapu(1) |
|
|
9,488,889 |
(1) |
|
|
5.8 |
% |
Jeffrey
Feike |
|
|
581,771 |
(5) |
|
|
* |
|
Dr.
Keow Lin Goh |
|
|
193,923 |
|
|
|
* |
|
Dr.
Curtis Patton |
|
|
969,618 |
|
|
|
* |
|
Susan
Podlogar |
|
|
193,923 |
(5) |
|
|
* |
|
Victor
Sordillo |
|
|
42,016 |
(6) |
|
|
* |
|
All
Tevogen directors and executive officers as a group (10 individuals) |
|
|
144,122,242 |
(7) |
|
|
85.7 |
% |
*
Less than 1%
(1) |
Represents
securities held by SSVK Associates, LLC (“SSVK”) and includes 500,000 shares underlying currently exercisable
warrants. Mr. Ajjarapu is the managing member of SSVK and may be deemed to have beneficial ownership of the ordinary shares held
directly by SSVK. Mr. Ajjarapu disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary
interest he may have therein, directly or indirectly. The business address of SSVK and Mr. Ajjarapu is c/o SSVK Associates, LLC,
767 Third Avenue, 38th Floor, New York, NY 10017. |
(2) |
Includes
646,412 RSUs that vested in connection with the Closing. Dr. Patel may be deemed to beneficially own 7,972,487 and 655,530 shares
of Common Stock held by HMP Partners, LLC (“HMP Partners”) and The Patel Family, LLP, respectively. The
address of HMP Partners is 5 Jennie Court, Cedar Grove, New Jersey 07009, and the address of Dr. Patel is c/o HMP Partners at its
address. The address of The Patel Family, LLP is 66 Macculloch Ave, Morristown, New Jersey 07960. Dr. Patel is the managing member
of HMP Partners and the spouse of the managing member of The Patel Family, LLP. Dr. Patel may be deemed to have beneficial ownership
over the securities held by each of these entities. |
(3) |
Except
as otherwise provided, the address of each of these individuals is c/o Tevogen Bio Inc, 15 Independence Boulevard, Suite 410, Warren,
New Jersey 07059. |
(4) |
Includes
193,923 shares of Common Stock underlying RSUs held by Dr. Saadi’s wife that vested in connection with the Closing. |
(5) |
Represents
shares of Common Stock underlying RSUs that vested in connection with the Closing. |
(6) |
Includes
33,734 shares of Common Stock underlying RSUs that vested in connection with the Closing and 8,282 shares issuable upon the
vesting of RSUs within 60 days of February 14, 2024 |
(7) |
Includes
4,445,498 shares of Common Stock underlying RSUs that vested in connection with the Closing, 8,282 shares issuable upon the
vesting of RSUs within 60 days of February 14, 2024, and 500,000 shares underlying currently exercisable warrants. |
Directors
and Executive Officers
The
Company’s directors and executive officers are described in the Definitive Proxy Statement in the section titled “Management
of New Tevogen Following the Business Combination”, which section is incorporated herein by reference.
Executive
and Director Compensation
References
in this section to “we,” “our,” “us” and the “Company” generally refer to Tevogen Bio
prior to the Business Combination and to Tevogen after giving effect to the Business Combination, as the context demands.
Overview
The
following tables and accompanying narrative set forth information about the 2023 and 2022 compensation provided to our principal executive
officer and the two most highly compensated executive officers (other than our principal executive officer) who were serving as executive
officers as of December 31, 2023. These executive officers consist of Dr. Ryan Saadi, our Chief Executive Officer, Kirti Desai, our Chief
Financial Officer, and Dr. Neal Flomenberg, our Chief Scientific Officer and Global R&D Lead, and are referred to in this section
as our “named executive officers” or “NEOs.”
This
discussion may contain forward-looking statements that are based on our current plans, considerations, expectations, and determinations
regarding future compensation practices. Actual compensation practices in the future may differ materially from the forward-looking statements
included in this discussion.
Summary
Compensation Table
The
following table presents summary information regarding the total compensation for services rendered in all capacities that was awarded
to, earned by, or paid to our named executive officers for the last two completed fiscal years.
Name and Principal Position | |
Year | | |
Salary ($) | | |
Stock Awards(1) ($) | | |
All Other Compensation ($) | | |
Total ($) | |
Ryan Saadi, M.D., M.P.H. Chief Executive Officer | |
| 2023 | | |
| 501,000 | | |
| 0 | | |
| 0 | | |
| 501,000 | |
| |
| 2022 | | |
| 453,375 | | |
| 0 | | |
| 470 | | |
| 453,845 | |
Kirti Desai Chief Financial Officer | |
| 2023 | | |
| 300,000 | | |
| 0 | | |
| 0 | | |
| 300,000 | |
| |
| 2022 | | |
| 225,000 | | |
| 0 | | |
| 0 | | |
| 225,000 | |
Neal Flomenberg, M.D. Chief Scientific Officer and Global R&D Lead | |
| 2023 | | |
| 350,000 | | |
| 2,576,000 | | |
| 0 | | |
| 2,926,000 | |
| |
| 2022 | | |
| 175,000 | | |
| 13,600,000 | | |
| 0 | | |
| 13,775,000 | |
|
(1) |
The
amount in this column reflects the full grant-date fair value of RSUs during 2023 computed in accordance with ASC Topic 718, excluding
estimates of forfeitures related to service-based vesting conditions, and assuming satisfaction of the liquidity event condition
contained in such awards (the “Liquidity Event Condition”). The amount reported reflects the accounting cost for
the RSU awards and does not correspond to the actual value that may be recognized by Dr. Flomenberg in connection with the applicable
award. |
Narrative
Disclosure to Summary Compensation Table
Base
Salary
The
named executive officers receive base salaries to compensate them for services rendered to us. The base salary payable to each named
executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role,
and responsibilities. The annual base salaries for Dr. Saadi, Mr. Desai, and Dr. Flomenberg for 2023 were $501,000, $300,000, and $350,000,
respectively.
Equity
Compensation
Prior
to the consummation of the Business Combination, from time to time, we granted equity awards under the Tevogen Bio Inc 2020 Equity Incentive
Plan (the “2020 Plan”) as incentives to attract, retain, and motivate our named executive officers. In July 2023,
we granted Dr. Flomenberg an equity award of 100,000 RSUs. The vesting of Dr. Flomenberg’s award requires the satisfaction of both
a service-based condition and the Liquidity Event Condition. The service-based condition was satisfied with respect to 50% of the RSUs
upon grant and is satisfied with respect to 25% of the RSUs on each of the first two anniversaries of the award. The Liquidity Event
Condition was satisfied upon the consummation of the Business Combination.
In
connection with the consummation of the Business Combination, we adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the
“2024 Plan”) and no longer grant awards pursuant to the 2020 Plan. Each RSU award granted under the 2020 Plan that
was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024 Plan with respect
to the Common Stock. Such converted awards remain subject to the same terms and conditions as set forth under the applicable award agreement
prior to the consummation of the Business Combination. For additional information about the 2024 Plan, see the section titled “2024
Omnibus Incentive Plan” under Item 5.02 to this Report.
Outstanding
Equity Awards at Fiscal Year-End
The
following table provides information regarding equity awards held by the Company’s named executive officers that were outstanding
as of December 31, 2023. The awards listed in this table were granted under the 2020 Plan, which is summarized above under “—Narrative
Disclosure to Summary Compensation Table—Equity Compensation.” The Company’s named executive officers did not hold
any outstanding stock options as of December 31, 2023.
| |
Stock Awards |
Name | |
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | |
Equity Incentive Plan Awards: Market Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
Ryan Saadi, M.D., M.P.H | |
| — | | |
| — | |
Kirti Desai | |
| — | | |
| — | |
Neal Flomenberg, M.D. | |
| 5,332,902 | (1) | |
$ | 34,177,000 | (2) |
|
(1) |
Reflects
an award of 1,000,000 RSUs of Tevogen Bio granted on July 1, 2022 (the “Initial Flomenberg Award”), 75% of which
vested upon the consummation of the Business Combination, and an award of 100,000 RSUs of Tevogen Bio granted on July 14, 2023 (the
“Additional Flomenberg Award”), all of which remain unvested, adjusted to reflect the Exchange Ratio and expressed
in shares of Common Stock. The vesting of each award requires the satisfaction of both a service-based condition and the Liquidity
Event Condition. The Liquidity Event Condition was satisfied with respect to both awards by the consummation of the Business Combination.
The RSUs begin to vest to the extent both conditions have been satisfied on the first date upon which both conditions have been satisfied.
The service-based condition was satisfied with respect to 75% of the RSUs of the Initial Flomenberg Award as of July 1, 2023, and
will be satisfied with respect to the remaining 25% on July 1, 2024. The Additional Flomenberg Award will vest with respect to 25%
of the RSUs on each anniversary of July 14, 2023. |
|
|
|
|
(2) |
Reflects
a fair market value per share of Tevogen Bio’s common stock of $34.77 based on Tevogen Bio’s most recent estimated fair
value of its common stock. |
Director
Compensation
In
the year ended December 31, 2023, we did not pay any fees to, or make any equity or non-equity awards to, or pay any other compensation
to the non-employee members of our board of directors for their services as directors, except that we granted Mr. Sordillo 19,000 RSUs
of Tevogen Bio on January 5, 2023. Except as described below for Mr. Sordillo, there were no outstanding stock awards
or option awards held by our non-employee directors as of December 31, 2023.
Name | |
Stock Awards ($) | | |
Total ($) | |
Victor Sordillo | |
| 253,460 | (1) (2) | |
| 253,460 | |
All other non-employee directors | |
| — | | |
| — | |
|
(1) |
As
of December 31, 2023, Mr. Sordillo held a total of 96,962 unvested RSUs, adjusted to reflect the Exchange Ratio and expressed in shares of Common Stock. |
|
(2) |
Reflects
a grant date fair value per share of Tevogen Bio common stock of $13.34 on the date of the grant. |
Certain
Relationships and Related Transactions, and Director Independence
Our
related party transactions are described in the Definitive Proxy Statement in the section titled “Certain Relationships and
Related Person Transactions”, which section is incorporated herein by reference. The description of the A&R Registration
Rights Agreement in Item 1.01 of this Report is also incorporated herein by reference.
Effective
on the Closing Date, the Board of Directors of the Company (the “Tevogen Board”) adopted the listing standards of
The Nasdaq Stock Market LLC (“Nasdaq”) to assess director independence. Under the Nasdaq Marketplace Rules (“Nasdaq
rules”), independent directors must comprise a majority of a listed company’s board of directors. In addition, the Nasdaq
rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and corporate
governance committees be independent. Under the Nasdaq rules, a director will only qualify as an “independent director” if
in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director. Audit committee members must also satisfy the additional
independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and the Nasdaq rules. Compensation committee members must also satisfy the additional independence criteria set forth in Rule 10C-1 under
the Exchange Act and the Nasdaq rules.
Each
of the Company’s directors, other than Dr. Saadi, has been determined to qualify as “independent” under the listing
requirements and the rules of Nasdaq and the applicable rules under the Exchange Act.
Legal
Proceedings
From
time to time, the Company may be subject to various legal proceedings, investigations, or claims that arise in the ordinary course of
our business activities. As of the date of this filing, the Company is not currently a party to any litigation, investigation, or claim
the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material
adverse effect on the Company’s business, financial position, results of operations, or cash flows or which otherwise is required
to be disclosed under Item 103 of Regulation S-K under the Securities Act of 1933, as amended (the “Securities Act”).
Market
Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters
The
Common Stock and warrants of the Company have been approved to begin trading on Nasdaq under the symbol “TVGN” and “TVGNW,”
respectively, on February 15, 2024.
As
of February 14, 2024, 163,754,418 shares of Common Stock were issued and outstanding, held of record by 20 holders.
The
Company has not paid any cash dividends on shares of its common stock to date and does not intend to pay cash dividends. The payment
of cash dividends in the future will be dependent upon the Company’s revenues and earnings, if any, capital requirements, lenders
consenting to current or future dividend payments and the Company’s general financial condition. The payment of any cash dividends
will be within the discretion of the Tevogen Board. It is the present intention of the Tevogen Board to retain all earnings, if any,
for use in the Company’s business operations.
Information
regarding the Common Stock and warrants and related stockholder matters are described in the Definitive Proxy Statement in the section
titled “Description of New Tevogen Securities” and such information is incorporated herein by reference.
Recent
Sales of Unregistered Securities
Reference
is made to the disclosure set forth under Item 3.02 of this Report.
Description
of Registrant’s Securities
The
description of the Company’s securities is contained in the Definitive Proxy Statement in the section titled “Description
of New Tevogen Securities” and is incorporated herein by reference.
Indemnification
of Directors and Officers
Reference
is made to the disclosure set forth in the section titled “Indemnification Agreements” under Item 1.01 of this Report
concerning indemnification agreements entered into with each of the Company’s directors and executive officers.
As
a Delaware corporation, the Company is subject to the provisions of the Delaware General Corporation Law (the “DGCL”).
Section 145(a) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than
an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person
acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its
equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably
believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had
reasonable cause to believe that such person’s conduct was unlawful.
Section
145(b) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason
of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise
against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or
settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not
opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter
as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court
of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of
liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses
which the Delaware Court of Chancery or such other court shall deem proper.
Section
145(c) of the DGCL provides that to the extent that a present or former director or officer of a corporation has been successful on the
merits or otherwise in defense of any action, suit or proceeding referred to in Section 145(a) and (b), or in defense of any claim, issue
or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred
by such person in connection therewith, and the corporation may indemnify any other person who is not a present or former director or
officer of the corporation against expenses (including attorneys’ fees) actually and reasonably incurred by such person to the
extent he or she has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 145(a)
and (b), or in defense of any claim, issue or matter therein. For indemnification with respect to any act or omission occurring after
December 31, 2020, references to “officer” for purposes of Section 145(c) shall mean only a person who at the time of such
act or omission is deemed to have consented to service by the delivery of process to the registered agent of the corporation pursuant
to section 3114(b) of title 10 (for purposes of this sentence only, treating residents of the State of Delaware as if they were nonresidents
to apply section 3114(b) of title 10 to this sentence).
Section
145(d) of the DGCL provides that any indemnification under Section 145(a) and (b) (unless ordered by a court) shall be made by the corporation
only as authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee
or agent is proper in the circumstances because such person has met the applicable standard of conduct set forth in Section 145(a) and
(b). Such determination shall be made, with respect to a person who is a director or officer of the corporation at the time of such determination,
(1) by a majority vote of the directors who were not parties to such action, suit or proceeding, even though less than a quorum; or (2)
by a committee of such directors designated by majority vote of such directors, even though less than a quorum; or (3) if there are no
such directors, or if such directors so direct, by independent legal counsel in a written opinion; or (4) by the stockholders.
Section
145(e) of the DGCL provides that expenses (including attorneys’ fees) incurred by an officer or director of the corporation in
defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of
the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to
repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized
in Section 145. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents
of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of another corporation,
partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the board of directors
deems appropriate.
Section
145(f) of the DGCL provides that the indemnification and advancement of expenses provided by, or granted pursuant to, Section 145 shall
not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any
bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity
and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under
a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to the certificate of
incorporation or the bylaws after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or
investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect
at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.
Section
145(g) of the DGCL provides that a corporation shall have the power to purchase and maintain insurance on behalf of any person who is
or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted
against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or
not the corporation would have the power to indemnify such person against such liability under Section 145.
Section
145(j) of the DGCL states that the indemnification and advancement of expenses provided by, or granted pursuant to, Section 145 shall,
unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or
agent and shall inure to the benefit of the heirs, executors and administrators of such a person.
Section
174 of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends
or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful
actions were approved or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the
books containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
director receives notice of the unlawful acts.
Further
information about the indemnification of the Company’s directors and officers is set forth in the Definitive Proxy Statement in
the sections titled “Description of New Tevogen Securities—Limitation on Liability” and “Description
of New Tevogen Securities—Indemnification and Advancement of Expenses”, and such information is incorporated herein by
reference.
Financial
Statements and Supplementary Data
Reference
is made to the disclosure set forth under Item 9.01 of this Report concerning the financial statements and supplementary data of Tevogen
and Semper Paratus.
Financial
Statements and Exhibits
Reference
is made to the disclosure set forth under Item 9.01 of this Report concerning the financial information of Tevogen and Semper Paratus.
Item
3.02. Unregistered Sales of Equity Securities.
On
May 3, 2023, Semper Paratus and the Original Sponsor entered into a subscription agreement (the “Subscription
Agreement”) with Polar Multi-Strategy Master Fund (“Polar”), and thereafter, the Sponsor assumed the
obligations of the Original Sponsor under the Subscription Agreement. Pursuant to the terms of the Subscription Agreement, Polar
agreed to make a cash contribution of $151,000 to the Sponsor (the “Initial Capital Contribution”) that would in
turn be loaned to Semper Paratus to cover working capital expenses. In consideration for the Initial Capital Contribution, we issued
151,000 shares of Common Stock to Polar at the closing of Semper Paratus’ initial business combination.
On
June 28, 2023, Semper Paratus and Cantor entered into a Fee Reduction Agreement pursuant to which Cantor agreed to forfeit a portion
of the deferred underwriting commission owed to Cantor as underwriter of Semper Paratus’s initial public offering, resulting in
a remainder of $5,000,000 of deferred underwriting fees payable by Semper Paratus to Cantor upon the closing of the Business Combination
in the form of 500,000 shares of common equity securities of the entity that survived the Business Combination.
The
shares of Common Stock issued to Polar and Cantor were issued pursuant to the exemption from registration under Section 4(a)(2) of the
Securities Act.
In
addition, reference is made to the disclosure set forth under Item 1.01 of this Report concerning the Note Assumption Agreement and Item
5.02 of this Report concerning the Special RSU Award (as defined in Item 5.02), which is incorporated by reference into this Item 3.02.
Item
3.03. Material Modification to Rights of Security Holders.
The
information set forth in Item 5.03 to this Report is incorporated by reference into this Item 3.03.
Item
5.01. Changes in Control of Registrant.
Reference
is made to the disclosure in the Definitive Proxy Statement in the section titled “Business Combination Proposal”,
which is incorporated herein by reference. Further reference is made to the information contained in the “Introductory Note”
to this Report, which is incorporated herein by reference.
Immediately
after giving effect to the Business Combination, there were 165,421,084 shares of Common Stock outstanding. As a result of the consummation
of the Business Combination, a change of control of Semper Paratus has occurred, as the stockholders of Semper Paratus as of immediately
prior to the Closing held 84.4% and Dr. Saadi held 72.3% of
the outstanding shares of Common Stock immediately following the consummation of the Business Combination.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Appointment
of Directors and Officers
Effective
as of the Closing Date, the Tevogen Board consists of seven individuals, divided into three classes. Dr. Curtis Patton and Jeffrey Feike
were made Class I directors; Surendra Ajjarapu, Victor Sordillo, and Dr. Keow Lin Goh were made Class II directors; and Dr. Ryan Saadi
and Susan Podlogar were made Class III directors.
The
following persons are serving as executive officers and directors of the Company effective as of the Closing Date, with each of the directors
having been elected by the Semper Paratus stockholders and each of the executive officers having been appointed by the Semper Paratus
Board, and ratified by the Tevogen Board, effective as of the Closing Date. For biographical information concerning the executive officers
and directors, see the disclosure in the Definitive Proxy Statement in the sections titled “Management of New Tevogen Following
the Business Combination” and “Tevogen Executive Officer and Director Compensation”, which are incorporated
herein by reference.
Name |
|
Age |
|
Position |
Executive
Officers |
|
|
|
|
Dr.
Ryan Saadi |
|
59 |
|
Chief
Executive Officer, Chairperson and Director Nominee |
Kirti
Desai |
|
67 |
|
Chief
Financial Officer |
Dr.
Neal Flomenberg |
|
70 |
|
Chief
Scientific Officer and Global R&D Lead |
Sadiq
Khan |
|
62 |
|
Chief
Commercial Officer |
Non-Employee
Directors |
|
|
|
|
Surendra
Ajjarapu |
|
53 |
|
Director
Nominee |
Jeffrey
Feike |
|
73 |
|
Director
Nominee |
Dr.
Keow Lin Goh |
|
52 |
|
Director
Nominee |
Dr.
Curtis Patton |
|
88 |
|
Director
Nominee |
Susan
Podlogar |
|
60 |
|
Director
Nominee |
Victor
Sordillo |
|
71 |
|
Director
Nominee |
The
information set forth in the sections titled “Directors and Executive Officers”, “Executive and Director
Compensation”, and “Certain Relationships and Related Transactions, and Director Independence” in this Report
is incorporated herein by reference.
2024
Omnibus Incentive Plan
At
the Extraordinary General Meeting of the stockholders of Semper Paratus held on January 31, 2024 (the “Extraordinary General
Meeting”), the stockholders of Semper Paratus considered and approved the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive
Plan (the “2024 Plan”). The 2024 Plan was previously approved, subject to stockholder approval, by the Board of Directors
of Semper Paratus on January 9, 2024 and became effective upon the Closing.
The
2024 Plan provides for grants of stock options (including incentive stock options and nonqualified stock options), stock appreciation
rights, restricted stock awards, RSUs, deferred stock units, performance awards, other equity-based awards, and cash. A more complete
summary of the terms of the 2024 Plan is set forth in the Definitive Proxy Statement in the section titled “Omnibus Incentive
Plan Proposal”, which summary is incorporated herein by reference. Such summary and the foregoing description of the 2024 Plan
are qualified in their entirety by reference to the full text of the 2024 Plan, a copy of which is filed as Exhibit 10.8 to this Report
and incorporated herein by reference.
Dr.
Saadi RSU Award
On
February 14, 2024, the Company issued an aggregate of 19,429,620 RSUs under the 2024 Plan to Dr. Saadi (the “Special RSU Award”).
The Special RSU Award was granted pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act. Such RSUs
were immediately vested into shares of restricted common stock (“Restricted Stock”) that vest in four equal annual
installments beginning on February 14, 2031. Pursuant to the terms of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted
Stock, but it may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will
automatically forfeit all unvested Restricted Stock in the event he departs the Company for any reason, unless termination of his service
triggers accelerated vesting pursuant to the terms of the Special RSU Award or the 2024 Plan.
Indemnification
Agreements for Company Directors and Officers
The
information set forth in the section titled “Indemnification Agreements” of Item 1.01 of this Report is incorporated
herein by reference.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
As
previously reported in the Current Report on Form 8-K filed with the SEC on February 1, 2024, the Semper Paratus stockholders approved
at the Extraordinary General Meeting, among other things, the proposals set forth in the Definitive Proxy Statement in the sections titled
“Domestication Proposal”, “Organizational Documents Proposal”, and “Advisory Charter Proposals”
(collectively, the “Organizational Documents Proposals”), which are incorporated herein by reference. The Certificate
of Incorporation of the Company (the “Charter”) described in the Organizational Documents Proposals became effective
upon filing with the Secretary of State of the State of Delaware on February 14, 2024. The Bylaws of the Company (the “Bylaws”)
described in the Organizational Documents Proposals were approved by the Board of Directors of Semper Paratus on January 31, 2024 and
by the Tevogen Board on February 14, 2024 and became effective as of the Closing Date.
The
disclosure regarding the Charter, and the general effect of the Charter and the Bylaws upon the rights of holders of the Company’s
capital stock, included in the Definitive Proxy Statement in the Organizational Documents Proposals and in the sections titled “Comparison
of Corporate Governance and Shareholder Rights” and “Description of Tevogen Securities” is incorporated
herein by reference. The disclosure set forth and incorporated by reference in this Item 5.03 is qualified in its entirety by reference
to the full text of the Charter and the Bylaws, copies of which are filed as Exhibit 3.1 and Exhibit 3.2, respectively, to this Report
and incorporated herein by reference.
Item
5.06. Change in Shell Company Status.
As
a result of the Business Combination, the Company ceased being a shell company. Reference is made to the disclosure in the Definitive
Proxy Statement in the section titled “Business Combination Proposal”, which is incorporated herein by reference.
Further reference is made to the information contained in the “Introductory Note” to this Report.
Item
9.01 Financial Statements and Exhibits.
(a)-(b)
Financial Statements.
The
(i) audited financial statements of Tevogen Bio as of and for the years ended December 31, 2022 and 2021 included in the Definitive Proxy
Statement beginning on page F-43; (ii) unaudited financial statements of Tevogen Bio as of and for the nine months ended September 30,
2023 and 2022 included in the Definitive Proxy Statement beginning on page F-57; and (iii) the unaudited pro forma condensed combined
financial information of Tevogen Bio and Semper Paratus as of and for the nine months ended September 30, 2023 and as of and for the
year ended December 31, 2022 included in the Definitive Proxy Statement beginning on page 215 are incorporated herein by reference.
(d)
Exhibits.
Exhibit |
|
Description |
2.1† |
|
Agreement and Plan of Merger, dated June 28, 2023, by and among Semper Paratus Acquisition Corporation, Semper Merger Sub, Inc., SSVK Associates, LLC, Tevogen Bio Inc, and Ryan Saadi, in his capacity as seller representative (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on June 29, 2023 (File No. 001-41002)). |
3.1* |
|
Certificate of Incorporation of Tevogen Bio Holdings Inc. |
3.2* |
|
Amended and Restated Bylaws of Tevogen Bio Holdings Inc. |
4.1 |
|
Warrant Agreement, dated November 3, 2021, by and between Semper Paratus Acquisition Corporation and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on November 8, 2021 (File No. 001-41002)). |
4.2* |
|
Convertible Promissory Note, dated January 22, 2021, by and between Tevogen Bio Inc and HMP Partners, LLC, as amended. |
4.3 |
|
Convertible Promissory Note, dated October 18, 2021, by and between Tevogen Bio Inc and HBP Investors LLC, as amended (incorporated by reference to Exhibit 4.6 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) (the “Form S-4”) filed with the SEC on November 22, 2023). |
4.4 |
|
Convertible Promissory Note, dated March 14, 2022, by and between Tevogen Bio Inc and HMP Partners, LLC, as amended (incorporated by reference to Exhibit 4.7 to Amendment No. 2 to the Form S-4). |
4.5 |
|
Convertible Promissory Note, dated December 23, 2022, by and between Tevogen Bio Inc and The Patel Family, LLP, as amended (incorporated by reference to Exhibit 4.8 to Amendment No. 2 to the Form S-4). |
4.6 |
|
Convertible Promissory Note, dated February 3, 2023, by and between Tevogen Bio Inc and The Patel Family, LLP, as amended (incorporated by reference to Exhibit 4.9 to Amendment No. 2 to the Form S-4). |
4.7 |
|
Convertible Promissory Note, dated September 26, 2023, by and between Tevogen Bio Inc and HMP Partners, LLC (incorporated by reference to Exhibit 4.10 to Amendment No. 2 to the Form S-4). |
4.8 |
|
Convertible Promissory Note, dated October 8, 2023, by and between Tevogen Bio Inc and HMP Partners, LLC (incorporated by reference to Exhibit 4.11 to Amendment No. 2 to the Form S-4). |
10.1 |
|
Service Agreement, dated as of April 15, 2022, between Tevogen Bio Inc and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.15 to the Form S-4). |
10.2 |
|
Lease Agreement, dated as of June 9, 2022, between Tevogen Bio Inc and Wanamaker Office Lease, LP (incorporated by reference to Exhibit 10.16 to the Form S-4). |
10.3 |
|
Lease Agreement, dated as of February 14, 2022, between Tevogen Bio Inc and Mitsui Sumitomo Insurance Company of America (incorporated by reference to Exhibit 10.17 to the Form S-4). |
10.4* |
|
Amended and Restated Registration Rights Agreement, dated February 14, 2024, by and among the Company, SSVK Associates, LLC, Semper Paratus Sponsor LLC, Cantor Fitzgerald & Co., and the other signatories thereto. |
10.5* |
|
Lock-Up Agreement, dated February 14, 2024, between the Company, Semper Paratus, SSVK Associates, LLC, Ryan Saadi, and the other signatories thereto. |
10.6*+ |
|
Non-Competition and Non-Solicitation Agreement, by and between Semper Paratus Acquisition Corporation and Ryan Saadi. |
10.7* |
|
Assignment and Assumption Agreement, dated February 14, 2024, by and between Semper Paratus Acquisition Corporation and Tevogen Bio Inc. |
10.8*+ |
|
Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan. |
10.9*+ |
|
Form of Restricted Stock Unit Agreement |
10.10*+ |
|
Form of Indemnification Agreement. |
104.1* |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
|
* |
Filed
herewith. |
|
† |
Schedules
and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a
copy of any omitted schedule or exhibit to the SEC upon request. |
|
+ |
Indicates
management contract or compensatory plan. |
|
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Tevogen
Bio Holdings Inc. |
|
|
|
Dated:
February 14, 2024 |
By: |
/s/
Ryan Saadi |
|
Name:
|
Ryan
Saadi |
|
Title: |
Chief
Executive Officer and Chairperson |
Exhibit
3.1
CERTIFICATE
OF INCORPORATION
OF
Tevogen
Bio Holdings Inc.
ARTICLE
I
NAME
OF THE CORPORATION
The
name of the corporation is Tevogen Bio Holdings Inc. (the “Corporation”).
ARTICLE
II
REGISTERED
AGENT
The
address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the
City of Wilmington, County of New Castle, Delaware 19801. The name of the registered agent of the Corporation at such address is The
Corporation Trust Company.
ARTICLE
III
BUSINESS
PURPOSE
The
nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law of the State of Delaware (the “DGCL”).
ARTICLE
IV
CAPITAL
STOCK
Section
4.01 Authorized Classes of Stock. The total number of shares of stock of all classes of capital stock that the Corporation is authorized
to issue is eight hundred twenty million (820,000,000), of which eight hundred million (800,000,000) shares shall be shares of common
stock having a par value of $0.0001 per share (“Common Stock”) and twenty million (20,000,000) shares shall be shares
of preferred stock having a par value of $0.0001 per share (“Preferred Stock”). Except as provided in any certificate
of designations of any series of Preferred Stock, the number of authorized shares of Preferred Stock and Common Stock may be increased
or decreased (but not below the number of shares thereof then outstanding) from time to time by the affirmative vote of the holders representing
at least a majority of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon, voting
together as a single class, irrespective of the provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto), and
no vote of the holders of any of the Common Stock or Preferred Stock voting separately as a class or series shall be required therefor.
Section
4.02 Common Stock. Except as otherwise required by law, as provided in this Certificate of Incorporation, and as otherwise provided
in the resolution or resolutions, if any, adopted by the board of directors of the Corporation (the “Board”) with
respect to any series of the Preferred Stock, the holders of the Common Stock shall exclusively possess all voting power and each holder
of Common Stock shall be entitled to vote on each matter submitted to a vote of stockholders and to one vote for each share held by such
holder. Subject to the rights of holders of any series of outstanding Preferred Stock, holders of shares of Common Stock shall have equal
rights of participation in the dividends and other distributions in cash, stock, or property of the Corporation when, as and if declared
thereon by the Board from time to time out of assets or funds of the Corporation legally available therefor and shall have equal rights
to receive the assets and funds of the Corporation available for distribution to stockholders in the event of any liquidation, dissolution,
or winding up of the affairs of the Corporation, whether voluntary or involuntary.
Section
4.03 Preferred Stock. The Board is hereby authorized to provide, out of the unissued shares of Preferred Stock, for one or more series
of Preferred Stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of
such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional, or other
special rights, if any, and any qualifications, limitations, or restrictions thereof, of the shares of such series, as shall be stated
in the resolution or resolutions providing for the issuance of such series adopted by the Board. The authority of the Board with respect
to each series of Preferred Stock shall include, but not be limited to, determination of the following:
(a)
the designation of the series;
(b)
the number of shares of the series;
(c)
the dividend rate or rates on the shares of that
series, whether dividends will be cumulative, and if so, from which date or dates, and the relative rights of priority, if any, of payment
of dividends on shares of that series;
(d)
whether the series will have voting rights, generally
or upon specified events, in addition to the voting rights provided by law, and, if so, the terms of such voting rights;
(e)
whether the series will have conversion privileges,
and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events as
the Board shall determine;
(f)
whether or not the shares of that series shall be
redeemable, in whole or in part, at the option of the Corporation or the holder thereof, and if made subject to such redemption, the
terms and conditions of such redemption, including the date or dates upon or after which they shall be redeemable, and the amount per
share payable in case of redemptions, which amount may vary under different conditions and at different redemption rates;
(g)
the terms and amount of any sinking fund provided
for the purchase or redemption of the shares of such series;
(h)
the rights of the shares of that series in the event
of voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, and the relative rights of priority, if any,
of payment of shares of that series;
(i)
the restrictions, if any, on the issue or reissue
of any additional Preferred Stock; and
(j)
any other relative rights, preferences, and limitations
of that series.
ARTICLE
V
BOARD
OF DIRECTORS
Section
5.01 General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board.
Section
5.02 Number. Subject to the rights, if any, of any holders of any series of Preferred Stock, the number of directors of the Corporation
that shall constitute the entire Board shall be fixed from time to time solely by resolution of a majority of the total number of directors
that the Corporation would have if there were no vacancies. During any period when the holders of any series of Preferred Stock have
the right to elect a specified number of additional directors as provided for or fixed pursuant to the provisions of Section 4.03 hereof,
then upon commencement and for the duration of the period during which such right continues, (a) the then otherwise number of directors
of the Corporation that shall constitute the entire Board shall automatically be increased by such specified number of directors, and
the holders of such Preferred Stock shall be entitled to elect the additional directors so provided for or fixed pursuant to said provisions,
and (b) each such additional director shall serve until such director’s successor shall have been duly elected and qualified, or
until such director’s right to hold such office terminates pursuant to said provisions, whichever occurs earlier, subject to such
director’s earlier death, disqualification, resignation or removal. Except as otherwise provided by the Board in the resolution
or resolutions establishing such series, whenever the holders of any series of Preferred Stock having such right to elect additional
directors are divested of such right pursuant to the provisions of such stock, all such additional directors elected by the holders of
such stock or elected to fill any vacancies resulting from the death, disqualification, resignation, or removal thereof shall automatically
cease to be qualified as directors, the term of office of all such directors shall forthwith terminate, and the total and authorized
number of directors of the Corporation shall be reduced accordingly.
Section
5.03 Classification. Subject to the rights, if any, or any holders of any series of Preferred Stock, and effective upon the effectiveness
of this Certificate of Incorporation (the “Effective Time”), the Board of the Corporation shall be divided into three
classes, designated Class I, Class II, and Class III. Each class shall consist, as nearly as may be possible, of one-third of the total
number of directors constituting the entire Board. The Board is authorized to assign members of the Board already in office to Class
I, Class II, or Class III at the Effective Time. The term of office of the initial Class I directors shall expire at the first annual
meeting of the stockholders following the Effective Time; the term of office of the initial Class II directors shall expire at the second
annual meeting of the stockholders following the Effective Time; and the term of office of the initial Class III directors shall expire
at the third annual meeting of the stockholders following the Effective Time. At each annual meeting occurring after the Effective Time,
each director elected to the class of directors expiring at such annual meeting shall be elected to hold office until the third annual
meeting following such director’s election and until such director’s successor shall have been duly elected and qualified,
or until such director’s earlier death, disqualification, resignation, or removal. Notwithstanding the foregoing provisions of
this section, each director shall serve until such director’s success is duly elected and qualified or until such director’s
earlier death, disqualification, resignation, or removal. No decrease in the number of directors constituting the full Board shall shorten
the term of any incumbent director.
Section
5.04 Newly Created Directorships and Vacancies. Except as otherwise required by law and subject to any rights of the holders of any
series of Preferred Stock to elect directors under specified circumstances, any newly created directorships resulting from an increase
in the authorized number of directors and any vacancies occurring in the Board shall be filled solely by the affirmative votes of a majority
of the remaining members of the Board, although less than a quorum, or by a sole remaining director. A director so elected shall be elected
to hold office until the earlier of the expiration of the term of office of the director whom such director has replaced, a successor
is duly elected and qualified, or the earlier of such director’s death, disqualification, resignation, or removal. Except as otherwise
provided by law, in the event of a vacancy in the Board, the remaining directors may exercise the powers of the full Board until the
vacancy is filled.
Section
5.05 Removal of Directors. Subject to the rights, if any, of the holders of any series of Preferred Stock, for so long as this Certificate
of Incorporation provides for a classified Board, any director may be removed from office at any time but only with cause, at a meeting
called for that purpose, by the affirmative vote of the holders representing at least a majority of the voting power of the outstanding
shares of capital stock of the Corporation entitled to vote generally in an election of directors, voting together as a single class.
Section
5.06 Written Ballot. Unless and except to the extent that the Bylaws of the Corporation (the “Bylaws”) shall so
require, the election of directors of the Corporation need not be by written ballot.
Section
5.07 Cumulative Votes. The right to cumulate votes in the election of directors shall not exist with respect to shares of stock in
the Corporation.
ARTICLE
VI
INDEMNIFICATION
AND LIMITATION OF LIABILITY
Section
6.01 Indemnification. The Corporation, to fullest extent permitted by the DGCL as it presently exists or may hereafter be amended,
may indemnify and advance expenses to any person made or threatened to any person threatened to be made a party to an action, suit, or
proceeding, whether criminal, civil, administrative, or investigative, by reason of the fact that such person, or such person’s
testator or intestate, is or was a director or officer of the Corporation or any predecessor of the Corporation, or serves or served
at any other enterprise as a director, employee, or agent at the request of the Corporation or any predecessor to the Corporation.
Section
6.02 Limitation of Liability. To the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, a director
or officer of the Corporation shall not be personally liable to the Corporation or to its stockholders for monetary damages for any breach
of fiduciary duty as a director or officer. No amendment to, modification of, or repeal of this Section 6.02 shall apply to or have any
effect on the liability or alleged liability of any director or officer of the Corporation for or with respect to any acts or omissions
of such director or officer occurring prior to such amendment.
ARTICLE
VII
STOCKHOLDER
ACTION
Section
7.01 Stockholder Consent Prohibition. Subject to the rights of the holders of any series of Preferred Stock, any action required
or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of the stockholders
of the Corporation and may not be effected by any consent by such stockholders.
Section
7.02 Special Meetings of Stockholders. Except as otherwise required by law and subject to the rights of the holders of any series
of Preferred Stock, special meetings of the stockholders of the Corporation shall be called only by or at the direction of the Board.
Any business transacted at any special meeting of stockholders shall be limited to matters properly brought before the meeting by or
at the direction of the Board.
ARTICLE
VIII
BYLAWS
In
furtherance and not in limitation of the powers conferred by law, the Bylaws may be adopted, amended, altered, or repealed by either
(a) the affirmative vote of at least a majority of the directors then in office, without any action on the part of the stockholders,
or (b) the affirmative vote of at least a majority of the voting power of all of the then-outstanding shares of the capital stock of
the Corporation entitled to vote generally in the election of directors, voting together as a single class, at any annual or special
meeting of stockholders, provided that such proposed action shall be stated in the notice of such meeting.
ARTICLE
IX
FORUM
AND JURISDICTION
Unless
the Corporation consents in writing to the selection of an alternative forum, (i) the Court of Chancery for the State of Delaware (or,
in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other
state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (A) any derivative
action or proceeding brought on behalf of the Corporation, (B) any action, suit, or proceeding asserting a claim of breach of a fiduciary
duty owed by any director, officer, or stockholder of the Corporation to the Corporation or the Corporation’s stockholders, (C)
any action, suit, or proceeding asserting a claim against the Corporation or any director or officer or stockholder of the Corporation
arising pursuant to any provision of the DGCL or this Certificate of Incorporation or the Bylaws, or (D) any action, suit, or proceeding
asserting a claim against the Corporation or any director, officer, or other employee or stockholder of the Corporation governed by the
internal affairs doctrine, and (ii) subject to the preceding provisions of this Article IX, the federal district courts of the United
States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act
of 1933, as amended. If any action, suit, or proceeding the subject matter of which is within the scope of clause (i) of the immediately
preceding sentence is filed in a court other than a court located within the State of Delaware (a “Foreign Action”) in the
name of any stockholder, such stockholder shall be deemed to have consented to (i) the personal jurisdiction of the state and federal
courts located within the State of Delaware in connection with any action brought in any such court to enforce the provisions of clause
(i) of the immediately preceding sentence and (ii) having service of process made upon such stockholder in any such action by service
upon such stockholder’s counsel in the Foreign Action as agent for such stockholder. The provisions of this Article IX shall not
apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended. Any person purchasing
or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to this Article
IX.
ARTICLE
X
DGCL
SECTION 203 OPT-OUT
The
Corporation shall not be governed by or subject to Section 203 of the DGCL.
ARTICLE
XI
AMENDMENTS
The
Corporation reserves the right to amend, alter, or repeal any provision contained in this Certificate of Incorporation, in the manner
now or hereafter prescribed by the laws of the State of Delaware, and all rights conferred herein are granted subject to this reservation;
provided however, that notwithstanding any other provision of this Certificate of Incorporation or applicable law that might permit a
lesser vote or no vote and in addition to any affirmative vote of the holders of any particular class or series of capital stock of the
Corporation required by applicable law or this Certificate of Incorporation, the affirmative vote of the holders of at least two-thirds
of the voting power of the shares of the then outstanding voting stock of the Corporation entitled to vote generally in the election
of directors, voting together as a single class, shall be required to amend, alter, repeal, or adopt any provisions inconsistent with
Section 5.03, 5.04, or 5.05, Article VI or VIII, or this Article XI of this Certificate of Incorporation.
Exhibit
3.2
Bylaws
OF
Tevogen
bio Holdings Inc.
Article
I. Corporate Offices.
Section
1.1. Registered Office and Agent. The registered office of Tevogen Bio Holdings Inc. (the “Corporation”)
shall be as set forth in the Charter of the Corporation (the “Charter”).
Section
1.2. Other Offices. The board of directors of the Corporation (the “Board”) may at any time establish other offices
at any place or places, either within or outside of the State of Delaware, where the Corporation is qualified to do business.
Article
II. Meetings of Stockholders.
Section
2.1. Place of Meetings. Meetings of stockholders shall be held at any place designated by the Board within or without outside the
State of Delaware, or by means of remote communication, in each case as may be determined by resolution of the Board from time to time
and stated in the notice of the meeting.
Section
2.2. Annual Meetings. The annual meeting of stockholders for the election of directors and for the transaction of such other business
as may properly come before the meeting shall be held at such date, time and place, if any, as shall be determined exclusively by resolution
of the Board in its sole and absolute discretion and stated in the notice of the meeting.
Section
2.3. Special Meetings. Special meetings of stockholders of the Corporation may only be called in the manner provided in the Charter.
Any business transacted at any special meeting of stockholders shall be limited to matters properly brought before the meeting by or
at the direction of the Board.
Section
2.4. Notice of Stockholders’ Meetings. All notices of meetings of stockholders shall be in the form of a writing or electronic
transmission and shall be sent or otherwise given to each stockholder entitled to vote at such meeting as of the record date for determining
the stockholders entitled to notice of the meeting in accordance with Section 2.5 of these bylaws of the Corporation (the “Bylaws”)
not less than ten nor more 60 days before the date of the meeting (unless a different time is specified by law). The notice shall specify
the place (if any), date, and hour of the meeting, and in the case of a special meeting, the purpose or purposes for which the meeting
is called. The means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and
vote at such meeting shall also be provided in the notice. Notice of any meeting need not be given to any stockholder who shall, either
before or after the meeting, submit a waiver of notice or who shall attend such meeting, except when the stockholder attends for the
express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully
called or convened. Any stockholder so waiving notice of the meeting shall be bound by the proceedings of the meeting in all respects
as if due notice thereof had been given.
Section
2.5. Manner of Giving Notice; Affidavit of Notice. Without limiting the manner by which notice otherwise may be given effectively
to stockholders, any notice to stockholders given by the Corporation under any provisions of the Delaware General Corporation Law (the
“DGCL”), the Charter, or these Bylaws, may be given in writing directed to the stockholder’s mailing address
(or by electronic transmission directed to the stockholder’s electronic mail address, as applicable) as it appears on the records
of the Corporation and shall be given (a) if mailed, when the notice is deposited in the U.S. mail, postage prepaid, (b) if delivered
by courier service, the earlier of when the notice is received or left at such stockholder’s address, or (c) if given by electronic
mail, when directed to such stockholder’s electronic mail address unless the stockholder has notified the Corporation in writing
or by electronic transmission of an objection to receiving notice by electronic mail. A notice by electronic mail must include a prominent
legend that the communication is an important notice regarding the Corporation. An affidavit of the Secretary or an assistant secretary
or of the transfer agent of the Corporation that the notice has been given by mail or by a form of electronic transmission, as applicable,
shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
Section
2.6. Quorum. The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in person or represented
by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business, except as otherwise provided
by statute or by the Charter or these Bylaws. If, however, such quorum is not present or represented at any meeting of the stockholders,
then either (a) the chairperson of the meeting or (b) the holders of a majority of the shares present in person or by proxy at the meeting
and entitled to vote thereat, whether or not a quorum is present, shall have power to adjourn the meeting from time to time, without
notice other than announcement at the meeting, until a quorum is present or represented.
Section
2.7. Adjourned Meeting; Notice. When a meeting is adjourned to another time or place, unless these Bylaws otherwise require, notice
need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communication, if any, are provided
in accordance with the DGCL. At the adjourned meeting, the Corporation may transact any business that might have been transacted at the
original meeting as originally noticed. If the adjournment is for more than 30 days, or if after the adjournment a new record date is
fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the
meeting.
Section
2.8. Conduct of Business. The chairperson of any meeting of stockholders shall determine the order of business and the procedure
at the meeting, including such matters as the regulation of the manner of voting and the conduct of business.
Section
2.9. Voting. The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions
of Section 2.11 of these Bylaws and subject to the provisions of Sections 217 and 218 of the DGCL (relating to voting rights of fiduciaries,
pledgors, and joint owners of stock and to voting trusts and other voting agreements). Voting at meetings of stockholders need not be
by written ballot and, unless otherwise required by law, need not be conducted by an inspector of election unless so determined by the
holders of the shares of stock having a majority of the votes which could be cast by the holders of all outstanding shares of stock entitled
to vote thereon which are present in person at such meeting.
Except
as may be otherwise provided in the Charter, each stockholder shall be entitled to one vote for each share of capital stock having voting
power held by such stockholder or by proxy.
A
nominee for director shall be elected to the Board if the votes cast for such nominee’s election exceed the votes cast against
such nominee’s election; provided, however, that directors shall be elected by a plurality of the votes of the shares represented
in person or by proxy at any meeting of stockholders at which a quorum is present and for which, as of the tenth day before the Corporation
first mails its notice of meeting for such meeting to the stockholders, the Secretary of the Corporation determines that the number of
nominees exceeds the number of directors to be elected. If directors are to be elected by a plurality of the votes cast, stockholders
shall not be permitted to vote against a nominee. A director standing for reelection in an uncontested election must tender a resignation
conditioned on the incumbent director’s failure to receive a majority of the votes cast. If an incumbent director who is standing
for reelection does not receive a majority of the votes cast, the Nominating and Corporate Governance Committee of the Board, or such
other committee designated by the Board pursuant to these Bylaws, will make a recommendation to the Board on whether to accept or reject
the resignation, or whether other action should be taken. The Board will act on the committee’s recommendation and publicly disclose
its decision and the rationale behind it within 90 days from the date of the certification of the election results. The director who
fails to receive a majority vote will not participate in the committee’s recommendation or the Board’s decision.
Section
2.10. Waiver of Notice. Whenever notice is required to be given under any provision of the DGCL, the Charter, or these Bylaws, a
written waiver thereof, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice,
whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute
a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of
the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted
at, nor the purpose of, any regular or special meeting of the stockholders need to be specified in any written waiver of notice, or any
waiver by electronic transmission, unless so required by the Charter or these Bylaws.
Section
2.11. Record Date for Stockholder Notice; Voting; Giving Consents. In order that the Corporation may determine the stockholders entitled
to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to express consent to corporate action
in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled
to exercise any rights in respect of any change, conversion, or exchange of stock or for the purpose of any other lawful action, the
Board may fix, in advance, a record date, which shall not be more than 60 nor less than ten days before the date of such meeting, nor
more than 60 days prior to any other action.
If
the Board does not so fix a record date:
|
(a) |
the
record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business
on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding
the day on which the meeting is held; |
|
|
|
|
(b) |
the
record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior
action by the Board is necessary, shall be the day on which the first written consent (including consent by electronic mail or other
electronic transmission as permitted by law) is delivered to the Corporation; and |
|
|
|
|
(c) |
the
record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts
the resolution relating thereto. |
A
determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment
of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting.
Section
2.12. Nominations and Proposals for Annual Meetings of Stockholders.
|
(a) |
Nominations
of persons for election to the Board and the proposal of business to be considered by the stockholders may only be made at an annual
meeting of stockholders (i) pursuant to the Corporation’s notice of meeting (or any supplement thereto), (ii) by or at the
direction of the Board or the chairperson of the meeting, or (iii) by any stockholder of the Corporation that (A) was a stockholder
of record at the time of giving of the notice provided for in this Section 2.12 and at the time of the annual meeting, (B) is entitled
to vote with respect to such matter at the meeting, and (C) complies in all applicable respects with the notice procedures set forth
in this Section 2.12. At any annual meeting of stockholders, the presiding officer of such meeting may announce the nominations and
other business to be considered which are set forth in the Corporation’s notice of meeting and proxy statement and, by virtue
thereof, such nominations and other business so announced shall be properly brought before such meeting and may be considered and
voted upon by the stockholders of the Corporation entitled to vote thereat without further requirement of nomination, motion, or
second. |
|
(b) |
For
nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of paragraph
(a) of this Section 2.12, the stockholder making such nominations or proposing such other business (the “Proposing Stockholder”)
must theretofore have given timely notice thereof in writing to the Secretary of the Corporation and such other business must otherwise
be a proper matter for stockholder action. To be timely, a Proposing Stockholder’s notice shall be delivered to the Secretary
at the principal executive offices of the Corporation not later than 5:00 p.m., Eastern Time, on the 90th day nor earlier than 5:00
p.m., Eastern Time on the 120th day prior to the first anniversary of the preceding year’s annual meeting; provided, however,
that in the event that the date of the annual meeting is changed by more than 30 days before or more than 60 days after the one-year
anniversary date of the previous year’s annual meeting, notice by the stockholder to be timely must be so delivered not later
than 5:00 p.m., Eastern Time, on the later of (x) the 90th day prior to the scheduled date of such annual meeting or (y) the tenth
day following the day on which Public Disclosure (as defined below) of the date of such meeting is first made by the Corporation.
In no event shall the Public Disclosure of an adjournment, recess, or postponement of an annual meeting commence a new time period
for the giving of a stockholder’s notice as described above. The number of nominees a stockholder may nominate for election
at an annual meeting shall not exceed the number of directors to be elected at such annual meeting, and for the avoidance of doubt,
no stockholder shall be entitled to make additional or substitute nominations following the expiration of the time periods set forth
in this Section 2.12. “Public Disclosure” shall mean disclosure in a press release reported by the Dow Jones News
Service, Associated Press, or a comparable national news service, in a document publicly filed by the Corporation with the Securities
and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder (the “Exchange Act”), or by such other means as is reasonably designed to inform
the public or stockholders of the Corporation in general of such information, including, without limitation, posting on the Corporation’s
investor relations website. |
|
|
|
|
(c) |
To
be in proper form, a Proposing Stockholder’s notice to the Secretary must: |
|
(i) |
set
forth, as to the Proposing Stockholder and the beneficial owner, if any, on whose behalf the nomination or proposal is made, (A)
the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner, if any,
(B) the class or series and number of shares of the Corporation that are, directly or indirectly, owned beneficially and of record
by the Proposing Stockholder and such beneficial owner, if any, as of the date of such notice, and any shares as to which such stockholder
and beneficial owner or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future
(which information shall be supplemented by such stockholder and beneficial owner not later than ten days after the record date for
the meeting to disclose such ownership as of the record date), (C) a description of all agreements, arrangements and understandings,
written or oral, between the Proposing Stockholder or such beneficial owner and any other person or persons (including their names)
in connection with the nomination or proposal of such business by such stockholder, (D) a representation that the Proposing Stockholder
is a holder of record of shares of the Corporation entitled to vote at the meeting and intends to appear in person or by proxy at
the meeting to nominate the person or persons specified in the notice or propose such other business proposal, (E) if the Proposing
Stockholder or such beneficial owner intends or is part of a group that intends to solicit proxies or votes in support of nominees
for director of the Corporation other than the Corporation’s nominees (unless such solicitation would not be subject to Rule
14a-19 under the Exchange Act), the information required to be included in a notice to the Corporation required by Rule 14a-19(b)
under the Exchange Act and (F) any other information relating to the Proposing Stockholder and such beneficial owner that would be
required to be disclosed in a proxy statement and form of proxy or other filings required to be made in connection with solicitations
of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to Section 14 of
the Exchange Act; |
|
|
|
|
(ii) |
if
the notice relates to any business other than the nomination of a director that the Proposing Stockholder proposes to bring before
the meeting, set forth a brief description of the business desired to be brought before the meeting (including the text of any resolutions
proposed for consideration and in the event that such business includes a proposal to amend these Bylaws, the language of the proposed
amendment), the reasons for conducting such business at the meeting and any material interest of such stockholder and beneficial
owner, if any, in such business; and |
|
|
|
|
(iii) |
set
forth, as to each person, if any, whom the Proposing Stockholder proposes to nominate for election or reelection as a director, (A)
such person’s name, age, business address, and current residential address, (B) such person’s principal occupation or
employment, (C) the class and number of shares of capital stock of the Corporation that are owned of record and beneficially by such
person, if any, (D) all information relating to such person that would be required to be disclosed in a proxy statement soliciting
proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved) or that
is otherwise required to be disclosed, under Section 14(a) of the Exchange Act (including such person’s written consent to
being named as a nominee in any proxy statement and any associated proxy card for the Corporation’s next meeting of stockholders
for the election of directors and to serving as a director if elected), and (E) a description of all direct and indirect compensation
and other monetary agreements, arrangements and understandings, written or oral, during the past three years, and any other relationships,
between or among such stockholder and beneficial owner, if any, and their respective affiliates and associates, or others acting
in concert therewith, on the one hand, and each proposed nominee, and their respective affiliates and associates, or others acting
in concert therewith, on the other hand. |
|
If
any stockholder provides notice to the Corporation pursuant to Rule 14a-19(b), such stockholder shall deliver to the Corporation,
no later than five business days prior to the annual meeting, reasonable evidence that it has met the requirements of Rule 14a-19(a).
If a nominating stockholder (i) provides notice pursuant to Rule 14a-19 promulgated and (ii) subsequently (A) notifies the Corporation
that such stockholder no longer intends to solicit proxies in support of director nominees other than the Corporation’s director
nominees in accordance with Rule 14a-19, (B) fails to comply with the requirements of Rule 14a-19 or these Bylaws, or (C) fails to
provide reasonable evidence sufficient to satisfy the Corporation that such requirements have been met, such stockholder’s
nomination(s) shall be deemed null and void and the Corporation shall disregard any proxies or votes solicited for any nominee proposed
by such shareholder notwithstanding that such nominee may be named in the notice of meeting or in any proxy statement or associated
proxy card and notwithstanding that proxies in respect of the election of such proposed nominees may have been received by the Corporation. |
|
|
|
In
addition, to be considered timely, a stockholder’s notice shall further be updated and supplemented, if necessary, so that
the information provided or required to be provided in such notice shall be true and correct as of the record date for the meeting
and as of the date that is ten days prior to the meeting or any adjournment, recess or postponement thereof, and such update and
supplement shall be delivered to the Secretary not later than five days after the record date for the meeting in the case of the
update and supplement required to be made as of the record date, and not later than eight days prior to the date for the meeting
or any adjournment or postponement thereof in the case of the update and supplement required to be made as of ten days prior to the
meeting or any adjournment or postponement thereof. No such supplement or update may include any new proposal not set forth in the
original notice or be deemed to cure any defects or limit the remedies (including without limitation under these Bylaws) available
to the Corporation relating to any defect. |
|
(d) |
To
be eligible to be a nominee for election or reelection as a director of the Corporation, a person must deliver (in accordance with
the time periods prescribed for delivery of notice under paragraph (b)) to the Secretary of the Corporation at the principal executive
offices of the Corporation a completed, written, and signed questionnaire (in the form customarily used by the Corporation for its
directors) with respect to the background and qualification of such person and the background of any other person or entity on whose
behalf the nomination is being made (which questionnaire shall be provided by the Secretary upon written request) and a written representation
and agreement (in the form provided by the Secretary upon written request) that such person: |
|
(i) |
is
not and will not become a party to (A) any agreement, arrangement or understanding, written or oral, with, and has not given any
commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or
vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or (B) any
Voting Commitment that could limit or interfere with such persons’ ability to comply, if elected as a director of the Corporation,
with such person’s fiduciary duties under applicable law; |
|
|
|
|
(ii) |
is
not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation
with respect to any direct or indirect compensation, reimbursement, or indemnification in connection with service or action as a
director that has not been disclosed therein; and |
|
|
|
|
(iii) |
in
such person’s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would
be in compliance, if elected as a director of the Corporation, and will comply with all applicable publicly disclosed corporate governance,
conflict of interest, confidentiality, and stock ownership and trading policies and guidelines of the Corporation. |
|
The
Corporation may require any proposed nominee to furnish such other information as may reasonably be required by the Corporation to
determine the eligibility of such proposed nominee to serve as an independent director of the Corporation or that could be material
to a reasonable stockholder’s understanding of the independence, or lack thereof, of such nominee. |
|
(e) |
Notwithstanding
the foregoing provisions of this Section 2.12, a stockholder shall also comply with all applicable requirements of the Exchange Act,
and the rules and regulations thereunder with respect to the matters set forth in this Section 2.12, and nothing in this Section
2.12 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement
pursuant to Rule 14a-8 under the Exchange Act (or any successor provision thereof) and, to the extent required by such rule, have
such proposals considered and voted on at an annual meeting. |
|
(f) |
Except
as otherwise provided by law, at any meeting of stockholders the chairperson of the meeting (and, in advance of any meeting of stockholders,
the Board or any committee designated by the Board pursuant to these Bylaws) shall have the power and duty (i) to determine whether
any nomination or business proposed to be brought before the meeting was made or proposed in accordance with the procedures set forth
in this Section 2.12 and (ii) if any nomination was not made or such other business was not made or proposed in compliance with this
Section 2.12, to declare that such nomination shall be disregarded or that such proposed business shall not be transacted. Notwithstanding
the foregoing provisions of this Section 2.12, unless otherwise required by law, if the stockholder (or a qualified representative
of the stockholder) does not appear at a meeting of stockholders of the Corporation to present the nomination or proposed business
advanced by such stockholder, such proposed business shall not be transacted, notwithstanding that such proposal is set forth in
the notice of meeting and notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes
of this Section 2.12, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer,
manager, or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission
delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such
writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. |
|
|
|
|
(g) |
Any
person directly or indirectly soliciting proxies from the stockholders of the Corporation must use a proxy card color other than
white, which shall be reserved for the exclusive use of the Board. |
Section
2.13. List of Stockholders Entitled to Vote. The Corporation shall, no later than the tenth calendar day before every meeting of
stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address
(but not the electronic address or other electronic contact information) of each stockholder and the number of shares registered in the
name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, for
a period of at least ten calendar days prior to the meeting (a) during ordinary business hours at the principal place of business of
the Corporation or (b) as otherwise provided by law. Such list shall presumptively determine the identity of the stockholders entitled
to vote at the meeting and the number of shares held by each of them.
Section
2.14. Proxies. Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action
in writing without a meeting may authorize another person or persons to act for them by proxy, but no such proxy shall be voted or acted
upon after three (3) years from its date, unless the proxy provides for a longer period. A proxy shall be deemed signed if the stockholder’s
name is placed on the proxy (whether by manual signature, typewriting, facsimile, electronic or telegraphic transmission or otherwise)
by the stockholder or the stockholder’s attorney-in-fact. A duly executed proxy shall be irrevocable if it states that it is irrevocable
and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A proxy may remain irrevocable
regardless of whether the interest with which it is coupled is an interest in the stock itself or an interest in the Corporation generally.
Article
III. Directors.
Section
3.1. Powers. Subject to the provisions of the DGCL and any limitation in the Charter or these Bylaws relating to action required
to be approved by the stockholders or by the outstanding shares, the business and affairs of the Corporation shall be managed and all
corporate powers shall be exercised by or under the direction of the Board.
Section
3.2. Number of Directors. The number of directors that shall constitute the whole Board shall be fixed from time to time solely by
resolution of a majority of the total number of directors that the Corporation would have if there were no vacancies. Each director shall
hold office until a successor is duly elected and qualified or until the director’s earlier death, resignation, disqualification
or removal. The directors shall be classified in the manner provided in the Charter. Each director shall hold office until such time
as provided in the Charter. Elections of directors need not be by written ballot.
Section
3.3. Resignation and Vacancies. Any director may resign at any time upon notice given in writing or by electronic transmission to
the attention of the Secretary of the Corporation. When one or more directors so resigns and the resignation is effective at a future
date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies,
the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold
office as provided in this section in the filling of other vacancies.
Unless
otherwise provided in the Charter or these Bylaws:
|
(a) |
Vacancies
and newly created directorships resulting from any increase in the authorized number of directors elected may be filled by a majority
of the directors then in office, even if less than a quorum, or by a sole remaining director. |
|
|
|
|
(b) |
Whenever
the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the
Charter, vacancies and newly created directorships of such class or classes or series may be filled by a majority of the directors
elected by such class or classes or series thereof then in office or by a sole remaining director so elected. |
If
at any time, by reason of death or resignation or other cause, the Corporation should have no directors in office, then any officer of
the Corporation may call a special meeting of stockholders in accordance with the provisions of the Charter or these Bylaws, or may apply
to the Court of Chancery for a decree summarily ordering an election as provided in Section 211 of the DGCL.
In
the event of a vacancy in the Board, the remaining directors, except as otherwise provided by law, may exercise the powers of the full
Board until such vacancy is filled.
Section
3.4. Place of Meetings; Remote Meetings. The Board may hold meetings, both regular and special, either within or outside the State
of Delaware. Unless otherwise restricted by the Charter or these Bylaws, members of the Board, or any committee designated by the Board,
may participate in a meeting of the Board, or any committee, by means of conference telephone, internet, video, or other communications
equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute
presence in person at the meeting.
Section
3.5. Regular Meetings. Regular meetings of the Board may be held without notice at such time and at such place as shall from time
to time be determined by the Board.
Section
3.6. Special Meetings; Notice. Special meetings of the Board for any purpose or purposes may be called at any time by the Chairperson
of the Board, the chief executive officer, any vice president, the Secretary or any two (2) directors.
Notice
of the time and place of special meetings shall be:
|
(a) |
delivered
personally by hand, by courier or by telephone; |
|
|
|
|
(b) |
sent
by United States first-class mail, postage prepaid; or |
|
|
|
|
(c) |
sent
by electronic transmission” as defined in Section 232 of the DGCL. |
If
the notice is (i) delivered personally by hand, by courier or by telephone, or (ii) sent by electronic mail, it shall be delivered or
sent at least forty-eight (48) hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall
be deposited in the United States mail at least four (4) days before the time of the holding of the meeting. Any oral notice may be communicated
to a director. If the notice is sent by electronic transmission, it shall be delivered to the extent and in accordance with applicable
law. The notice need not specify the place of the meeting (if the meeting is to be held at the Corporation’s principal executive
office) nor the purpose of the meeting.
Section
3.7. Quorum. At all meetings of the Board, a majority of the authorized number of directors then in office shall constitute a quorum
for the transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum shall be
the act of the Board, except as may be otherwise specifically provided by statute or by the Charter. If a quorum is not present at any
meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement
at the meeting, until a quorum is present. A meeting at which a quorum is initially present may continue to transact business notwithstanding
the withdrawal of directors, if any action taken is approved by at least a majority of the required quorum for that meeting.
Section
3.8. Waiver of Notice. Whenever notice is required to be given under any provision of the DGCL, the Charter, or these Bylaws, a written
waiver thereof, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether
before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a
waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of
the meeting, to the transaction of any business because the meeting is not lawfully called and convened. Neither the business to be transacted
at, nor other purpose of, any regular or special meeting of the directors, or a committee of directors, need to be specified in any written
waiver of notice or any waiver by electronic transmission unless so required by the Charter or these Bylaws.
Section
3.9. Board Action by Written Consent Without a Meeting. Unless otherwise restricted by the Charter or these Bylaws, any action required
or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the
Board or committee, as the case may be, consent thereto in writing or by electronic transmission, and any consent may be documented,
signed and delivered in any manner permitted by Section 116 of the DGCL. After an action is taken, the consent or consents relating thereto
shall be filed with the minutes of proceedings of the Board or committee in the same paper or electronic form as the minutes are maintained.
Section
3.10. Fees and Compensation of Directors. Unless otherwise restricted by the Charter or these Bylaws, the Board shall have the authority
to fix the compensation of directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board and
may be paid a fixed sum for attendance at each meeting of the Board or a stated salary as director. No such payment shall preclude any
director from serving the Corporation in any other capacity and receiving compensation therefor. Members of special or standing committees
may be allowed like compensation for attending committee meetings.
Section
3.11. Approval of Loans. The Corporation shall not, either directly or indirectly, including through any subsidiary, extend or maintain
credit, arrange for the extension of credit, or renew an extension of credit, in the form of a personal loan to or for any director,
executive officer (or equivalent thereof), or control person, but may lend money to and use its credit to assist any employee, excluding
such executive officers, directors, or other control persons of the Corporation or of a subsidiary, whenever, in the judgment of the
directors, such loan, guarantee, or assistance may reasonably be expected to benefit the Corporation. The loan, guarantee or other assistance
may be with or without interest and may be unsecured or secured in such manner as the Board shall approve, including, without limitation,
a pledge of shares of stock of the Corporation. Nothing contained in this section shall be deemed to deny, limit or restrict the powers
of guarantee or warranty of the Corporation at common law or under any statute.
Section
3.12. Removal of Directors. Directors may be removed from office by stockholders only in the manner provided in the Charter.
Article
IV. Committees.
Section
4.1. Committees of Directors. The Board may, by resolution passed by a majority of the whole Board, designate one or more committees,
with each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate
members of any committee who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification
of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not they
constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified
member. Any such committee, to the extent provided in the resolution of the Board or in the Bylaws of the Corporation, shall have and
may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize
the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority
to (a) approve, adopt or recommend to the stockholders any action or matter the DGCL expressly requires be submitted to the stockholders
for approval, or (b) adopt, amend, or repeal the Bylaws.
Section
4.2. Committee Minutes. Each committee shall keep regular minutes of its meetings and report the same to the Board when required.
Section
4.3. Meetings and Action of Committees. Meetings and actions of committees shall be governed by, and held and taken in accordance
with, the provisions of Article III and Sections 3.4 through 3.9 of these Bylaws, with such changes in the context of those Bylaws as
are necessary to substitute the committee and its members for the Board and its members; provided, however, that the time of regular
meetings of committees may be determined either by resolution of the Board or by resolution of the committee, that special meetings of
committees may also be called by resolution of the Board and that notice of special meetings of committees shall also be given to all
alternate members, who shall have the right to attend all meetings of the committee. The Board may adopt rules for the government of
any committee not inconsistent with the provisions of these Bylaws.
Article
V. Officers.
Section
5.1. Officers. The officers of the Corporation shall be a Chief Executive Officer, a President, a Chief Financial Officer, and a
Secretary. The Board, in its discretion, may also elect one or more vice presidents, assistant treasurers, assistant secretaries, and
other officers in accordance with these Bylaws. Any two or more offices may be held by the same person.
Section
5.2. Appointment of Officers. The officers of the Corporation, except such officers as may be appointed in accordance with the provisions
of Section 5.3 or Section 5.5 of these Bylaws, shall be appointed by the Board, subject to the rights, if any, of an officer under any
contract of employment.
Section
5.3. Subordinate Officers. The Board may appoint, or empower the Chief Executive Officer to appoint, such other officers and agents
as the business of the Corporation may require, each of whom shall hold office for such period, have such authority, and perform such
duties as are provided in these Bylaws or as the Board may from time to time determine.
Section
5.4. Removal and Resignation of Officers. Subject to the rights, if any, of an officer under any contract of employment, any officer
may be removed, either with or without cause, by an affirmative vote of the majority of the Board at any regular or special meeting of
the Board or, except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by
the Board.
Any
officer may resign at any time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt
of that notice or at any later time specified in that notice; and, unless otherwise specified in that notice, the acceptance of the resignation
shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any
contract to which the officer is a party.
Section
5.5. Vacancies in Offices. Any vacancy occurring in any office of the Corporation shall be filled by the Board.
Section
5.6. Authority and Duties of Officers. All officers of the Corporation shall respectively have such authority and perform such duties
in the management of the business of the Corporation as may be provided herein or designated from time to time by the Board and, to the
extent not so provided, as generally pertain to their respective offices, subject to the control of the Board.
Section
5.7. Compensation. The compensation of the officers of the Corporation for their services as such shall be fixed from time to time
by or at the direction of the Board. An officer of the Corporation shall not be prevented from receiving compensation by reason of the
fact that the officer is also a director of the Corporation.
Article
VI. Indemnity.
Section
6.1. Third-Party Actions. Subject to the provisions of this Article VI, the Corporation shall indemnify and hold harmless any person
who was or is a party or is threatened to be made a party to any threatened, pending, or completed action, suit, or proceeding, whether
civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that
they are or were a director or officer of the Corporation, or are or were serving at the request of the Corporation as a director, officer,
employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys’
fees), judgments, fines and amounts paid in settlement (if such settlement is approved in advance by the Corporation, which approval
shall not be unreasonably withheld) actually and reasonably incurred by them in connection with such action, suit, or proceeding if such
person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. The termination
of any action, suit, or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent,
shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed
to be in or not opposed to the best interest of the Corporation, and, with respect to any criminal action or proceeding, had reasonable
cause to believe that their conduct was unlawful.
Section
6.2. Actions by or in the Right of the Corporation. Subject to the provisions of this Article VI, the Corporation shall indemnify
any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in
the right of the Corporation to procure a judgment in its favor by reason of the fact that they are or were a director, officer, employee
or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee, or agent of another
corporation, partnership, joint venture, trust, or other enterprise against expenses (including attorneys’ fees) actually and reasonably
incurred by them in connection with the defense or settlement of such action or suit, if such person acted in good faith and in a manner
such person reasonably believed to be in or not opposed to the best interests of the Corporation, except that no indemnification shall
be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless
and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon
application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper. Notwithstanding any
other provision of this Article VI, no person shall be indemnified hereunder for any expenses or amounts paid in settlement with respect
to any action to recover short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended.
Section
6.3. Successful Defense. To the extent that a director, officer, employee or agent of the Corporation has been successful on the
merits or otherwise in defense of any action, suit, or proceeding referred to in Sections 6.1 or 6.2, or in defense of any claim, issue
or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred
by them in connection therewith.
Section
6.4. Determination of Conduct. Any indemnification under Sections 6.1 or 6.2 (unless ordered by a court) shall be made by the Corporation
only as authorized in the specific case upon a determination that the indemnification of the director, officer, employee or agent is
proper in the circumstances because they have met the applicable standard of conduct set forth in Sections 6.1 or 6.2, as applicable.
Such determination shall be made (a) by the Board by a majority vote of a quorum consisting of directors who were not parties to such
action, suit, or proceeding, (b) if such quorum is not obtainable or, even if obtainable, as a quorum of disinterested directors so directs,
by independent legal counsel in a written opinion, or (c) by the stockholders. Notwithstanding the foregoing, a director, officer, employee,
or agent of the Corporation shall be entitled to contest any determination that the director, officer, employee, or agent has not met
the applicable standard of conduct set forth in Sections 6.1 or 6.2 by petitioning a court of competent jurisdiction.
Section
6.5. Payment of Expenses in Advance. To the fullest extent permitted by law, expenses (including attorneys’ fees) incurred
in defending a civil or criminal action, suit, or proceeding, by an individual who may be entitled to indemnification pursuant to Section
6.1 or 6.2, shall be paid by the Corporation in advance of the final disposition of such action, suit, or proceeding upon receipt of
an undertaking by or on behalf of the director, officer, employee or agent to repay such amount if it shall ultimately be determined
that they are not entitled to be indemnified by the Corporation as authorized in this Article VI.
Section
6.6. Indemnity Not Exclusive. The indemnification and advancement of expenses provided by or granted pursuant to the other sections
of this Article VI shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses
may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in their
official capacity and as to action in another capacity while holding such office.
Section
6.7. Insurance Indemnification. The Corporation shall have the power to purchase and maintain insurance on behalf of any person who
is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation, as a director,
officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against any liability asserted
against them and incurred by them in any such capacity or arising out of their status as such, whether or not the Corporation would have
the power to indemnify them against such liability under this Article VI.
Section
6.8. The Corporation. For purposes of this Article VI references to the “Corporation” shall include, in addition to the
resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger
which, if its separate existence had continued, would have had the power and authority to indemnify its directors and officers, so that
any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request
of such constituent corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust,
or other enterprise, shall stand in the same position under and subject to the provisions of this Article VI (including, without limitation,
the provisions of Section 6.4) with respect to the resulting or surviving corporation as such person would have with respect to such
constituent corporation if its separate existence had continued.
Section
6.9. Employee Benefit Plans. For purposes of this Article VI, references to “other enterprises” shall include employee
benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit
plan; and references to “serving at the request of the corporation” shall include any service as a director, officer, employee
or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect
to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably
believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner
“not opposed to the best interests of the Corporation” as referred to in this Article VI.
Section
6.10. Indemnity Fund. Upon resolution passed by the Board, the Corporation may establish a trust or other designated account, grant
a security interest or use other means (including, without limitation, a letter of credit), to ensure the payment of certain of its obligations
arising under this Article VI and/or agreements which may be entered into between the Corporation and its officers and directors from
time to time.
Section
6.11. Indemnification of Other Persons. The provisions of this Article VI shall not be deemed to preclude the indemnification of
any person who is not a director or officer of the Corporation or is not serving at the request of the Corporation as a director, officer,
employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, but whom the Corporation has the power
or obligation to indemnify under the DGCL or otherwise. The Corporation may, in its sole discretion, indemnify an employee, trustee,
or other agent as permitted by the DGCL. The Corporation shall indemnify an employee, trustee, or other agent where required by law.
Section
6.12. Savings Clause. If this Article VI or any portion thereof shall be invalidated on any ground by any court of competent jurisdiction,
then the Corporation shall nevertheless indemnify each person entitled to indemnification hereunder against expenses (including attorney’s
fees), judgments, fines, and amounts paid in settlement with respect to any action, suit, proceeding, or investigation, whether civil,
criminal or administrative, and whether internal or external, including a grand jury proceeding and an action or suit brought by or in
the right of the Corporation, to the full extent permitted by any applicable portion of this Article VI that shall not have been invalidated,
or by any other applicable law.
Section
6.13. Continuation of Indemnification and Advancement of Expenses. The indemnification and advancement of expenses provided by, or
granted pursuant to, this Article VI shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased
to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.
Section
6.14. Conflicts. No indemnification or advance shall be made under this Article VI, except where such indemnification or advance
is mandated by law or the order, judgment or decree of any court of competent jurisdiction, in any circumstance where it appears:
|
(a) |
That
it would be inconsistent with a provision of the Charter, these Bylaws, a resolution of the stockholders or an agreement in effect
at the time of the accrual of the alleged cause of the action asserted in the proceeding in which the expenses were incurred or other
amounts were paid, which prohibits or otherwise limits indemnification; or |
|
|
|
|
(b) |
That
it would be inconsistent with any condition expressly imposed by a court in approving a settlement. |
Section
6.15. Amendment or Repeal. Any repeal or modification of the foregoing provisions of this Article VI shall not adversely affect any
right or protection (a) hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification
or (b) under any agreement providing for indemnification or advancement of expenses to an officer or director of the Corporation in effect
prior to the time of such repeal or modification.
Article
VII. General Matters.
Section
7.1. Stock Certificates; Partly Paid Shares. Shares of the Corporation’s stock may be certified or uncertified, as provided
under Delaware law, and shall be entered in the books of the Corporation and registered as they are issued. Every holder of stock represented
by certificates shall entitled to have a certificate signed by, or in the name of, the Corporation by any two authorized officers of
the Corporation (it being understood that each of the Chairperson of the Board, vice chairperson of the Board or the Chief Executive
Officer, President, a Vice President, the Chief Financial Officer, an assistant treasurer, the Secretary, or an assistant secretary of
the Corporation shall be an authorized officer for such purpose), representing the number of shares and the class or series of shares
owned by the stockholder. Any or all of the signatures on the certificate may be a facsimile or electronic (e.g., PDF) signature.
In case any officer, transfer agent or registrar who has signed or whose facsimile or electronic signature has been placed upon a certificate
has ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued by the Corporation with
the same effect as if such person were such officer, transfer agent, or registrar at the date of issue.
The
Corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to
be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, upon the books and
records of the Corporation in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor
and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the Corporation shall declare
a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.
Section
7.2. Lost Certificates. Except as provided in this Section 7.2, no new certificates for shares shall be issued to replace a previously
issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new
certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen
or destroyed upon the making of an affidavit of that fact by the person claiming the certificate to be lost, stolen or destroyed, and
the Corporation may require the owner of the lost, stolen or destroyed certificate, or their legal representative, to give the Corporation
a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft, or destruction
of any such certificate or the issuance of such new certificate or uncertificated shares.
Section
7.3. Construction; Definitions. Unless the context requires otherwise, the general provisions, rules of construction, and definitions
in the DGCL shall govern the construction of these Bylaws. Without limiting the generality of this provision, the singular number includes
the plural, the plural number includes the singular, and the term “person” includes both a corporation and a natural person.
Section
7.4. Dividends. The Board of Directors may declare dividends upon the capital stock of the Corporation, subject to the provisions
of the Charter and the laws of the State of Delaware.
Section
7.5. Fiscal Year. The fiscal year of the Corporation shall be fixed by resolution of the Board and may be changed by the Board.
Section
7.6. Seal. The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board, and may use
the same by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.
Section
7.7. Registered Stockholders. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books
as the owner of shares to receive dividends and to vote as such owner, shall be entitled to hold liable for calls and assessments the
person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest
in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise
provided by the laws of the State of Delaware.
Section
7.8. Conflicts with Charter. In the event of any conflict between the provisions of the Corporation’s Charter and these Bylaws,
the provisions of the Charter shall govern.
Article
VIII. Amendments.
Except
as provided in the Certificate of Incorporation and consistent therewith, or as provided otherwise by law, these Bylaws may be adopted,
amended, altered, or repealed by either (a) the affirmative vote of at least a majority of the directors then in office, without any
action on the part of the stockholders, or (b) the affirmative vote of at least a majority of the voting power of all of the then-outstanding
shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class,
at any annual or special meeting of stockholders, provided that such proposed action shall be stated in the notice of such meeting.
Adopted:
February 14, 2024 |
|
Exhibit
4.2
THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT
WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933.
CONVERTIBLE
PROMISSORY NOTE
$10,000,000 |
January
22, 2021 (the “Issue Date”) |
CPN-1 |
Metuchen,
New Jersey |
For
value received TEVOGEN BIO INC, a Delaware corporation having its office at 48 Bridge Street, Metuchen, NJ 08840 (the “Company”)
promises to pay to HMP Partners, LLC, or its assigns, with an address of 5 Jennie Ct, Cedar Grove, NJ, 07009 (the “Holder”)
the principal sum of $10,000,000 with simple interest on the outstanding principal amount at the rate of six percent (6.0%) per annum.
Simple interest shall commence on the Issue Date and shall continue on the outstanding principal until paid in full or converted in accordance
with this note (this “Note”). Interest shall be computed on the basis of a year of three hundred sixty-five (365)
days for the actual number of days elapsed. This Note is subject to the following terms and conditions:
1.
Maturity.
(a)
Repayment. Unless converted or repaid (as applicable) as provided in Sections 1(b), 2, 3, 5 or 6,
all outstanding principal and any accrued but unpaid interest under this Note (the “Conversion Amount”) shall be due
and payable upon demand of the Holder any time on or after January 22, 2024 (the “Maturity Date”).
(b)
Conversion upon Maturity. In the event that neither a Qualified Financing nor a Change of Control (each as defined below) has been
consummated on or before the Maturity Date, the Holder may, upon written notice to the Company at least five (5) days prior to the Maturity
Date, effective upon the Maturity Date, elect to convert the Notes and the Conversion Amount with respect to each Note into shares of
the Company’s Common Stock, $0.01 par value per share (“Common Stock”), at a price per share equal to three
(3) times the fair market value of a share of the Company’s Common Stock, as set forth in the Company’s most recent 409A
valuation determined by an independent third party valuation firm, or, if no such valuation has been completed, as determined by the
Board.
2.
Conversion upon a Qualified Financing.
(a)
Automatic Conversion. Concurrently with the closing of a Qualified Financing (as defined below), this Note and the Conversion
Amount shall be automatically converted into the same class and series of convertible preferred stock, with the same rights,
preferences, powers privileges and restrictions, qualifications and limitations, as issued and sold in the Qualified Financing to
other investors (the “Next Equity Securities”). “Qualified Financing” means the first issuance
of shares of convertible preferred stock by the Company following the date hereof in a single transaction or a series of related
transactions primarily for capital raising purposes resulting in aggregate gross sale proceeds to the Company of at least
$25,000,000 (excluding conversion of the Notes and any other convertible notes or such other convertible securities issued by the
Company and then outstanding that convert in connection with such a Qualified Financing), and with a price per share set based on
agreement with one or more unaffiliated third party investors in such financing; provided, that any such third party investor
setting the price per share may be the Holder and the Note held by the Holder shall not be considered in determining such
affiliation status.
(b)
Terms of Conversion.
(i)
Upon conversion of this Note pursuant to this Section 2, the total number of shares of Next Equity Securities to be issued to
the Holder shall be equal to the quotient obtained by dividing the Conversion Amount by the Conversion Price, rounded down to the nearest
whole share. The “Conversion Price” means a price per share equal to the lesser of (x) eighty percent (80.0%) of the
Qualified Financing Price Per Share, and (y) the price per share as calculated by dividing $200,000,000.00 by the number of shares used
to calculate the price per share of the Next Equity Securities (other than shares included in such calculation to reflect conversion
of this Note). The term “Qualified Financing Price Per Share” means the price per share paid for each share of the
Next Equity Securities purchased by the investors in the Qualified Financing (other than through the conversion of any of the Notes or
any other convertible notes or such other convertible securities issued by the Company that will convert in connection with the Qualified
Financing). Provided that the maximum number of shares issuable upon such conversion shall not exceed 7% of the total issued and outstanding
shares of the Company, as calculated immediately prior to the issuance of Next Equity Securities purchased in the Qualified Financing.
(ii)
Upon the conversion of this Note pursuant to this Section 2, the Holder hereby agrees to execute and deliver to the Company all
transaction documents related to the Qualified Financing, including a purchase agreement and other ancillary agreements, with customary
representations and warranties and transfer restrictions (including a lock-up agreement in connection with a potential future public
offering by the Company). The Holder agrees to execute all such agreements in connection with the conversion so long as the issuance
of shares of the Company’s capital stock issued pursuant to the conversion of this Note are subject to the same terms and conditions
applicable to the shares of capital stock sold in such Qualified Financing. The issuance of Next Equity Securities upon such conversion
shall be upon the terms and subject to the conditions applicable to the Qualified Financing and the Company’s Articles of Incorporation
and Bylaws and such other corporate governing documents.
3.
Change of Control. In the event of a Change of Control (as defined below) prior to repayment of this Note in full pursuant to
Sections 1(a), 5 or 6 or conversion of this Note pursuant to Sections 1(b) or 2, (a) the Company shall
give written notice to the Holder of such Change of Control at least five (5) days prior to the anticipated closing date of such Change
of Control and (b) immediately prior to such Change of Control, an amount in cash equal to the greater of (x) one hundred fifty percent
(150%) of the Conversion Amount and (y) the amount the Holder would receive pursuant to such Change of Control had the Conversion Amount
converted into shares of Common Stock pursuant to Section 1(b) immediately prior to such Change of Control shall become immediately
due and payable immediately prior to the closing of such Change of Control, senior in preference to any payment in respect of any equity
of the Company, in full satisfaction of the Company’s obligations under this Note and in lieu of the repayment of this Note pursuant
to Section 1(a). The parties agree that for purposes of calculating original issue discount under this debt instrument, it shall
be assumed that no payments will be due under this Section 3. The term “Change of Control” means (i) any merger
or consolidation to which the Company is a party (except any merger or consolidation in which the holders of capital stock of the Company
immediately prior to such merger or consolidation continue to hold, immediately following such merger or consolidation and in approximately
the same relative proportions as they held voting stock of the Company, at least fifty-one percent (51%) of the voting power of the capital
stock of (A) the surviving or resulting corporation or (B) if the surviving or resulting corporation is a wholly-owned subsidiary of
another corporation immediately following such merger or consolidation, of the parent corporation of such surviving or resulting corporation),
(ii) the sale by the stockholders of the Company, in a single transaction or series of related transactions, of capital stock representing
at least seventy-five percent (75%) of the outstanding voting power of the Company, or (iii) the sale, transfer, lease, exclusive license
or exclusive sublicense, or other disposition, in a single transaction or a series of related transactions, of all or substantially all
of the assets of the Company; provided that a bona fide third party equity financing primarily for capital raising purposes shall
not be deemed to be a Change of Control.
4.
Mechanics and Effect of Conversion.
(a)
Effectiveness of Conversion. Upon conversion of this Note, the Company will be forever released from all of its obligations and liabilities
under this Note with regard to that portion of the principal amount and accrued interest being converted, including without limitation
the obligation to pay such portion of the principal amount and accrued interest. Any interest accrued on this Note, including with respect
to the payment for fractional shares pursuant to Section 4(c), that is not simultaneously converted into such equity securities
by reason of such conversion shall be paid by the Company to the Holder at the time of such conversion. Upon conversion of this Note,
the Company shall take all such actions as are necessary in order to ensure that the capital stock issuable with respect to such conversion
shall be validly issued, fully paid and nonassessable.
(b)
Issuance of Certificates. Upon conversion of this Note, the Holder shall surrender this Note, duly endorsed, at the principal offices
of the Company or any transfer agent of the Company. At its expense, the Company shall, as soon as practicable thereafter, issue and
deliver to such Holder, at such principal office, a certificate or certificates for the number of shares to which such Holder is entitled
upon such conversion, together with any other securities and property to which the Holder is entitled upon such conversion under the
terms of this Note, including a check payable to the Holder for any cash amounts payable as described herein.
(c)
Fractional Shares. No fractional shares of the Company’s capital stock will be issued upon conversion of this Note. If any
fractional share of capital stock would, except for the provisions hereof, be deliverable upon conversion of this Note, the Company,
in lieu of delivering such fractional share, shall pay an amount equal to the value of such fractional share, as determined by the per
share conversion price used to effect such conversion.
(d)
Reservation of Stock Issuable Upon Conversion. Immediately prior to any conversion of this Note into shares of Common Stock or Next
Equity Securities, as applicable, the Company shall use best efforts to at all times thereafter reserve and keep available out of its
authorized but unissued shares of Common Stock or Next Equity Securities, as applicable, solely for purposes of effecting the conversion
of this Note such number of shares of Next Equity Securities and Common Stock, as applicable, as shall from time to time be sufficient
to effect the conversion of this Note.
5.
Events of Default; Remedies.
(a)
Events of Default. Each of the following shall constitute an event of default (an “Event of Default”) under the
Note: (i) the Company fails to pay any and all unpaid principal, accrued interest and all other amounts owing under the Note when due
and payable pursuant to the terms of the Note; (ii) the Company files any petition or action for relief under any bankruptcy, reorganization,
insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any general
assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing; (iii) an involuntary petition
is filed against the Company (unless such petition is dismissed or discharged within sixty (60) days) under any bankruptcy statute now
or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed
to take possession, custody or control of any property of the Company; (iv) the Company breaches any material term of the Note (unless
such material breach is cured within twenty (20) days of notice to the Company of such breach); or (v) a default by the Company under
any other indebtedness for borrowed money with an aggregate principal amount then outstanding in excess of $1,000,000 that results in
the acceleration of payment of such indebtedness such that all principal and unpaid accrued interest becomes due and payable.
(b)
Remedies. Subject to the provisions hereof, the Holder shall have all rights and may exercise any remedies available to it under
law, successively or concurrently. If there shall be any Event of Default, this Note shall accelerate and all outstanding principal and
unpaid accrued interest shall become due and payable (i) with respect to an Event of Default under Sections 5(a)(i) or 5(a)(iv)
above, automatically and immediately following the declaration of such Event of Default by the Holder in a written notice to the
Company, or (ii) with respect to an Event of Default under Sections 5(a)(ii), 5(a)(iii) or 5(a)(v), automatically
and immediately upon the occurrence of such Event of Default. From and after the date set forth in clause (i) or (ii) above, as applicable,
until the date this Note is repaid or converted in full, the outstanding principal amount shall bear interest at a rate of ten percent
(10%) per annum.
6.
Payment; Prepayment. All payments shall be made in lawful money of the United States of America at such place as the Holder hereof
may from time to time designate in writing to the Company. Payment shall be credited first to the accrued interest then due and payable
and the remainder shall be applied to principal. The Company may prepay this Note only with the written consent of the Holder.
7.
Updates. From the Issue Date of this Note to the Holder, until the earlier of the closing of the Qualified Financing or the consummation
of a Change of Control, the Company shall, upon the request of the Holder made no more frequently than once per calendar quarter, provide
the Holder with a high-level oral update on the status of the Company’s affairs, finances and accounts; provided, however,
that the Company shall not be obligated pursuant to this Section 7 to provide access to any information that it reasonably and
in good faith, after consultation with its legal counsel and advisors, considers to be a trade secret or confidential information (unless
covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect
the attorney-client privilege between the Company and its counsel.
8.
Representations and Warranties of the Company. By issuance and delivery of this Note, the Company hereby represents and warrants
to the Holder as follows:
(a)
The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company
has all requisite legal and corporate power and authority to execute and deliver this Note and to carry out and perform its obligations
under the terms of this Note.
(b)
Neither the execution nor delivery of this Note, nor the compliance with the terms of this Note, will conflict with or result in
the breach of under the terms, conditions or provisions of, or constitute a default under, the Certificate of Incorporation or Bylaws
of the Company or of any material agreement or instrument to which the Company is now a party.
(c)
This Note has been duly executed and delivered by the Company.
(d)
The Company has exercised reasonable care, in accordance with Securities and Exchange Commission rules and guidance, to determine
whether any Covered Person (as defined below) is subject to any of the “bad actor” disqualifications described in Rule 506(d)(1)(i)
through (viii) under the Securities Act of 1933, as amended (the “Act”) (“Disqualification Events”).
To the Company’s knowledge, no Covered Person is subject to a Disqualification Event, except for a Disqualification Event covered
by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has complied, to the extent applicable, with any disclosure obligations
under Rule 506(e) under the Securities Act. “Covered Persons” are those persons specified in the first paragraph of
Rule 506(d)(1) under the Securities Act, including the Company; any predecessor or affiliate of the Company; any director, executive
officer, other officer participating in the offering, general partner or managing member of the Company; any beneficial owner of 20%
or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power; any promoter (as defined
in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of the sale of this Note; and any person
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of this
Note (a “Solicitor”), any general partner or managing member of any Solicitor, and any director, executive officer
or other officer participating in the offering of any Solicitor or general partner or managing member of any Solicitor.
9.
Representations and Warranties of the Holder. By acceptance of this Note, the Holder hereby represents and warrants to the Company
as follows:
(a)
The Holder has been advised that this Note, the shares of the Company’s capital stock issuable upon the conversion of this
Note (the “Conversion Securities”) and the shares of the Company’s capital stock issuable upon the conversion
of such Conversion Securities (collectively, the “Securities”) have not been registered under the Act, or any state
securities laws and, therefore, cannot be resold unless they are registered under the Act and applicable state securities laws or unless
an exemption from such registration requirements is available. The Holder is aware that the Company is under no obligation to effect
any such registration with respect to the Securities or to file for or comply with any exemption from registration. The Holder further
acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including,
but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which
are outside of the Holder’s control, and which the Company is under no obligation and may not be able to satisfy. The Holder understands
that no public market now exists for the Securities, and that the Company has made no assurances that a public market will ever exist
for the Securities. The Holder has not been formed solely for the purpose of making this investment and the Securities will be acquired
by the Holder hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection
with, the distribution thereof, and the Holder has no present intention of selling, granting any participation in, or otherwise distributing
the same. The Holder has such knowledge and experience in financial and business matters that the Holder is capable of evaluating the
merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Holder’s financial
condition and is able to bear the economic risk of such investment for an indefinite period of time. Neither the Holder, nor any of its
officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder
(i) engaged in any general solicitation, or (ii) published any advertisement in connection with the offer and sale of the Securities.
The Holder is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities Act. The Holder has furnished
or made available any and all information requested by the Company or otherwise necessary to satisfy any applicable verification requirements
as to accredited investor status. Any such information is true, correct, timely and complete. The residency of the Holder (or, in the
case of a partnership or corporation, such entity’s principal place of business) is correctly set forth on the Holder’s signature
page hereto.
(b)
The Holder acknowledges that the Company has given the Holder an opportunity to discuss the Company’s business, management,
financial affairs and the terms and conditions of the offering of this Note with the Company’s management.
(c)
The Holder has reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax consequences of this investment
and the transactions contemplated by this Note. With respect to such matters, the Holder relies solely on any such advisors and not on
any statements or representations of the Company or any of its agents, written or oral. The Holder understands that it (and not the Company)
shall be responsible for its own tax liability that may arise as a result of this investment and the transactions contemplated by this
Agreement.
(d)
None of (i) the Holder or (ii) to its knowledge, any of its directors, executive officers, other officers that may serve as a director
or officer of any company in which it invests, general partners or managing members, is subject to any Disqualification Event (as defined
in Section 2(p)), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Securities Act and disclosed
reasonably in advance of the date of this Note in writing in reasonable detail to the Company.
10.
Confidentiality. The Holder agrees that it will keep confidential and will not disclose, divulge, or use for any purpose (other than
to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Note,
unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Section 10 by the Holder), (b) is or has been independently developed or conceived by the Holder without use of the Company’s
confidential information, or (c) is or has been made known or disclosed to the Holder by a third party without a breach of any obligation
of confidentiality such third party may have to the Company; provided, however, that the Holder may disclose confidential information
(i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection
with monitoring its investment in the Company; or (ii) as may otherwise be required by law, regulation, rule, court order or subpoena,
provided that the Holder promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such
required disclosure.
11.
Transfer; Successors and Assigns. The terms and conditions of this Note shall inure to the benefit of and be binding upon the respective
successors and assigns of the Company and the Holder. Notwithstanding the foregoing, and except with respect to a transfer of this Note
by the Holder to the Holder’s affiliates (for which no consent shall be required), the Holder may not assign, pledge or otherwise
transfer this Note without the prior written consent of the Company. Subject to the preceding sentence, this Note may be transferred
only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument
of transfer in form satisfactory to the Company. Thereupon, a new note for the same principal amount and interest will be issued to,
and registered in the name of, the transferee. Interest and principal are payable only to the registered holder of this Note.
12.
Governing Law. This Note and all acts and transactions pursuant hereto and the rights and obligations of the Company and the Holder
shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles
of conflicts of law.
13.
Notices. Any notice required or permitted by this Note shall be in writing and shall be deemed sufficient when delivered personally
or by overnight courier or sent by email or fax (upon customary confirmation of receipt), or forty-eight (48) hours after being deposited
in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party’s address
or fax number as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature
page, at the most recent address set forth in the Company’s books and records.
14.
Amendments and Waivers. Any term of this Note may be amended or waived only with the written consent of the Company and the Holder.
Any amendment or waiver effected in accordance with this Section 14 shall be binding upon the Company, the Holder and each permitted
transferee of this Note.
12.
Entire Agreement. This Note is the entire agreement between the Company and the Holder pertaining to the subject matter hereof, and
any and all other written or oral agreements existing between the Company and the Holder are expressly canceled.
13.
Counterparts. This Note may be executed in any number of counterparts, each of which will be deemed to be an original and all of
which together will constitute a single agreement.
14.
Action to Collect on Note. If action is instituted to collect on this Note, the Company promises to pay all costs and expenses, including
reasonable attorney’s fees, incurred in connection with such action.
15.
Stockholders, Officers and Directors Not Liable. In no event shall any, stockholder, officer or director of the Company be liable
for any amounts due or payable pursuant to this Note.
16.
Loss of Note. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Note
or any Note exchanged for it, and indemnity satisfactory to the Company (in case of loss, theft or destruction) or surrender and cancellation
of such Note (in the case of mutilation), the Company will make and deliver, in lieu of such Note, a new Note of like tenor.
17.
Interest Rate Limitation. Notwithstanding anything to the contrary contained in this Note, the interest paid or agreed to be paid
under this Note shall not exceed the maximum rate of non-usurious interest permitted by applicable law (the “Maximum Rate”).
If the Holder shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal
remaining owed under this Note or, if it exceeds such unpaid principal, refunded to the Company. In determining whether the interest
contracted for, charged, or received by the Holder exceeds the Maximum Rate, the Holder may, to the extent permitted by applicable law,
(i) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (ii) exclude voluntary prepayments
and the effects thereof, and (iii) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout
the contemplated term of this Note.
18.
No Rights as a Stockholder. Until the conversion of this Note, the Holder shall not have or exercise any rights as a stockholder
of the Company.
[Remainder
of Page Intentionally Left Blank]
IN
WITNESS WHEREOF, the parties have caused this Convertible Promissory Note to be executed as of the date first above written.
|
|
TEVOGEN
BIO INC |
|
|
|
|
By: |
/s/
Kirti Desai |
|
Name: |
Kirti
Desai, CPA |
|
Title: |
CFO |
Acknowledged
and Agreed:
HMP
Partners, LLC |
|
|
|
|
By: |
/s/
Manmohan Patel |
|
Name: |
Manmohan
Patel, MD |
|
Title: |
CEO |
|
September
12, 2023
HMP
Partners, LLC
5
Jennie Ct.
Cedar
Grove, NJ 07009
Dear
Manmohan Patel,
Reference
is made to that certain Convertible Promissory Note (the “Existing Note”) dated January 22, 2021, made by Tevogen
Bio Inc (the “Company”) in favor of HMP Partners, LLC (the “Holder,” and, together with the Company,
the “Parties”).
This
letter agreement to amend the Existing Note (this “Amendment”) is entered into between the Company and the Holder
as of the date first written above and hereby amends the Existing Note. Capitalized terms used but not defined herein shall have the
meaning ascribed to them in the Existing Note. The Parties acknowledge and agree that the terms, conditions, agreements, and understandings
described in this Amendment shall be binding solely between the Parties and solely with respect to the Existing Note. Under the terms
of this Amendment, the Parties hereby agree to amend the Existing Note as follows:
|
A. |
A
new Section 22 shall be added to the Existing Note and shall read as set forth below: |
|
22. |
SPAC
Transaction. Notwithstanding anything to the contrary in this Note: |
(a)
this Note shall convert as of immediately following the consummation of any SPAC Transaction (as defined below) into the number of shares
of the special purpose acquisition company (the “SPAC”) that is a counterparty to the Company or its stockholders
in the SPAC Transaction equal to (x) the quotient obtained by dividing the Conversion Amount by the Conversion Price, multiplied by (y)
the number of shares of capital stock of the SPAC for which each Pre-Closing Issued and Outstanding Share is exchanged in the SPAC Transaction;
(b)
“SPAC Transaction” means a transaction or series of related transactions whereby the Company merges with or into,
or otherwise combines with, a publicly listed SPAC or a subsidiary thereof and the Pre-Closing Issued and Outstanding Shares are exchanged
for shares of capital stock of the SPAC;
(c)
with respect to a SPAC Transaction, “Conversion Price” means a price per share equal to the lesser of (x) 80% of the
SPAC Price Per Share and (y) the price per share calculated by dividing $200,000,000 by the number of Pre-Closing Issued and Outstanding
Shares;
(d)
the “SPAC Price Per Share” means the quotient obtained by dividing the enterprise value attributable to the Pre-Closing
Issued and Outstanding Shares in the SPAC Transaction (assuming for the avoidance of doubt that no contingent payments will be received
in the SPAC Transaction), as determined by the Board of Directors of the Company in good faith, by the Pre-Closing Issued and Outstanding
Shares; and
(e)
the “Pre-Closing Issued and Outstanding Shares” means the shares of voting and non-voting common stock of the Company
outstanding as of immediately prior to the consummation of the SPAC Transaction.
This
Amendment and the Existing Note constitute the entire agreement between the Company and the Holder pertaining to the subject matter hereof,
and any and all other written or oral agreements existing between the Company and the Holder pertaining to the subject matter hereof
are expressly canceled. This Amendment may be amended or waived only with the written consent of the Company and the Holder. Sections
10 (Confidentiality), 12 (Governing Law), and 13 (Notices) are incorporated herein by reference.
[Signature
Page Follows]
|
|
TEVOGEN
BIO INC. |
|
|
|
|
By: |
/s/
Kirti Desai |
|
Name: |
Kirti Desai |
|
Title: |
Chief Financial Officer |
Acknowledged
and Agreed:
HMP
PARTNERS, LLC |
|
|
|
|
By: |
/s/
Manmohan Patel |
|
Name: |
Manmohan
Patel, MD |
|
Title: |
CEO |
|
[Signature
Page to Convertible Note Amendment Letter Agreement]
BY
EMAIL
January
25, 2024
Dr.
Manmohan Patel
HMP
Partners, LLC
5
Jennie Court
Cedar
Grove, New Jersey 07009
mopatel1002@gmail.com
|
Re:
January 22, 2021 Convertible Promissory Note Amendment |
Dear
Dr. Patel,
Reference
is made to that certain Convertible Promissory Note dated January 22, 2021, as previously amended (the “Existing Note”),
made by Tevogen Bio Inc (the “Company”) in favor of HMP Partners, LLC (the “Holder” and, together
with the Company, the “Parties”). This letter agreement to amend the Existing Note (this “Amendment”)
is entered into between the Company and the Holder as of the date first written above.
The
Parties hereby amend the Existing Note to change the definition of “Maturity Date” as defined in Section 1(a) of the
Existing Note to mean July 22, 2024.
The
Existing Note, as amended by this Amendment, constitute the entire agreement between the Company and the Holder pertaining to the subject
matter hereof and thereof, and any and all other written or oral agreements existing between the Company and the Holder pertaining to
the subject matter hereof or thereof are expressly canceled. This Amendment may be amended or waived only with the written consent of
the Company and the Holder. Sections 10 (Confidentiality), 12 (Governing Law), and 13 (Notices) are incorporated herein by reference.
If
you agree with the terms and conditions of this Amendment, please sign below to evidence such acknowledgement and agreement to its terms.
Sincerely,
|
TEVOGEN
BIO INC |
|
|
|
|
By: |
/s/
Ryan Saadi |
|
Name: |
Dr.
Ryan Saadi |
|
Title: |
Chief
Executive Officer and Chairperson |
Acknowledged
and Agreed:
HMP
PARTNERS, LLC |
|
|
|
|
By: |
/s/
Manmohan Patel |
|
Name: |
Manmohan
Patel, MD |
|
Title: |
CEO |
|
Exhibit
10.4
AMENDED
AND RESTATED
REGISTRATION
RIGHTS AGREEMENT
THIS
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February
14, 2024 (the “Effective Date”) by and among (i) Tevogen Bio Holdings, Inc., a Delaware corporation (formerly known
as Semper Paratus Acquisition Corporation) (the “Company”), (ii) SSVK Associates, LLC, a Delaware limited liability
company (the “Sponsor”), (iii) Semper Paratus Sponsor LLC, a Delaware limited liability company (the “Original
Sponsor”), (iv) each of the undersigned parties listed on Schedule 1-A attached hereto (collectively, the “Company
Holders”); (v) each of the parties listed on Schedule 1-B attached hereto (collectively, the “Sponsor Holders”);
(vi) Cantor Fitzgerald & Co. (“Cantor”) and (vii) any person or entity who hereafter becomes a party to this Agreement
pursuant to Section 3.11 of this Agreement (together with the Sponsor, the Original Sponsor, the Company Holders, the Sponsor
Holders, and Cantor, at all times when such parties hold Registrable Securities (as defined below), the “Holders”
and each, a “Holder” and may be referred to herein as a “Party” and collectively as the “Parties”).
Capitalized terms used but not otherwise defined herein shall have the respective meanings set forth in the BCA (as defined below).
RECITALS
WHEREAS,
the Company, Merger Sub, and Tevogen Bio Inc, a Delaware corporation (“Tevogen”), have entered into that certain Agreement
and Plan of Merger, dated as of June 28, 2023 (as it may be amended, supplemented or restated from time to time in accordance with the
terms of such agreement, the “BCA”), pursuant to which Merger Sub is merging with and into Tevogen, with Tevogen as
the surviving company;
WHEREAS,
on November 3, 2021, the Company entered into a Registration and Shareholder Rights Agreement with the Original Sponsor and Cantor (the
“Original RRA”);
WHEREAS,
on June 7, 2023, upon the closing of the May 4, 2023 Purchase Agreement between the Company, the Original Sponsor, and the Sponsor, the
Sponsor acquired certain shares of capital stock of the Company from the Original Sponsor (the “Transferred Shares”)
and assumed certain obligations of the Original Sponsor;
WHEREAS,
the Original Sponsor has effectively assigned to the Sponsor its rights and obligations under the Original RRA with respect to the Transferred
Shares;
WHEREAS,
as a condition to the consummation of the transactions contemplated by the BCA, the Company, Cantor, the Original Sponsor, and the Sponsor
desire to amend and restate the Original RRA in the form of this Agreement; and
WHEREAS,
on the Effective Date, the Parties desire to set forth their agreement with respect to registration rights in accordance with the terms
and conditions of this Agreement.
NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained in this Agreement, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows:
Article
I
DEFINITIONS
1.1
Definitions. As used in this Agreement, the following
terms shall have the following meanings:
“Additional
Holder” has the meaning set forth in Section 3.11.
“Additional
Holder Common Stock” has the meaning set forth in Section 3.11.
“Adverse
Disclosure” means any public disclosure of material non-public information, which disclosure, in the good faith determination
of the board of directors of the Company, after consultation with counsel to the Company, (a) would be required to be made in any Registration
Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements contained therein (in the case of any Prospectus and any preliminary
Prospectus, in the light of the circumstances under which they were made) not misleading, (b) would not be required to be made at such
time if the Registration Statement were not being filed, declared effective or used, as the case may be, and (c) the Company has a bona
fide business purpose for not making such information public.
“Affiliate”
of any particular Person means any other Person controlling, controlled by or under common control with such Person, where “control”
means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership
of voting securities, its capacity as a sole or managing member or otherwise.
“Agreement”
has the meaning set forth in the Preamble.
“Automatic
Shelf Registration Statement” has the meaning set forth in Rule 405 promulgated by the SEC pursuant to the Securities Act.
“BCA”
has the meaning set forth in the Recitals.
“Beneficially
Own” has the meaning set forth in Rule 13d-3 promulgated under the Exchange Act.
“Common
Stock” means the common stock, par value $0.001 per share of the Company.
“Company”
has the meaning set forth in the Preamble.
“Company
Holder” has the meaning set forth in the Preamble.
“Confidential
Information” means any confidential, non-public information of the Company or its subsidiaries.
“Demanding
Holders” has the meaning set forth in Section 2.1(c).
“Effective
Date” has the meaning set forth in the Preamble.
“Equity
Securities” means, with respect to any Person, all of the shares of capital stock or equity of (or other ownership or profit
interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of
capital stock or equity of (or other ownership or profit interests in) such Person, all of the securities convertible into or exchangeable
for shares of capital stock or equity of (or other ownership or profit interests in) such Person or warrants, rights or options for the
purchase or acquisition from such Person of such shares or equity (or such other interests), restricted stock awards, restricted stock
units, equity appreciation rights, phantom equity rights, profit participation and all of the other ownership or profit interests of
such Person (including partnership or member interests therein), whether voting or nonvoting.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and any successor thereto, as the same shall be in effect from
time to time.
“FINRA”
means the Financial Industry Regulatory Authority, Inc.
“Form
S-1 Shelf” has the meaning set forth in Section 2.1(a).
“Form
S-3 Shelf” means a Shelf Registration on Form S-3 or any similar short-form registration.
“Holder”
has the meaning set forth in the Preamble and includes any holder of Registrable Securities who is or becomes a Party to, or who succeeds
to rights under this Agreement pursuant to Section 3.1.
“Holder
Information” has the meaning set forth in Section 2.10(b).
“Joinder”
has the meaning set forth in Section 3.1(b).
“Lock-Up
Period” means the period during which a Holder is prohibited from selling Registrable Securities pursuant to contractual arrangements
with the Company.
“Maximum
Number of Securities” has the meaning set forth in Section 2.1(e).
“Minimum
Takedown Threshold” has the meaning set forth in Section 2.1(c).
“Misstatement”
means an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus, in the light of the circumstances under
which they were made, not misleading.
“Original
RRA” has the meaning set forth in the Recitals.
“Party”
has the meaning set forth in the Preamble.
“Potential
Takedown Participant” has the meaning set forth in Section 2.1(d).
“Private
Placement Warrants” means each one warrant of the Company entitling the holder thereof to purchase one share of Common Stock
in accordance with terms described in the final prospectus for the Company’s initial public offering with respect to the private
warrants of the Company.
“Prospectus”
means the prospectus included in any Registration Statement, all amendments (including post-effective amendments) and supplements to
such prospectus, and all material incorporated by reference in such prospectus.
“Registrable
Securities” means (i) any Common Stock held by the Holders immediately following the closing of the Business Combination, (ii)
the Private Placement Warrants held by the Holders immediately following the closing of the Business Combination and any Common Stock
issued or issuable upon the exercise of any such Private Placement Warrants, (iii) any Common Stock issued or issuable upon the exercise
of Rollover RSUs held by the Holders immediately following the closing of the Business Combination, and (iv) any Common Stock that may
be issued or issuable with respect to any of the foregoing by way of conversion, dividend, stock split, combination, distribution, consolidation,
exchange, recapitalization, reclassification, or similar event, in each case held by a Holder; provided, however, that
any such Registrable Securities shall cease to be Registrable Securities to the extent (A) a Registration Statement with respect to the
sale of such Registrable Securities has become effective under the Securities Act and such Registrable Securities have been sold, transferred,
disposed of or exchanged in accordance with the plan of distribution set forth in such Registration Statement, (B) such Registrable Securities
shall have ceased to be issuable or outstanding, (C) such Registrable Securities have been sold to, or through, a broker, dealer or underwriter
in a public distribution or other public securities transaction, (D) such Registrable Securities shall have been otherwise transferred,
new certificates for them not bearing a legend restricting further transfer shall have been delivered by Company and subsequent public
distribution of them shall not require registration under the Securities Act or (E) such Common Stock is eligible for resale without
any volume restrictions pursuant to Rule 144.
“Registration”
means a registration, including any related Shelf Takedown, effected by preparing and filing a registration statement, prospectus or
similar document in compliance with the requirements of the Securities Act, and such registration statement becoming effective.
“Registration
Expenses” means the expenses of a Registration pursuant to the terms of this Agreement, including the following:
(a)
all SEC or securities exchange registration and filing fees (including fees with respect to filings required to be made with FINRA);
(b)
all fees and expenses of compliance with securities or blue sky Laws (including fees and disbursements of counsel for the Underwriters
in connection with blue sky qualifications of Registrable Securities);
(c)
all printing, messenger, telephone and delivery expenses;
(d)
all fees and disbursements of counsel for the Company;
(e)
all fees and disbursements of all independent registered public accountants of the Company incurred in connection with such Registration,
including the expenses of any special audits and/or comfort letters required or incident to such performance and compliance;
(f)
reasonable and documented out-of-pocket fees and expenses of (a) one (1) U.S. legal counsel and (b) local counsel in any other applicable
jurisdiction(s), in each case selected by the majority-in-interest of the Demanding Holders; and
(g)
the costs and expenses of the Company relating to analyst and investor presentations or any “road show” undertaken in connection
with the Registration and/or marketing of the Registrable Securities; and
(h)
any other fees and disbursements incident to the Company’s performance of or compliance with this Agreement in connection with
such Registration and customarily paid by the issuers of securities.
“Registration
Statement” means any registration statement that covers the Registrable Securities pursuant to the provisions of this Agreement,
including the Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements to
such registration statement, and all exhibits to and all material incorporated by reference in such registration statement.
“Representatives”
means, with respect to any Person, any of such Person’s officers, directors, managers, members, equityholders, employees, agents,
attorneys, accountants, actuaries, consultants, or financial advisors or other Person acting on behalf of such Person.
“Requesting
Holder” has the meaning set forth in Section 2.1(d).
“SEC”
means the United States Securities and Exchange Commission.
“Securities
Act” means the Securities Act of 1933, as amended, and any successor thereto, as the same shall be in effect from time to time.
“Shelf”
has the meaning set forth in Section 2.1(a).
“Shelf
Registration” means a registration of securities pursuant to a Registration Statement filed with the SEC in accordance
with and pursuant to Rule 415 promulgated under the Securities Act.
“Shelf
Takedown” means an Underwritten Shelf Takedown or any proposed transfer or sale using a Registration Statement.
“Shelf
Takedown Request” has the meaning set forth in Section 2.1(d).
“Special
Holders” means, together, the Sponsor, the Sponsor Holders, the Original Sponsor, and the Company Holders.
“Sponsor”
has the meaning set forth in the Preamble.
“Sponsor
Holders” has the meaning set forth in the Preamble.
“Subsequent
Shelf Registration” has the meaning set forth in Section 2.1(b).
“Transfer”
means, when used as a noun, any voluntary or involuntary transfer, sale, pledge or hypothecation or other disposition by the Transferor
(whether by operation of law or otherwise) and, when used as a verb, the Transferor voluntarily or involuntarily, transfers, sells, pledges
or hypothecates or otherwise disposes of (whether by operation of law or otherwise), including, in each case, (a) the establishment or
increase of a put equivalent position or liquidation with respect to, or decrease of a call equivalent position within the meaning of
Section 16 of the Exchange Act with respect to, any security or (b) entry into any swap or other arrangement that transfers to another
Person, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction is to be settled
by delivery of such securities, in cash or otherwise. The terms “Transferee,” “Transferor,” “Transferred,”
and other forms of the word “Transfer” shall have the correlative meanings.
“Underwriter”
means any investment banker(s) and manager(s) appointed to administer the offering of any Registrable Securities as principal in an Underwritten
Offering.
“Underwritten
Offering” means a Registration in which securities of the Company are sold to an Underwriter for distribution to the public.
“Underwritten
Shelf Takedown” has the meaning set forth in Section 2.1(c).
“Warrant
Agreement” has the meaning set forth in Section 2.10.
“Well-Known
Seasoned Issuer” has the meaning set forth in Rule 405 promulgated by the SEC pursuant to the Securities Act.
“Withdrawal
Notice” has the meaning set forth in Section 2.1(f).
1.2
Interpretive Provisions. For all purposes of
this Agreement, except as otherwise provided in this Agreement or unless the context otherwise requires:
(a)
the singular shall include the plural, and the plural
shall include the singular, unless the context clearly prohibits that construction.
(b)
the words “hereof”, “herein”,
“hereunder” and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to
any particular provision of this Agreement.
(c)
references in this Agreement to any Law shall be deemed
also to refer to such Law, and all rules and regulations promulgated thereunder.
(d)
whenever the words “include”, “includes”
or “including” are used in this Agreement, they shall mean “without limitation.”
(e)
the captions and headings of this Agreement are for
convenience of reference only and shall not affect the interpretation of this Agreement.
(f)
pronouns of any gender or neuter shall include, as appropriate,
the other pronoun forms.
(g)
the word “or” shall be construed to mean
“and/or” and the words “neither,” “nor,” “any,” “either” and “or”
shall not be exclusive, unless the context clearly prohibits that construction.
Article
II
REGISTRATION
RIGHTS
2.1
Shelf Registration.
(a)
Filing. The Company shall file, as promptly as
reasonably practicable, but in no event later than sixty (60) days after the Closing Date, a Registration Statement for a Shelf Registration
on Form S-1, or any similar long-form registration (the “Form S-1 Shelf,” and, together with any Subsequent Shelf
Registration, the “Shelf”), in each case, covering the resale of all Registrable Securities (determined as of two
(2) Business Days prior to such filing) on a delayed or continuous basis. The Company shall use its commercially reasonable efforts to
cause the Shelf to become effective as promptly as reasonably practicable after such filing, but in no event later than sixty (60) days
after the initial filing thereof, which shall be extended to one hundred twenty (120) days after the initial filing thereof if the Registration
Statement is reviewed by, and comments thereto are provided from, the SEC. The Shelf shall provide for the resale of the Registrable
Securities included therein pursuant to any method or combination of methods legally available to, and reasonably requested by, any Special
Holder. The Company shall use commercially reasonable efforts to maintain the Shelf in accordance with the terms of this Agreement, and
to prepare and file with the SEC such amendments, including post-effective amendments, and supplements as may be necessary to keep such
Shelf, continuously effective, available for use and in compliance with the provisions of the Securities Act until such time as there
are no longer any Registrable Securities. The Company shall use its commercially reasonable efforts to convert the Form S-1 Shelf (and
any Subsequent Shelf Registration) to a Form S-3 Shelf as promptly as reasonably practicable after the Company is eligible to use Form
S-3 or any similar short-form registration.
(b)
Subsequent Shelf Registration. If the Shelf ceases
to be effective under the Securities Act for any reason at any time while there are any Registrable Securities outstanding, the Company
shall use its commercially reasonable efforts to cause such Shelf to again become effective under the Securities Act (including by taking
action to seek the prompt withdrawal of any order suspending the effectiveness of such Shelf) as promptly as reasonably practicable,
and shall use its commercially reasonable efforts to as promptly as reasonably practicable amend such Shelf in a manner reasonably expected
to result in the withdrawal of any order suspending the effectiveness of such Shelf or file an additional Registration Statement as a
Shelf Registration (a “Subsequent Shelf Registration”) registering the resale of all outstanding Registrable Securities
from time to time, and pursuant to any method or combination of methods legally available to, and reasonably requested by, any Special
Holder. If a Subsequent Shelf Registration is filed, the Company shall use its commercially reasonable efforts to (i) cause such Subsequent
Shelf Registration to become effective under the Securities Act as promptly as reasonably practicable after the filing thereof (it being
agreed that the Subsequent Shelf Registration shall be an Automatic Shelf Registration Statement if the Company is a Well-Known Seasoned
Issuer at the time of filing) and (ii) keep such Subsequent Shelf Registration continuously effective, available for use and in compliance
with the provisions of the Securities Act until such time as there are no longer any Registrable Securities outstanding. Any such Subsequent
Shelf Registration shall be on Form S-3, or any similar short-form registration to the extent that the Company is eligible to use such
form. Otherwise, such Subsequent Shelf Registration shall be on another appropriate form that the Company is eligible to use. In the
event that any Holder holds Registrable Securities that are not registered for resale on a delayed or continuous basis, the Company,
upon request of a Holder, shall use its commercially reasonable efforts to cause the resale of such Registrable Securities to be covered
by either, at the Company’s option, the Shelf (including by means of a post-effective amendment) or a Subsequent Shelf Registration
and cause the same to become effective as promptly as reasonably practicable after such filing, and such Shelf or Subsequent Shelf Registration
shall be subject to the terms of this Agreement.
(c)
Requests for Underwritten Shelf Takedowns. At
any time and from time to time after the Shelf has been declared effective by the SEC, Special Holders representing a majority in interest
of the Registrable Securities may request to sell all or any portion of their Registrable Securities in an underwritten offering that
is registered pursuant to the Shelf (each, an “Underwritten Shelf Takedown” and such Special Holders the “Demanding
Holders”); provided that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering
shall include securities with a total offering price (including piggyback securities and before deduction of underwriting discounts)
reasonably expected to exceed, in the aggregate, $25 million (the “Minimum Takedown Threshold”). All requests for
Underwritten Shelf Takedowns shall be made by giving written notice to the Company, which shall specify the approximate number of Registrable
Securities proposed to be sold in the Underwritten Shelf Takedown and the expected price range (net of underwriting discounts and commissions)
of such Underwritten Shelf Takedown; provided that each Special Holder agrees that the fact that such a notice has been delivered
shall constitute Confidential Information and shall not be disclosed to any third party (other than any Affiliate, Representative, limited
partner or shareholder of such Special Holder), unless (a) such information becomes known to the public through no fault of such Special
Holder or (b) disclosure is required by applicable Law or court of competent jurisdiction or requested by a Governmental Authority. The
Company shall have the right to select the Underwriters for such offering (which shall consist of one (1) or more reputable nationally
or regionally recognized investment banks) and to agree to the pricing and other terms of such offering; provided that such selection
shall be subject to the consent of the Demanding Holders of a majority in interest of the Registrable Securities for which an Underwritten
Shelf Takedown has been requested, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding anything
to the contrary contained in this Agreement, in no event shall any Special Holder or any Transferee thereof request an Underwritten Shelf
Takedown during the Lock-Up Period applicable to such Person. The Special Holders may in the aggregate demand not more than two (2) Underwritten
Shelf Takedowns pursuant to this Section 2.1(c) in any twelve (12) month period, subject to the proviso in the first sentence
of this Section 2.1(c). For the avoidance of doubt, Underwritten Shelf Takedowns shall include underwritten block trades.
(d)
Shelf Takedown Participation. Promptly upon receipt
of a Shelf Takedown Request (but in no event more than three (3) Business Days thereafter (or more than twenty-four (24) hours thereafter
in connection with an underwritten “block trade”)) for any Underwritten Shelf Takedown, the Company shall deliver a notice
(a “Shelf Takedown Notice”) to each other Special Holder (each, a “Potential Takedown Participant”),
setting forth the number of Registrable Securities covered by the applicable Shelf Takedown Request. The Shelf Takedown Notice shall
offer each such Potential Takedown Participant the opportunity to include in any Underwritten Shelf Takedown such number of Registrable
Securities as each such Potential Takedown Participant may request in writing (each a “Requesting Holder”). The Company
shall include in the Underwritten Shelf Takedown all such Registrable Securities with respect to which the Company has received written
requests for inclusion therein within three (3) Business Days (or within twenty-four (24) hours in connection with an underwritten “block
trade”) after the date that the Shelf Takedown Notice has been delivered. Any Requesting Holder’s request to participate
in an Underwritten Shelf Takedown shall be binding on the Requesting Holder; provided that each such Requesting Holder that elects
to participate may condition its participation on the Underwritten Shelf Takedown being completed within ten (10) Business Days of delivery
of the Shelf Takedown Notice at a price per share (after giving effect to any underwriters’ discounts or commissions) to such Requesting
Holder of not less than a percentage of the closing price for the shares on their principal trading market on the Business Day immediately
prior to such Requesting Holder’s election to participate, as specified in such Requesting Holder’s request to participate
in such Underwritten Shelf Takedown (the “Participation Conditions”). Notwithstanding the delivery of any Shelf Takedown
Notice, but subject to the Participation Conditions (to the extent applicable), all determinations as to whether to complete any Underwritten
Shelf Takedown and as to the timing, manner, price and other terms of any Underwritten Shelf Takedown contemplated by this Section
2.1(d) shall be determined by the Demanding Holders.
(e)
Reduction of Underwritten Shelf Takedowns. If
the managing Underwriter or Underwriters in an Underwritten Shelf Takedown, in good faith, advise the Company, the Demanding Holders
and the Requesting Holders (if any) in writing that the dollar amount or number of Registrable Securities that the Demanding Holders
and the Requesting Holders (if any) desire to sell, taken together with all other Common Stock or other Equity Securities that the Company
desires to sell and all other Common Stock or other Equity Securities, if any, that have been requested to be sold in such Underwritten
Offering pursuant to separate written contractual piggyback registration rights held by any other stockholders, exceeds the maximum dollar
amount or maximum number of Equity Securities that can be sold in the Underwritten Offering without adversely affecting the proposed
offering price, the timing, the distribution method, or the probability of success of such offering (such maximum dollar amount or maximum
number of such securities, as applicable, the “Maximum Number of Securities”), then the Company shall include in such
Underwritten Offering, as follows: at all times (i) first, the Registrable Securities of the Demanding Holders and the Requesting Holders
(if any) (pro rata based on the respective then-ownership of Registrable Securities of each Demanding Holder and Requesting Holder (if
any) that has requested to be included in such Underwritten Shelf Takedown) that can be sold without exceeding the Maximum Number of
Securities; (ii) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (i),
the Common Stock or other Equity Securities that the Company desires to sell, which can be sold without exceeding the Maximum Number
of Securities; and (iii) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses
(i) and (ii), the Common Stock or other Equity Securities of other Persons that the Company is obligated to include in such
Underwritten Offering pursuant to separate written contractual arrangements with such Persons and that can be sold without exceeding
the Maximum Number of Securities.
(f)
Withdrawal. Any of the Demanding Holders initiating
an Underwritten Shelf Takedown shall have the right to withdraw from such Underwritten Shelf Takedown for any or no reason whatsoever
upon written notification (a “Withdrawal Notice”) to the Company and the Underwriter or Underwriters (if any) of such
Demanding Holder’s intention to withdraw from such Underwritten Shelf Takedown, prior to the public announcement of the Underwritten
Shelf Takedown by the Company; provided that a Special Holder not so withdrawing may elect to have the Company continue an Underwritten
Shelf Takedown if the Minimum Takedown Threshold would still be satisfied. Following the receipt of any Withdrawal Notice, the Company
shall promptly forward such Withdrawal Notice to any other Special Holders that had elected to participate in such Underwritten Shelf
Takedown. If all Demanding Holders of any given Underwritten Shelf Takedown exercise their withdrawal right under this Section 2.1(f)
such that no Demanding Holders remain, the Demanding Holders have the option to reimburse the Company for all Registration Expenses,
at which point such Underwritten Shelf Takedown shall not be subject to the limitation set forth in Section 2.1(c). Notwithstanding
anything to the contrary contained in this Agreement, but except as set forth in the immediately preceding sentence, the Company shall
be responsible for the Registration Expenses incurred in connection with the Underwritten Shelf Takedown prior to delivery of a Withdrawal
Notice under this Section 2.1(f).
2.2
Restrictions on Transfer. In connection with
any Underwritten Offering of Equity Securities of the Company, (i) each Holder agrees that it shall not Transfer any Common Stock (other
than those included in such offering pursuant to this Agreement), without the prior written consent of the Company, during the seven
(7) calendar days prior (to the extent notice of such Underwritten Offering has been provided) to and the 90-day period beginning on
the date of pricing of such offering, except in the event the Underwriter managing the offering otherwise agrees to a reduced period
(or no such period) or to a restriction on less than all Holders, which shall then apply in lieu of the restrictions on transfer imposed
hereby, and further agrees to execute a customary lock-up agreement in favor of the Underwriters to such effect if requested (in each
case on substantially the same terms and conditions as all such Holders), and (ii) the Company will cause each of its directors and executive
officers to execute a lock-up on terms at least as restrictive as that contemplated by the preceding clause (i) and (iii) the
Company will not effect any public offering or distribution of its equity securities or any securities convertible or exchangeable or
exercisable for such securities during the period contemplated in clause (i) (other than (a) as part of any such Underwritten
Offering, (b) in connection with a registration related to any employee stock option or other benefit plan, (c) pursuant to an exchange
offer or offering in connection with a business acquisition or combination pursuant to a Registration Statement on Form S-4 or such other
similar form as may be applicable, (d) for an offering of debt that is convertible into equity securities of the Company, (e) for a dividend
reinvestment plan, (f) securities issuable upon the conversion, exchange, or exercise of securities that are outstanding and the sale
of which is registered as of the date of the Underwritten Offering, or (g) securities issued pursuant to acquisitions, joint ventures,
strategic alliances, or other strategic transactions, including without limitation collaborations or arrangements involving research
and development or the sale or licensing of intellectual property, approved by a majority of the disinterested directors of the Company,
except for a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities), except to the extent the Underwriter managing the offering otherwise agrees to a reduced
period (or no such period) or to different exceptions, in which case such period and exceptions shall apply.
2.3
General Procedures. In connection with effecting
any Registration and/or Shelf Takedown, subject to applicable Law and any regulations promulgated by any securities exchange on which
the Company’s Equity Securities are then listed, each as interpreted by the Company with the advice of its counsel, the Company
shall use its commercially reasonable efforts (except as set forth in clause (d) below) to effect such Registration to permit
the sale of the Registrable Securities included in such Registration in accordance with the intended plan of distribution thereof, and
pursuant thereto the Company shall:
(a)
prepare and file with the SEC as promptly as reasonably
practicable a Registration Statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause
such Registration Statement to become effective and remain effective until all Registrable Securities covered by such Registration Statement
have been sold;
(b)
prepare and file with the SEC such amendments and post-effective
amendments to the Registration Statement, and such supplements to the Prospectus, as may be required by the rules, regulations or instructions
applicable to the registration form used by the Company or by the Securities Act or rules and regulations thereunder to keep the Registration
Statement effective until all Registrable Securities covered by such Registration Statement are sold in accordance with the intended
plan of distribution set forth in such Registration Statement or supplement to the Prospectus;
(c)
prior to filing a Registration Statement or Prospectus,
or any amendment or supplement thereto, furnish without charge to the Underwriters, if any, and the Special Holders of Registrable Securities
included in such Registration, and such Special Holders’ legal counsel, if any, copies of such Registration Statement as proposed
to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto and documents
incorporated by reference therein), the Prospectus included in such Registration Statement (including each preliminary Prospectus), and
such other documents as the Underwriters or Special Holders of Registrable Securities included in such Registration or the legal counsel
for any such Special Holders, if any, may reasonably request in order to facilitate the disposition of the Registrable Securities owned
by such Special Holders;
(d)
prior to any public offering of Registrable Securities,
use its commercially reasonable efforts to (i) register or qualify the Registrable Securities covered by the Registration Statement under
such securities or “blue sky” Laws of such jurisdictions in the United States as the Holders of Registrable Securities included
in such Registration Statement (in light of their intended plan of distribution) may request (or provide evidence satisfactory to such
Holders that the Registrable Securities are exempt from such registration or qualification) and (ii) take such action necessary to cause
such Registrable Securities covered by the Registration Statement to be registered with or approved by such other Governmental Authorities
as may be necessary by virtue of the business and operations of the Company and do any and all other acts and things that may be necessary
or advisable to enable the Holders of Registrable Securities included in such Registration Statement to consummate the disposition of
such Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required to qualify
generally to do business in any jurisdiction where it would not otherwise be required to qualify or take any action to which it would
be subject to general service of process or taxation in any such jurisdiction where it is not then otherwise so subject;
(e)
cause all such Registrable Securities to be listed on
each securities exchange or automated quotation system on which similar securities issued by the Company are then listed, if any;
(f)
advise each Holder of Registrable Securities covered
by a Registration Statement, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by
the SEC suspending the effectiveness of such Registration Statement or the initiation or threatening of any proceeding for such purpose
and promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such stop
order should be issued;
(g)
at least three (3) calendar days prior to the filing
of any Registration Statement or Prospectus or any amendment or supplement to such Registration Statement or Prospectus or any document
that is to be incorporated by reference into such Registration Statement or Prospectus furnish a draft thereof to each Special Holder
of Registrable Securities included in such Registration Statement, or its counsel, if any (excluding any exhibits thereto and any filing
made under the Exchange Act that is to be incorporated by reference therein);
(h)
notify the Holders at any time when a Prospectus relating
to such Registration Statement is required to be delivered under the Securities Act, of the happening of any event as a result of which
the Prospectus included in such Registration Statement, as then in effect, includes a Misstatement, and then to correct such Misstatement
as set forth in Section 2.6;
(i)
permit Representatives of the Special Holders, the Underwriters,
if any, and any attorney, consultant or accountant retained by such Special Holders or Underwriter to participate, at each such Person’s
own expense except to the extent such expenses constitute Registration Expenses, in the preparation of the Registration Statement, and
cause the Company’s officers, directors and employees to supply all information reasonably requested by any such Representative,
Underwriter, attorney, consultant or accountant in connection with the Registration; provided, however, that such Persons
agree to confidentiality arrangements reasonably satisfactory to the Company, prior to the release or disclosure of any such information;
(j)
obtain a “cold comfort” letter, and a bring-down
thereof, from the Company’s independent registered public accountants in the event of an Underwritten Offering which the participating
Special Holders may rely on, in customary form and covering such matters of the type customarily covered by “cold comfort”
letters as the managing Underwriter may reasonably request, and reasonably satisfactory to the participating Special Holders;
(k)
on the date the Registrable Securities are delivered
for sale pursuant to such Registration, obtain an opinion and negative assurance letter, dated such date, of counsel representing the
Company for the purposes of such Registration, addressed to the Special Holders, the placement agent or sales agent, if any, and the
Underwriters, if any, covering such legal matters with respect to the Registration in respect of which such opinion is being given as
the Special Holders, placement agent, sales agent, or Underwriter may reasonably request and as are customarily included in such opinions
and negative assurance letters, and reasonably satisfactory to the participating Special Holders;
(l)
in the event of any Underwritten Offering, enter into
and perform its obligations under an underwriting agreement, in usual and customary form, with the managing Underwriter of such offering;
(m)
make available to its security holders, as promptly
as reasonably practicable, an earnings statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder
(or any successor rule promulgated thereafter by the SEC); and
(n)
otherwise, in good faith, cooperate reasonably with,
and take such customary actions as may reasonably be requested by, the Holders, in connection with such Registration, including causing
senior management to participate in meetings with Underwriters, attorneys, accountants and potential investors.
2.4
Registration Expenses. The Registration Expenses
of all Registrations shall be borne by the Company. It is acknowledged by the Holders that the Holders selling any Registrable Securities
in an offering shall bear all incremental selling expenses relating to the sale of Registrable Securities, such as Underwriters’
commissions and discounts, brokerage fees, Underwriter marketing costs and, other than as set forth in the definition of “Registration
Expenses,” all reasonable fees and expenses of any legal counsel representing such Holders, in each case pro rata based on the
number of Registrable Securities that such Holders have sold in such Registration.
2.5
Requirements for Participating in Underwritten Offerings.
Notwithstanding anything to the contrary contained in this Agreement, if any Holder does not provide the Company with its requested Holder
Information, the Company may exclude such Holder’s Registrable Securities from the applicable Registration Statement or Prospectus
if the Company determines, based on the advice of counsel, that such information is necessary to effect the registration and such Holder
continues thereafter to withhold such information. No Person may participate in any Underwritten Offering of Equity Securities of the
Company pursuant to a Registration Statement under this Agreement unless such Person (a) agrees to sell such Person’s Registrable
Securities on the basis provided in any underwriting and other arrangements approved by (i) the Company in the case of an Underwritten
Offering initiated by the Company or (ii) by the Demanding Holders in the case of an Underwritten Offering initiated by the Demanding
Holders and (b) completes and executes all customary questionnaires, powers of attorney, custody agreements, indemnities, lock-up agreements,
underwriting agreements and other customary documents as may be reasonably required under the terms of such underwriting arrangements.
Subject to the minimum thresholds set forth in Section 2.1(c) and 2.3(o), the exclusion of a Holder’s Registrable
Securities as a result of this Section 2.5 shall not affect the registration of the other Registrable Securities to be included
in such Registration.
2.6
Suspension of Sales; Adverse Disclosure. Upon
receipt of written notice from the Company that a Registration Statement or Prospectus contains a Misstatement, each of the Holders shall
forthwith discontinue disposition of Registrable Securities until it has received copies of a supplemented or amended Prospectus correcting
the Misstatement (and the Company hereby covenants to prepare and file such supplement or amendment as promptly as reasonably practicable
after giving such notice), or until it is advised in writing by the Company that the use of the Prospectus may be resumed. If the filing,
initial effectiveness or continued use of a Registration Statement in respect of any Registration at any time would require the Company
to make an Adverse Disclosure or would require the inclusion in such Registration Statement of financial statements that are unavailable
to the Company for reasons beyond the Company’s control, the Company may, upon giving prompt written notice of such action to the
Holders, delay the filing or initial effectiveness of, or suspend use of, such Registration Statement for the shortest period of time,
but in no event more than 90 days in any 12-month period, determined in good faith by the Company to be necessary for such purpose. In
the event the Company exercises its rights under the preceding sentence, the Holders agree to suspend, immediately upon their receipt
of the notice referred to above, their use of the Prospectus relating to such Registration in connection with any sale or offer to sell
Registrable Securities. The Company shall immediately notify the Holders of the expiration of any period during which it exercised its
rights under this Section 2.6.
2.7
Reporting Obligations. As long as any Holder
shall own Registrable Securities, the Company, at all times while it shall be a reporting company under the Exchange Act, covenants to
use its reasonable best efforts to file timely (or obtain extensions in respect thereof and file within the applicable grace period)
all reports required to be filed by the Company after the Effective Date pursuant to Sections 13(a) or 15(d) of the Exchange Act and
to promptly furnish the Holders with true and complete copies of all such filings; provided that any documents publicly filed
or furnished with the SEC pursuant to the Electronic Data Gathering, Analysis and Retrieval System shall be deemed to have been furnished
to the Holders pursuant to this Section 2.7.
2.8
Other Obligations. In connection with a Transfer
of Registrable Securities exempt from Section 5 of the Securities Act or through any broker-dealer transactions described in the plan
of distribution set forth within the Prospectus and pursuant to the Registration Statement of which such Prospectus forms a part, the
Company shall, subject to applicable Law, as interpreted by the Company with the advice of counsel, and the receipt of any customary
documentation required from the applicable Holders in connection therewith, (a) promptly instruct its transfer agent to remove any restrictive
legends applicable to the Registrable Securities being Transferred and (b) cause its legal counsel to deliver the necessary legal opinions,
if any, to the transfer agent in connection with the instruction under clause (a). In addition, the Company shall cooperate reasonably
with, and take such customary actions as may reasonably be requested by the Holders, and the Holders shall cooperate reasonably with,
and take such customary actions as may be reasonably be requested by the Company, in connection with the aforementioned Transfers; provided,
however, that the Company shall have no obligation to participate in any “road shows” or assist with the preparation
of any offering memoranda or related documentation with respect to any Transfer of Registrable Securities in any transaction that does
not constitute an Underwritten Offering.
2.9
Indemnification and Contribution.
(a)
The Company agrees to indemnify and hold harmless each
Holder, its officers, managers, directors, trustees, equityholders, beneficiaries, affiliates, agents and Representatives and each Person
who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities and expenses (including
attorneys’ fees) (or actions in respect thereto) caused by, resulting from, arising out of or based upon (i) any untrue or alleged
untrue statement of material fact contained in any Registration Statement, Prospectus or preliminary Prospectus or similar document incident
to any Registration, qualification, compliance or sale effected pursuant to this Article II or any amendment thereof or supplement thereto,
or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not
misleading, or (ii) any violation or alleged violation by the Company of the Securities Act or any other similar federal or state securities
Laws, and will reimburse, as incurred, each such Holder, its officers, managers, directors, trustees, equityholders, beneficiaries, affiliates,
agents and Representatives and each Person who controls such Holder (within the meaning of the Securities Act) for any documented legal
expenses and any other documented expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage,
liability or action; provided that, the Company will not be liable in any such case to the extent that any such claim, damage, loss,
liability or expense are caused by or arises out of or is based on any untrue statement or omission made in reliance and in conformity
with written information furnished to the Company by or on behalf of such Holder expressly for use therein.
(b)
In connection with any Registration Statement in which
a Holder of Registrable Securities is participating, such Holder shall furnish to the Company in writing such information and affidavits
as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus (the “Holder Information”)
and, to the extent permitted by Law, such Holder shall indemnify and hold harmless the Company, its directors, officers, employees, equityholders,
affiliates and agents and each Person who controls the Company (within the meaning of the Securities Act) against any losses, claims,
damages, liabilities and expenses (including reasonable attorneys’ fees) (or actions in respect thereof) arising out of, resulting
from or based on any untrue statement of material fact contained in the Registration Statement, Prospectus or preliminary Prospectus
or similar document or any amendment thereof or supplement thereto, or any omission of a material fact required to be stated therein
or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained
in any information or affidavit so furnished in writing by or on behalf of such Holder expressly for use therein; provided, however,
that the obligation to indemnify shall be several, not joint and several, among such Holders of Registrable Securities, and the liability
of each such Holder of Registrable Securities shall be in proportion to and limited to the net proceeds received by such Holder from
the sale of Registrable Securities pursuant to such Registration Statement.
(c)
Any Person entitled to indemnification under this Section
2.9 shall (i) give prompt written notice, after such Person has actual knowledge thereof, to the indemnifying party of any claim
with respect to which such Person seeks indemnification (provided that the failure to give prompt notice shall not impair any Person’s
right to indemnification hereunder to the extent such failure has not materially prejudiced the indemnifying party in the defense of
any such claim or any such litigation) and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party (not be unreasonably withheld, conditioned or delayed) and the indemnified party may participate
in such defense at the indemnifying party’s expense if representation of such indemnified party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. An
indemnifying party, in the defense of any such claim or litigation, without the consent of each indemnified party, may only consent to
the entry of any judgment or enter into any settlement that (i) includes as a term thereof the giving by the claimant or plaintiff therein
to such indemnified party of an unconditional release from all liability with respect to such claim or litigation and (ii) does not include
any recovery (including any statement as to or an admission of fault, culpability or a failure to act by or on behalf of such indemnified
party) other than monetary damages, and provided, that any sums payable in connection with such settlement are paid in full by the indemnifying
party.
(d)
The indemnification provided under this Agreement shall
remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party or any officer, manager,
director, Representative or controlling Person of such indemnified party and shall survive the Transfer of securities.
(e)
If the indemnification provided in this Section 2.9
from the indemnifying party is unavailable or insufficient to hold harmless an indemnified party in respect of any losses, claims,
damages, liabilities and expenses referred to herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall
contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses
in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any
other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference
to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified
party, and the indemnifying party’s and indemnified party’s relative intent, knowledge, access to information and opportunity
to correct or prevent such action; provided, however, that the liability of any Holder under this Section 2.9(e)
shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability. The amount
paid or payable by a Party as a result of the losses or other liabilities referred to above shall be deemed to include, subject to the
limitations set forth in Sections 2.9(a), 2.9(b) and 2.9(c), any legal or other fees, charges or expenses reasonably
incurred by such Party in connection with any investigation or proceeding. The Parties agree that it would not be just and equitable
if contribution pursuant to this Section 2.9(e) were determined by pro rata allocation or by any other method of allocation, which
does not take account of the equitable considerations referred to in this Section 2.9(e). No Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution pursuant to this Section 2.9(e)
from any Person who was not guilty of such fraudulent misrepresentation.
2.10
Other Registration Rights. The parties hereby
amend and restate the Original RRA, which shall be of no further force and effect and is hereby superseded and replaced in its entirety
by this Agreement. Without the prior written consent of the majority in interest of the Special Holders, the Company shall not hereafter
enter into any agreement with respect to its securities that is inconsistent with or violates the rights granted to the Holders hereunder.
Except with the prior written consent of the majority in interest of the Special Holders, in the event that the Company desires to enter
into any agreement with any Person, including any holder or prospective holder of any securities of the Company, granting any registration
rights the terms of that are more favorable than or senior to the rights granted to the Holders of Registrable Securities hereunder,
then (i) the Company shall provide prior written notice thereof to the Holders of Registrable Securities and (ii) upon execution by the
Company of such other agreement, the terms and conditions of this Agreement shall be, without any further action by the Holders or the
Company, automatically amended and modified in an economically and legally equivalent manner such that the Holders shall receive the
benefit of the more favorable terms and/or conditions (as the case may be) set forth in such other agreement, provided that upon written
notice to the Company at any time, any Holder may elect not to accept the benefit of any such amended or modified term or condition,
in which event the term or condition contained in this Agreement shall apply to such Holder as it was in effect immediately prior to
such amendment or modification as if such amendment or modification never occurred with respect to such Holder.
2.11
Rule 144. With a view to making available to
the Holders the benefits of Rule 144 promulgated under the Securities Act, the Company covenants that it will (a) use its commercially
reasonable efforts to make available at all times information necessary to comply with the current public information requirements of
Rule 144, if such Rule is available with respect to resales of the Registrable Securities under the Securities Act, and (b) take such
further action as the Holders may reasonably request, all to the extent required from time to time to enable them to sell Registrable
Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 promulgated under
the Securities Act (if available with respect to resales of the Registrable Securities), as such rule may be amended from time to time.
Upon the request of any Holder, the Company will deliver to such Holder a written statement as to whether the Company has complied with
such information requirements, and, if not, the specific reasons for non-compliance.
2.12
Term. Article II shall terminate with
respect to any Holder on the date that such Holder no longer holds any Registrable Securities. The provisions of Section 2.9 shall
survive any such termination with respect to such Holder.
2.13
Holder Information. Each Holder agrees, if requested
in writing by the Company, to represent to the Company the total number of Registrable Securities held by such Holder in order for the
Company to make determinations under this Agreement, including for purposes of Section 2.11. A Party who does not hold Registrable
Securities as of the Closing Date and who acquires Registrable Securities after the Closing Date will not be a “Holder” until
such Party gives the Company a representation in writing of the number of Registrable Securities it holds.
2.14
Distributions; Direct Ownership.
(a)
In the event that the Sponsor distributes all of its
Registrable Securities to its members, the members of the Sponsor shall be treated as the Sponsor under this Agreement; provided that
each of the members agrees in writing to be bound by the terms of this Agreement; provided, further, that such members
of the Sponsor, taken as a whole, shall (i) exercise their rights based on the majority-in-interest of such distributees holding Registrable
Securities; and (ii) not be entitled to rights in excess of those conferred on the Sponsor, as if the Sponsor remained a single entity
party to this Agreement.
(b)
Notwithstanding the foregoing, no distribution for purposes
of this Section 2.14 may occur prior to the conclusion of any Lock-Up Period applicable to the Sponsor except as expressly permitted
under the Lock-Up Agreement.
2.15
Adjustments. If there are any changes in the
Common Stock as a result of stock split, stock dividend, combination or reclassification, or through merger, consolidation, recapitalization
or other similar event, this Agreement shall be interpreted, and appropriate adjustment shall be made in the provisions of this Agreement,
as may be required, so that the rights, privileges, duties and obligations under this Agreement shall continue with respect to the Common
Stock as so changed.
Article
III
GENERAL
PROVISIONS
3.1
Assignment; Successors and Assigns; No Third-Party
Beneficiaries.
(a)
Except as otherwise permitted pursuant to this Agreement,
and other than assignments in connection with a distribution pursuant to Section 2.14, no Party may assign such Party’s
rights and obligations under this Agreement, in whole or in part, without the prior written consent of the Company. Any such assignee
may not again assign those rights, other than in accordance with this Article III. Any attempted assignment of rights or obligations
in violation of this Article III shall be null and void.
(b)
Notwithstanding anything to the contrary contained in
this Agreement, prior to the expiration of the Lock-Up Period applicable to such Holder, no Holder may Transfer such Holder’s rights
or obligations under this Agreement in connection with a Transfer of such Holder’s Registrable Securities, in whole or in part,
except as expressly permitted under the Lock-up Agreement. Any Transferee of Registrable Securities (other than pursuant to an effective
Registration Statement or a Rule 144 transaction) pursuant to this Section 3.1(b) shall be required, at the time of and as a condition
to such Transfer, to become a party to this Agreement by executing and delivering a joinder in the form attached to this Agreement as
Exhibit A (a “Joinder”), whereupon such Transferee will be treated as a Party (with the same rights and obligations
as the Transferor) for all purposes of this Agreement. No Transfer of Registrable Securities by a Holder shall be registered on the Company’s
books and records, and such Transfer of Registrable Securities shall be null and void and not otherwise effective, unless any such Transfer
is made in accordance with the terms and conditions of this Agreement, and the Company is hereby authorized by all of the Holders to
enter appropriate stop transfer notations on its transfer records to give effect to this Agreement.
(c)
All of the terms and provisions of this Agreement shall
be binding upon the Parties and their respective successors, assigns, heirs and representatives, but shall inure to the benefit of and
be enforceable by the successors, assigns, heirs and representatives of any Party only to the extent that they are permitted successors,
assigns, heirs and representatives pursuant to the terms of this Agreement.
(d)
Nothing in this Agreement, express or implied, is intended
to confer upon any Party, other than the Parties and their respective permitted successors, assigns, heirs and representatives, any rights
or remedies under this Agreement or otherwise create any third-party beneficiary hereto.
3.2
Termination. Article II of this Agreement
shall terminate as set forth in Section 2.12. The remainder of this Agreement shall terminate automatically (without any action
by any Party) as to each Holder when such Holder ceases to Beneficially Own any Registrable Securities; provided that, the provisions
of Section 2.9 shall survive any such termination with respect to such Holder.
3.3
Severability. If any provision of this Agreement
is determined to be invalid, illegal or unenforceable by any Governmental Authorities, the remaining provisions of this Agreement, to
the extent permitted by Law shall remain in full force and effect.
3.4
Entire Agreement; Amendments; No Waiver.
(a)
This Agreement, together with the Exhibit to this Agreement,
the BCA, and all other Ancillary Documents, constitute the entire agreement among the Parties with respect to the subject matter hereof
and thereof and supersede all prior and contemporaneous agreements, understandings and discussions, whether oral or written, relating
to such subject matter in any way and there are no warranties, representations or other agreements among the Parties in connection with
such subject matter except as set forth in this Agreement and therein.
(b)
No provision of this Agreement may be amended, modified
or waived in whole or in part at any time without the express written consent of (i) the Company, and (ii) Holders holding an aggregate
of more than fifty percent (50%) of the Registrable Securities Beneficially Owned by the Holders immediately after the Closing; provided
that any such amendment, modification or waiver that would be materially disproportionate and adverse in any respect to any Sponsor
Holder shall require the prior written consent of Sponsor.
3.5
Counterparts; Electronic Delivery. This Agreement
and any other agreements, certificates, instruments and documents delivered pursuant to this Agreement may be executed and delivered
in one or more counterparts and by fax, email or other electronic transmission, each of which shall be deemed an original and all of
which shall be considered one and the same agreement. No Party shall raise the use of a fax machine or email to deliver a signature or
the fact that any signature or agreement or instrument was transmitted or communicated through the use of a fax machine or email as a
defense to the formation or enforceability of a contract and each Party forever waives any such defense.
3.6
Notices. All notices, demands and other communications
to be given or delivered under this Agreement shall be in writing and shall be deemed to have been given (a) when personally delivered
(or, if delivery is refused, upon presentment) or received by email (with confirmation of transmission) prior to 5:00 p.m. eastern time
on a Business Day and, if otherwise, on the next Business Day, (b) one (1) Business Day following sending by reputable overnight express
courier (charges prepaid) or (c) three (3) calendar days following mailing by certified or registered mail, postage prepaid and return
receipt requested. Unless another address is specified in writing pursuant to the provisions of this Section 3.6, notices, demands
and other communications shall be sent to the addresses indicated below:
if
to the Company, to:
Tevogen
Bio Holdings, Inc.
15
Independence Boulevard, Suite 410
Warren,
New Jersey 07059
Attention:
Dr. Ryan Saadi
Email:
ryan.saadi@tevogen.com
with
copies (which shall not constitute notice) to:
Hogan
Lovells US LLP
100
International Drive, Suite 2000
Baltimore,
Maryland 21202
Attn:
William Intner and Nick Hoover
Telephone
No.: (410) 659-2778; (410) 659-2790
Email:
william.intner@hoganlovells.com; nick.hoover@hoganlovells.com
if
to a Company Holder, to the Company Holder at the physical or email address set forth opposite the Company Holder’s name on Schedule
1-A.
if
to the Sponsor or a Sponsor Holder, as applicable, to:
SSVK
Associates, LLC
8911
Regents Park Drive, Suite 550
Tampa,
FL, 33647
Attention:
Suren Ajjarapu
Email:
suren@semperparatusspac.com
with
a copy (which shall not constitute notice) to:
Attn:
Andrew M. Tucker
Facsimile
No.: (202) 689-2860
Telephone
No.: (202) 689-2987
Email:
Andy.Tucker@nelsonmullins.com
if
to the Original Sponsor, to:
Semper
Paratus Sponsor LLC
767
Third Avenue, 37th Floor
New
York, New York 10017
Attention:
Jeff Rogers
Email:
yabjar@yahoo.com
3.7
Governing Law; Waiver of Jury Trial; Jurisdiction.
This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect
to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the
application of the laws of any jurisdiction other than those of the State of Delaware. Each party hereto hereby irrevocably consents
to the exclusive jurisdiction of the courts of the State of Delaware and the United States District Court therein in connection with
any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement. EACH
PARTY TO THIS REGISTRATION RIGHTS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY PROCEEDING BROUGHT TO RESOLVE
ANY DISPUTE BETWEEN OR AMONG ANY OF THE PARTIES (WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH, RELATED
OR INCIDENTAL TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND/OR THE RELATIONSHIPS ESTABLISHED AMONG THE PARTIES
UNDER THIS AGREEMENT. THE PARTIES HERETO FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND
THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. Each Party agrees that a
final judgment in any proceeding so brought shall be conclusive and may be enforced by suit on the judgment or in any other manner provided
by Law or at equity.
3.8
Specific Performance. Each Party hereby agrees
and acknowledges that it will be impossible to measure in money the damages that would be suffered if the Parties fail to comply with
any of the obligations imposed on them by this Agreement and that, in the event of any such failure, an aggrieved Party will be irreparably
damaged and will not have an adequate remedy at Law. Any such Party shall, therefore, be entitled (in addition to any other remedy to
which such Party may be entitled at Law or in equity) to seek injunctive relief, including specific performance, to enforce such obligations,
without the posting of any bond, and if any Proceeding should be brought in equity to enforce any of the provisions of this Agreement,
none of the Parties shall raise the defense that there is an adequate remedy at Law.
3.9
Legends. Each of the Holders acknowledges that
(i) no Transfer, hypothecation or assignment of any Registrable Securities Beneficially Owned by such Holder may be made except in compliance
with applicable federal and state securities laws and (ii) to the extent that any of the Registrable Securities constitute “restricted
securities” as defined in Rule 144, the Company shall place customary restrictive legends substantially in the form set forth below
on the certificates or book entries representing the Registrable Securities subject to this Agreement.
THE
SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS
OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT
UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH LAWS.
THESE
SECURITIES ARE SUBJECT TO THE RESTRICTIONS SET FORTH IN THE REGISTRATION RIGHTS AGREEMENT, DATED FEBRUARY 14, 2024 (THE “REGISTRATION
RIGHTS AGREEMENT”), BY AND AMONG TEVOGEN BIO HOLDINGS, INC, A DELAWARE CORPORATION, AND CERTAIN OTHER PARTIES THERETO, AS THE
SAME MAY BE AMENDED OR RESTATED FROM TIME TO TIME (COPIES OF WHICH ARE ON FILE WITH THE SECRETARY OF THE COMPANY AND SHALL BE PROVIDED
FREE OF CHARGE TO ANY PARTY MAKING A BONA FIDE REQUEST THEREFOR) AND NO TRANSFER OF THESE SECURITIES WILL BE VALID OR EFFECTIVE UNTIL
ANY CONDITIONS CONTAINED IN THE REGISTRATION RIGHTS AGREEMENT, IF ANY, HAVE BEEN FULFILLED.
3.10
Additional Holders; Joinder. In addition to persons
or entities who may become Holders pursuant to Section 3.1 hereof, the Company may make any person or entity who has or acquires
Common Stock or rights to acquire Common Stock after the date hereof a party to this Agreement (each such person or entity, an “Additional
Holder”) by obtaining an executed Joinder from such Additional Holder. Such Joinder shall specify the rights and obligations
of the applicable Additional Holder under this Agreement. Upon the execution and delivery and subject to the terms of a Joinder by such
Additional Holder, the Common Stock of the Company then owned, or underlying any rights then owned, by such Additional Holder (the “Additional
Holder Common Stock”) shall be Registrable Securities to the extent provided herein and therein and such Additional Holder
shall be a Holder under this Agreement with respect to such Additional Holder Common Stock.
3.11
No Third-Party Liabilities. This Agreement may
only be enforced against the named parties hereto (and their transferees). All claims or causes of action (whether in contract or tort)
that may be based upon, arise out of or relate to any of this Agreement, or the negotiation, execution or performance of this Agreement
(including any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement),
may be made only against the Persons that are expressly identified as parties hereto (and their transferees), as applicable; and no past,
present or future direct or indirect director, officer, employee, incorporator, member, partner, stockholder, Affiliate, portfolio company
in which any such Party or any of its investment fund Affiliates have made a debt or equity investment (and vice versa), agent, attorney
or representative of any Party hereto (including any Person negotiating or executing this Agreement on behalf of a Party hereto), unless
a Party to this Agreement, shall have any liability or obligation with respect to this Agreement or with respect any claim or cause of
action (whether in contract or tort) that may arise out of or relate to this Agreement, or the negotiation, execution or performance
of this Agreement (including a representation or warranty made in or in connection with this Agreement or as an inducement to enter into
this Agreement).
[Signature
Pages Follow]
IN
WITNESS WHEREOF, each of the Parties has duly executed this Agreement as of the Effective Date.
|
TEVOGEN
BIO HOLDINGS, INC. |
|
|
|
By:
|
|
|
Name: |
|
|
Title: |
|
|
|
|
SSVK
ASSOCIATES, LLC |
|
|
|
By:
|
|
|
Name: |
|
|
Title: |
|
|
|
|
SEMPER
PARATUS SPONSOR LLC |
|
|
|
By:
|
|
|
Name: |
|
|
Title: |
|
|
|
|
|
CANTOR
FITZGERALD & CO. |
|
|
|
By:
|
|
|
Name: |
|
|
Title: |
|
[Signature
Page to Registration Rights Agreement]
IN
WITNESS WHEREOF, each of the Parties has duly executed this Agreement as of the Effective Date.
|
Sponsor
Holders: |
|
|
|
[_______________________] |
|
|
|
By:
|
|
|
Name: |
|
|
Title: |
|
|
|
|
[_______________________] |
|
|
|
By:
|
|
|
Name: |
|
|
Title: |
|
[Signature
Page to Registration Rights Agreement]
IN
WITNESS WHEREOF, each of the Parties has duly executed this Agreement as of the Effective Date.
|
Company
Holders: |
|
|
|
|
|
Ryan
Saadi, M.D., M.P.H. |
|
|
|
|
|
Kirti
Desai |
|
|
|
|
|
Neal
Flomenberg, M.D. |
[Signature
Page to Registration Rights Agreement]
Schedule
1-A
Company
Holders
Company
Holder |
Address |
Email
Address |
Ryan
Saadi, M.D., M.P.H. |
15
Independence Boulevard, Suite #410, Warren, New Jersey, 07059 |
info@tevogen.com |
Kirti
Desai |
15
Independence Boulevard, Suite #410, Warren, New Jersey, 07059 |
info@tevogen.com |
Neal
Flomenberg, M.D. |
15
Independence Boulevard, Suite #410, Warren, New Jersey, 07059 |
info@tevogen.com |
Schedule
1-B
Sponsor
Holders
Exhibit
A
Form
of Joinder
This
Joinder (this “Joinder”) to the Registration Rights Agreement made as of [_______], is between [__________] (“Transferor”)
and [______________] (“Transferee”).
WHEREAS,
as of the date hereof, Transferee is acquiring Registrable Securities (the “Acquired Interests”) from Transferor;
WHEREAS,
Transferor is a party to that certain Registration Rights Agreement, dated as of [●], by and among Tevogen Bio Holdings, Inc. and
certain other parties thereto (the “Registration Rights Agreement”); and
WHEREAS,
Transferee is required, at the time of and as a condition to such Transfer, to become a party to the Registration Rights Agreement by
executing and delivering this Joinder, whereupon such Transferee will be treated as a Party (with the same rights and obligations as
the Transferor) for all purposes of the Registration Rights Agreement.
NOW,
THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth herein, and intending to be legally
bound hereby, the parties hereto agree as follows:
Section
1.1 Definitions. To the extent capitalized words used in this Joinder are not defined in this Joinder, such words shall have the
respective meanings set forth in the Registration Rights Agreement.
Section
1.2 Acquisition. The Transferor hereby Transfers to the Transferee all the Acquired Interests.
Section
1.3 Joinder. Transferee hereby acknowledges and agrees that (a) such Transferee has received and read the Registration Rights Agreement,
(b) such Transferee is acquiring the Acquired Interests in accordance with and subject to the terms and conditions of the Registration
Rights Agreement and (c) such Transferee will be treated as a Party (with the same rights and obligations as the Transferor) for all
purposes of the Registration Rights Agreement.
Section
1.4 Notice. All notices, demands and other communications to be given or delivered under the Registration Rights Agreement shall
be in writing and shall be deemed to have been given (a) when personally delivered (or, if delivery is refused, upon presentment) or
received by email (with confirmation of transmission) prior to 5:00 p.m. eastern time on a Business Day and, if otherwise, on the next
Business Day, (b) one (1) Business Day following sending by reputable overnight express courier (charges prepaid) or (c) three (3) calendar
days following mailing by certified or registered mail, postage prepaid and return receipt requested. Unless another address is specified
in writing pursuant to the provisions of this Section 1.4, notices, demands and other communications shall be sent to the addresses
set forth on such party’s signature page hereto.
Section
1.5 Governing Law. This Joinder shall be governed by and construed in accordance with the Law of the State of Delaware.
Section
1.6 Third Party Beneficiaries. The Company, the Sponsor, the Original Sponsor and the other persons party to the Registration Rights
Agreement are intended third party beneficiaries of this Joinder and shall be entitled to enforce this Agreement against the undersigned
in accordance with its terms. Except as provided in the immediately preceding sentence, nothing in this Agreement is intended to, nor
shall be constructed to, confer upon any other person any rights or remedies hereunder.
Section
1.7 Counterparts; Electronic Delivery. This Joinder may be executed and delivered in one or more counterparts, by fax, email or other
electronic transmission, each of which shall be deemed an original and all of which shall be considered one and the same agreement. The
words “execution,” “signed,” “signature,” “delivery,” and words of like import in or
relating to this Joinder or any document to be signed in connection with this Joinder shall be deemed to include electronic signatures,
deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability
as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and
the parties hereto consent to conduct the transactions contemplated hereunder by electronic means.
IN
WITNESS WHEREOF, this Joinder has been duly executed and delivered by the parties as of the date first above written.
|
[TRANSFEROR] |
|
|
|
|
By:
|
|
|
Name:
|
|
|
Title:
|
|
|
|
|
|
[TRANSFEREE] |
|
|
|
|
By:
|
|
|
Name:
|
|
|
Title:
|
|
|
|
|
|
Address
for notices: |
Exhibit
10.5
LOCK-UP
AGREEMENT
This
Lock-Up Agreement (the “Agreement”) is dated as of February 14, 2024 and is between Tevogen Bio Holdings Inc.,
a Delaware corporation (formerly known as Semper Paratus Acquisition Corporation, a Cayman Islands exempted company) (the “Company”),
SSVK Associates, LLC, a Delaware limited liability company (“Sponsor”), each of the stockholder parties identified
on Exhibit A hereto, each of the directors and executive officers of Sponsor identified on Exhibit B hereto and the other
Persons who enter into a joinder to this Agreement substantially in the form of Exhibit C hereto with the Company in order to
become a “Stockholder Party” for purposes of this Agreement (collectively, the “Stockholder Parties”
and together with the Sponsor, the “Locked-Up Parties”). Capitalized terms used but not defined herein shall
have the meanings assigned to them in the Merger Agreement (as defined below).
BACKGROUND:
WHEREAS,
the Locked-Up Parties own or will own equity interests in the Company;
WHEREAS,
the execution and delivery of this Agreement is a closing condition to that certain Agreement and Plan of Merger (as amended or modified
from time to time, the “Merger Agreement”) entered into by the Company, Tevogen Bio Inc, a Delaware corporation
(“Target”) and Semper Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company
(“Merger Sub”), pursuant to which, among other transactions, Merger Sub will merge with and into Target, with
Target continuing on as the surviving entity (the “Merger”), and as a result of which, (i) Target will become
a wholly-owned subsidiary of the Company and (ii) each issued and outstanding security of Target immediately prior to the Effective Time
will no longer be outstanding and will automatically be cancelled in exchange for a substantially equivalent security of the Company,
all on the terms and conditions set forth in the Merger Agreement;
WHEREAS,
in connection with the Domestication, each issued and outstanding Company Class A Ordinary Share of the Company will be converted into
one share of Company Common Stock, on the terms and conditions set forth in the Merger Agreement; and
WHEREAS,
in connection with the Merger, the parties hereto wish to set forth herein certain understandings between such parties with respect to
restrictions on transfer of equity interests in the Company either owned prior to the Closing Date or acquired pursuant to the terms
of the Merger Agreement.
NOW,
THEREFORE, the parties agree as follows:
ARTICLE
I
INTRODUCTORY
MATTERS
1.1
Defined Terms. In addition to the terms defined elsewhere herein, the following terms have the following meanings when
used herein with initial capital letters:
“Action”
has the meaning set forth in Section 3.8.
“Affiliate”
has the meaning ascribed to such term in Rule 12b-2 of the General Rules and Regulations under the Exchange Act.
“Agreement”
means this Lock-Up Agreement, as the same may be amended, supplemented, restated or otherwise modified from time to time in accordance
with the terms hereof.
“Business
Combination” means the Merger and the other transactions contemplated by the Merger Agreement, collectively.
“Change
of Control” means any transaction or series of transactions (A) the result of which is that a Person or “group”
(within the meaning of Section 13(d) of the Exchange Act) of Persons (other than the Company or any of its Subsidiaries), has direct
or indirect beneficial ownership of securities (or rights convertible or exchangeable into securities) representing fifty percent (50%)
or more of the voting power of or economic rights or interests in the Company, (B) constituting a merger, consolidation, reorganization
or other Merger, however effected, following which either (1) the members of the Board of Directors of the Company immediately prior
to such merger, consolidation, reorganization or other Merger do not constitute at least a majority of the Board of Directors of the
Company surviving the combination or (2) the voting securities of the Company immediately prior to such merger, consolidation, reorganization
or other Merger do not continue to represent or are not converted into fifty percent (50%) or more of the combined voting power of the
then outstanding voting securities of the Person resulting from such combination, or (C) the result of which is a sale of all or substantially
all of the assets of the Company (as appearing in its most recent balance sheet) to any Person.
“Closing
Date” means the closing date of the Merger.
“Company”
has the meaning set forth in the Preamble.
“Company
Class A Ordinary Shares” means the designated Class A ordinary shares, par value $0.0001 per share, of the Company, prior
to the Domestication.
“Company
Common Stock” means the Common Stock, par value $0.0001 per share of the Company, following the Domestication and Merger.
“Company
Warrants” means the Company’s public warrants and private placement warrants.
“Domestication”
means the transfer by way of continuation and deregistration of the Company from the Cayman Islands and the continuation and domestication
of the Company as a corporation incorporated in the State of Delaware at least one day prior to the Merger.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, as the
same may be amended from time to time.
“Lock-Up”
has the meaning set forth in Section 2.1(a).
“Lock-Up
Period” has the meaning set forth in Section 2.1(d).
“Lock-Up
Securities” has the meaning set forth in Section 2.1(d).
“Lock-Up
Shares” has the meaning set forth in Section 2.1(d).
“Lock-Up
Warrants” has the meaning set forth in Section 2.1(d).
“Locked-Up
Parties” has the meaning set forth in the Preamble.
“Merger”
has the meaning set forth in the Background.
“Merger
Agreement” has the meaning set forth in the Background.
“Merger
Sub” has the meaning set forth in the Background.
“Permitted
Transferees” has the meaning set forth in Section 2.1(d).
“Stockholder
Parties” has the meaning set forth in the Preamble.
“Trading
Day” means any day on which shares of Company Common Stock are actually traded on the principal securities exchange or
securities market on which the Company Common Stock are then traded.
“Transfer”
has the meaning set forth in Section 2.1(d).
1.2
Construction. Unless the context otherwise requires: (a) “including” (and with correlative meaning “include”)
means including without limiting the generality of any description preceding or succeeding such term and shall be deemed in each case
to be followed by the words “without limitation”; (b) “or” is disjunctive but not exclusive, (c) words in the
singular include the plural, and in the plural include the singular, and (d) the words “hereof”, “herein”, and
“hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular
provision of this Agreement, and Section references are to sections of this Agreement unless otherwise specified. The parties have participated
jointly in the negotiation and drafting of this Agreement. Consequently, in the event an ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.
ARTICLE
II
LOCK-UP
2.1
Lock-Up.
(a)
Subject to Section 2.1(b), each Locked-Up Party shall not Transfer any Lock-Up Securities until the end of the Lock-Up Period
(the “Lock-Up”).
(b)
Each Locked-Up Party or any of its Permitted Transferees may Transfer any Lock-Up Securities it holds during the Lock-Up Period (a) to
other Locked-Up Parties or any direct or indirect partners, members or equity holders of such Locked-Up Party, any Affiliates of such
Locked-Up Party or any related investment funds or vehicles controlled or managed by such Persons or their respective Affiliates; (b)
by gift to a charitable organization; or, in the case of an individual, by gift to a member of the individual’s immediate family
or to a trust, the primary beneficiaries of which are one or more members of the individual’s immediate family or an Affiliate
of such Person; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual; (d) in
the case of an individual, pursuant to a qualified domestic relations order; or (e) to the Company, in each case of clauses (a)–(d),
if the transferee is not another Locked-Up Party, subject to prior receipt by the Company of a duly executed joinder to this Agreement
substantially in the form of Exhibit C hereto.
(c)
Notwithstanding the provisions set forth in this Section 2.1, if the Lock-Up Period is scheduled to end during a Blackout Period
or within five (5) Trading Days prior to the commencement of a Blackout Period, the Lock-Up Period shall end ten (10) Trading Days prior
to the commencement of the Blackout Period (the “Blackout-Related Release”); provided that the Company
shall announce the date of the expected Blackout-Related Release through a major news service, or on a Form 8-K, at least two (2) Trading
Days in advance of the Blackout-Related Release.
(d)
For purposes of this Section 2.1:
(i)
The term “Blackout Period” means a broadly applicable and regularly scheduled period during which trading in
the Company’s securities would not be permitted under the Company’s insider trading policy.
(ii)
The term “Lock-Up Period” means the period beginning on the Closing Date and ending on the date that is the
earlier of (A) six months after the completion of the Business Combination and (B) subsequent to the Business Combination, (x) if the
closing price of the Company Common Stock equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days
after the Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar
transaction that results in all of its stockholders having the right to exchange their shares of Company Common Stock for cash, securities
or other property.
(iii)
The term “Lock-Up Securities” means, collectively, the Lock-Up Shares and the Lock-Up Warrants.
(iv)
The term “Lock-Up Shares” means with respect to any Locked-Up Party and its respective Permitted Transferees,
shares of Company Common Stock held by such Person immediately following the closing of the Merger other than any shares purchased pursuant
to a subscription agreement.
(v)
The term “Lock-Up Warrants” means the Company Warrants held by any Locked-Up Party immediately following the
closing of the Merger and any shares of Company Common Stock received upon exercise of such Company Warrants.
(vi)
The term “Permitted Transferees” means, prior to the expiration of the Lock-Up Period, any Person to whom such
Locked-Up Party or any other Permitted Transferee of such Locked-Up Party is permitted to transfer such Lock-Up Securities pursuant to
Section 2.1(b).
(vii)
The term “Transfer” means the (A) sale of, offer to sell, contract or agreement to sell, hypothecation or pledge
of, grant of any option to purchase or otherwise dispose of or agreement to dispose of, in each case, directly or indirectly, or establishment
or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position with respect to, any
security, (B) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or
(C) public announcement of any intention to effect any transaction specified in clause (A) or (B).
(e)
Each Shareholder Party shall be permitted to enter into a trading plan established in accordance with Rule 10b5-1 under the Exchange
Act during the applicable Lock-Up Period so long as no Transfers of such Shareholder Party’s Lock-Up Securities in contravention
of this Section 2.1 are effected prior to the expiration of the applicable Lock-Up Period.
(f)
Each Locked-Up Party also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and
registrar against the transfer of any Lock-Up Securities except in compliance with the foregoing restrictions and to the addition of
a legend to such Locked-Up Party’s Lock-Up Securities describing the foregoing restrictions.
(g)
For the avoidance of doubt, each Locked-Up Party shall retain all of its rights as a shareholder of the Company with respect to the Lock-Up
Shares during the Lock-Up Period, including the right to vote any Lock-Up Shares.
ARTICLE
III
GENERAL
PROVISIONS
3.1
Notices. All notices and other communications among the parties shall be in writing and shall be deemed to have been duly
given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or certified
mail return receipt requested, postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight delivery service,
or (iv) when delivered by email (in each case in this clause (iv), solely if receipt is confirmed, but excluding any automated reply,
such as an out-of-office notification), addressed as follows:
If
to the Company, to:
Tevogen
Bio Holdings Inc.
15
Independence Boulevard, Suite #410
Warren,
New Jersey 07059
Attention:
Dr. Ryan Saadi, Chief Executive Officer and Chairperson
Email:
ryan.saadi@tevogen.com
with
a copy (not constituting notice) to:
Hogan
Lovells US LLP
100
International Drive, Suite 2000
Baltimore,
Maryland 21202
Attn:
William Intner
E-mail:
william.intner@hoganlovells.com
If
to any Shareholder Party, to such address indicated on the Company’s records with respect to such Shareholder Party or to such
other address or addresses as such Shareholder Party may from time to time designate in writing.
3.2
Amendment; Waiver.
(a)
The terms and provisions of this Agreement may be amended or modified in whole or in part only by a duly authorized agreement in writing
executed by the Company and the Locked-Up Parties holding a majority of the shares then held by the Locked-Up Parties in the aggregate
as to which this Agreement has not been terminated.
(b)
Except as expressly set forth in this Agreement, neither the failure nor delay on the part of any party hereto to exercise any right,
remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right,
remedy, power or privilege preclude any other or further exercise of the same or of any other right, remedy, power or privilege, nor
shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy,
power or privilege with respect to any other occurrence.
(c)
No party shall be deemed to have waived any claim arising out of this Agreement, or any right, remedy, power or privilege under this
Agreement, unless the waiver of such claim, right, remedy, power or privilege is expressly set forth in a written instrument duly executed
and delivered on behalf of such party; and any such waiver shall not be applicable or have any effect except in the specific instance
in which it is given.
(d)
The Company and any party hereto may unilaterally waive any of its rights hereunder in a signed writing delivered to (i) in the case
of a waiver by the Company, the applicable Locked-Up Parties, and (ii) in the case of a waiver by a Locked-Up Party, the Company.
(e)
Notwithstanding anything to the contrary, any amendment, modification or waiver of any provision herein that would (i) adversely affect
any Locked-Up Party, or (ii) disproportionately affect any Locked-Up Party as compared to any other Locked-Up Party, in each case, will
not bind any such Locked-Up Party without such Locked-Up Party’s prior written approval.
3.3
Further Assurances. The parties hereto will sign such further documents, cause such meetings to be held, resolutions passed,
exercise their votes and do and perform and cause to be done such further acts and things necessary, proper or advisable in order to
give full effect to this Agreement and every provision hereof.
3.4
Assignment. No party hereto shall assign this Agreement or any part hereof without the prior written consent of the other
parties. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
permitted successors and assigns. Any attempted assignment in violation of the terms of this Section 3.4 shall be null and void,
ab initio.
3.5
Effectiveness; Termination. Other than Article III, this Agreement shall take effect if and only when the Closing is consummated.
If the Merger Agreement is terminated in accordance with its terms, this Agreement shall be null and void, ab initio.
3.6
Third Parties. Nothing expressed or implied in this Agreement is intended or shall be construed to confer upon or give
any person, other than the parties hereto, any right or remedies under or by reason of this Agreement, as a third party beneficiary or
otherwise.
3.7
Governing Law. THIS AGREEMENT, AND ALL CLAIMS OR CAUSES OF ACTION BASED UPON, ARISING OUT OF, OR RELATED TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, WITHOUT
GIVING EFFECT TO PRINCIPLES OR RULES OF CONFLICT OF LAWS TO THE EXTENT SUCH PRINCIPLES OR RULES WOULD REQUIRE OR PERMIT THE APPLICATION
OF LAWS OF ANOTHER JURISDICTION.
3.8
Jurisdiction. Any claim, action, suit, assessment, arbitration or proceeding (an “Action”) based
upon, arising out of or related to this Agreement, or the transactions contemplated hereby, shall be brought in the Court of Chancery
of the State of Delaware (or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of
Delaware), or, if it has or can acquire jurisdiction, in the United States District Court for the District of Delaware, and each of the
parties irrevocably submits to the exclusive jurisdiction of each such court in any such Action, waives any objection it may now or hereafter
have to personal jurisdiction, venue or to convenience of forum, agrees that all claims in respect of the Action shall be heard and determined
only in any such court, and agrees not to bring any Action arising out of or relating to this Agreement or the transactions contemplated
hereby in any other court. Nothing herein contained shall be deemed to affect the right of any party to serve process in any manner permitted
by law, or to commence legal proceedings or otherwise proceed against any other party in any other jurisdiction, in each case, to enforce
judgments obtained in any Action brought pursuant to this Section 3.8.
3.9
Waiver of Jury Trial. EACH PARTY HERETO HEREBY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO
THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION,
SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH
SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS,
THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 3.9.
3.10
Specific Performance. The parties agree that irreparable damage for which monetary damages, even if available, would not
be an adequate remedy, would occur in the event that the parties do not perform their obligations under the provisions of this Agreement
(including failing to take such actions as are required of them hereunder to consummate this Agreement) in accordance with its specified
terms or otherwise breach such provisions. The parties acknowledge and agree that (a) the parties shall be entitled to an injunction,
specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions
hereof, without proof of damages, prior to the valid termination of this Agreement, and (b) the right of specific enforcement is an integral
part of the transactions contemplated by this Agreement and without that right, none of the parties would have entered into this Agreement.
Each party agrees that it will not oppose the granting of specific performance and other equitable relief on the basis that the other
parties have an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at law or
equity. The parties acknowledge and agree that any party seeking an injunction to prevent breaches of this Agreement and to enforce specifically
the terms and provisions of this Agreement in accordance with this Section 3.10 shall not be required to provide any bond or other
security in connection with any such injunction.
3.11
Entire Agreement. Except as otherwise set forth herein, this Agreement constitutes the full and entire understanding and
agreement among the parties relating to the transactions contemplated hereby and supersedes any other agreements, whether written or
oral, that may have been made or entered into by or among any of the parties hereto relating to the transactions contemplated hereby.
No representations, warranties, covenants, understandings, agreements, oral or otherwise, relating to the transactions contemplated by
this Agreement exist between the parties except as expressly set forth or referenced in this Agreement. Notwithstanding the foregoing,
nothing in this Agreement shall limit any of the rights, remedies or obligations of the Company or any of the Locked-Up Parties under
any other agreement between any of the Locked-Up Parties and the Company, and nothing in any other agreement, certificate or instrument
shall limit any of the rights, remedies or obligations of any of the Locked-Up Parties or the Company under this Agreement.
3.12
Severability. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction,
the other provisions of this Agreement shall remain in full force and effect. The parties further agree that if any provision contained
herein is, to any extent, held invalid or unenforceable in any respect under the laws governing this Agreement, they shall take any actions
necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by law and, to the
extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable
with a valid and enforceable provision giving effect to the intent of the parties.
3.13
Captions; Counterparts. The captions in this Agreement are for convenience only and shall not be considered a part of or
affect the construction or interpretation of any provision of this Agreement. This Agreement may be executed in two (2) or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
3.14
Several Liability. The liability of any Locked-Up Party hereunder is several (and not joint). Notwithstanding any other
provision of this Agreement, in no event will any Locked-Up Party be liable for any other Locked-Up Party’s breach of such other
Locked-Up Party’s obligations under this Agreement.
3.15
Effectiveness. This Agreement shall be valid and enforceable as of the date of this Agreement and may not be revoked by
any party hereto.
[Remainder
of Page Intentionally Left Blank]
IN
WITNESS WHEREOF, the parties hereto have executed this Lock-Up Agreement on the day and year first above written.
|
TEVOGEN
BIO HOLDINGS INC. |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
|
|
|
SSVK
ASSOCIATES, LLC |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
|
|
|
RYAN
SAADI |
|
|
|
|
/s/
Ryan Saadi |
Exhibit
A
1.
None
Exhibit
B
1.
[●]
Exhibit
C
FORM
OF JOINDER TO LOCK-UP AGREEMENT
[______],
20__
Reference
is made to the Lock-Up Agreement, dated as of February 14, 2024, by and among Tevogen Bio Holdings Inc. (the “Company”)
and the other Locked-Up Parties (as defined therein) from time to time party thereto (as amended from time to time, the “Lock-Up
Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the
Lock-Up Agreement.
Each
of the Company and each undersigned holder of shares of the Company (each, a “New Locked-Up Party”) agrees that this
Joinder to the Lock-Up Agreement (this “Joinder”) is being executed and delivered for good and valuable consideration.
Each
undersigned New Locked-Up Party hereby agrees to and does become party to the Lock-Up Agreement as a Locked-Up Party. This Joinder shall
serve as a counterpart signature page to the Lock-Up Agreement and by executing below each undersigned New Locked-Up Party is deemed
to have executed the Lock-Up Agreement with the same force and effect as if originally named a party thereto.
This
Joinder may be executed in multiple counterparts, including by means of facsimile or electronic signature, each of which shall be deemed
an original, but all of which together shall constitute the same instrument.
[Remainder
of Page Intentionally Left Blank.]
IN
WITNESS WHEREOF, the undersigned have duly executed this Joinder as of the date first set forth above.
|
[NEW
LOCKED-UP PARTY] |
|
|
|
|
By: |
|
|
Name: |
|
|
Title |
|
|
|
|
|
SEMPER
PARATUS ACQUISITION CORP |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
Exhibit
10.6
NON-COMPETITION
AND NON-SOLICITATION AGREEMENT
THIS
NON-COMPETITION AND NON-SOLICITATION AGREEMENT (this “Agreement”) has been executed, and is effective as of
the Closing Date, by Dr. Ryan Saadi, Chief Executive Officer of the Company and stockholder of the Company (defined below) (the “Subject
Party”), in favor of and for the benefit of Semper Paratus Acquisition Corporation, a Cayman Islands exempted company (including
any successor entity thereto, the “Purchaser”), and each of the Purchaser’s Affiliates, successors, and
direct and indirect Subsidiaries (collectively with the Purchaser, the “Covered Parties”). Any capitalized
term used, but not defined in this Agreement will have the meaning ascribed to such term in the Merger Agreement (defined below).
WHEREAS,
on June 28, 2023, (i) the Purchaser; (ii) Semper Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Purchaser
(“Merger Sub”); (iii) SSVK Associates, LLC, a Delaware limited liability company (the “Purchaser
Representative”); (iv) Dr. Ryan Saadi (the “Seller Representative”); and (v) Tevogen Bio Inc,
a Delaware corporation (the “Company”) entered into that certain Merger Agreement (as amended from time to
time in accordance with the terms thereof, the “Merger Agreement”), pursuant to which the parties thereto intend
to effect the merger of Merger Sub with and into the Company, with the Company continuing as the surviving entity and a wholly owned
subsidiary of the Purchaser (the “Merger”);
WHEREAS,
the Company is a clinical-stage specialty immunotherapy company that harnesses CD8+ CTLs to develop off-the-shelf therapies for the treatment
of infectious diseases, cancers, and neurological disorders with the aim of addressing unmet needs of large patient populations (the
“Business”);
WHEREAS,
in connection with, and as a condition to the consummation of the Merger and the other transactions contemplated thereby (the “Transactions”),
and to enable the Purchaser to secure more fully the benefits of the Transactions, including the protection and maintenance of the goodwill
and confidential information of the Company, the Purchaser has required that the Subject Party enter into this Agreement;
WHEREAS,
the Subject Party is entering into this Agreement in order to induce the Purchaser to consummate the Transactions, pursuant to which
the Subject Party will directly or indirectly receive a material benefit; and
WHEREAS,
the Subject Party, as a former stockholder of the Company, has contributed to the value of the Company and has obtained extensive and
valuable knowledge and confidential information concerning the business of the Company.
NOW,
THEREFORE, in order to induce the Purchaser to consummate the Transactions, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Subject Party hereby agrees as follows:
1.
Restriction on Competition.
(a)
Restriction. The Subject Party hereby agrees that during the period from the Closing until the five (5) year anniversary of the
Closing Date (the “Termination Date,” and such period from the Closing until the Termination Date, the “Restricted
Period”), the Subject Party will not, and will cause its Affiliates not to, without the prior written consent of the Purchaser
(which may be withheld in its sole discretion), (i) anywhere in the United States and (ii) in any other jurisdictions in which the Company
is engaged, or is actively contemplating to become engaged, in the Business as of the Closing Date (clauses (i) and (ii), collectively,
the “Territory”), directly or indirectly engage in the Business (other than through a Covered Party) or own,
manage, finance, or control, or participate in the ownership, management, financing, or control of, or become engaged or serve as an
officer, director, member, partner, employee, agent, consultant, advisor, or representative of, a business or entity (other than a Covered
Party) that engages in the Business (a “Competitor”). Notwithstanding the foregoing, the Subject Party and
its Affiliates may own passive investments of no more than two percent (2%) of any class of outstanding equity interests in a Competitor
that is publicly traded, so long as the Subject Party and its Affiliates or any immediate family member of the Subject Party are not
involved in the management or control of such Competitor (“Permitted Ownership”).
(b)
Acknowledgment. The Subject Party acknowledges and agrees, that (i) the Subject Party possesses knowledge of confidential information
of the Company and the Business, (ii) the Subject Party’s execution of this Agreement is a material inducement to the Purchaser
to consummate the Transactions and to realize the goodwill of the Company, for which the Subject Party and/or its Affiliates will receive
a substantial direct or indirect financial benefit, and that the Purchaser would not have entered into the Merger Agreement or consummated
the Transactions but for the Subject Party’s agreements set forth in this Agreement, (iii) it would substantially impair the goodwill
of the Company and materially reduce the value of the assets of the Company and cause serious and irreparable injury if the Subject Party
were to use its ability and knowledge by engaging in the Business in competition with a Covered Party, and/or to otherwise breach the
obligations contained herein and that the Covered Parties would not have an adequate remedy at law because of the unique nature of the
Business, (iv) the Subject Party and its Affiliates have no intention of engaging in the Business (other than through the Covered Parties)
during the Restricted Period other than through Permitted Ownership, (v) the relevant public policy aspects of restrictive covenants,
covenants not to compete, and non-solicitation provisions have been discussed, and every effort has been made to limit the restrictions
placed upon the Subject Party to those that are reasonable and necessary to protect the Covered Parties’ legitimate interests,
(vi) the Covered Parties conduct and intend to conduct the Business everywhere in the Territory and compete with other businesses that
are or could be located in any part of the Territory, (vii) the foregoing restrictions on competition are fair and reasonable in type
of prohibited activity, geographic area covered, scope, and duration, (viii) the consideration provided to the Subject Party under this
Agreement and the Merger Agreement is not illusory, and (ix) such provisions do not impose a greater restraint than is necessary to protect
the goodwill or other business interests of the Covered Parties.
2.
No Solicitation.
(a)
No Solicitation of Employees and Consultants. The Subject Party agrees that, during the Restricted Period, the Subject
Party will not, and will not permit its Affiliates to, without the prior written consent of the Purchaser (which may be withheld in its
sole discretion), either on its own behalf or on behalf of any other Person (other than, if applicable, a Covered Party in the performance
of the Subject Party’s duties on behalf of the Covered Parties), directly or indirectly: (i) hire or engage as an employee, independent
contractor, consultant, or otherwise any Covered Personnel (as defined below); (ii) solicit, induce, encourage, or otherwise knowingly
cause (or attempt to do any of the foregoing) any Covered Personnel to leave the service (whether as an employee, consultant, or independent
contractor) of any Covered Party; or (iii) in any way interfere with or attempt to interfere with the relationship between any Covered
Personnel and any Covered Party; provided, however, the Subject Party and its Affiliates will not be deemed to have violated
this Section 2(a) if any Covered Personnel voluntarily and independently solicits an offer of employment from the Subject Party or any
of its Affiliates by responding to a general advertisement or solicitation program conducted by or on behalf of the Subject Party or
any of its Affiliates (or such other Person whom any of them is acting on behalf of) that is not targeted at such Covered Personnel or
Covered Personnel generally. For purposes of this Agreement, “Covered Personnel” shall mean any Person who
is or was an employee, consultant, or independent contractor of the Covered Parties, as of the Closing Date, at any time during the Restricted
Period, or as of the relevant time of determination.
(b)
Non-Solicitation of Customers and Suppliers. The Subject Party agrees that, during the Restricted Period, the Subject Party and
its Affiliates will not, without the prior written consent of the Purchaser (which may be withheld in its sole discretion), individually
or on behalf of any other Person (other than, if applicable, a Covered Party in the performance of the Subject Party’s duties on
behalf of the Covered Parties), knowingly and for a purpose competitive with a Covered Party as it related to the Business as of the
Closing Date: (i) solicit, induce, encourage, or otherwise knowingly cause (or attempt to do any of the foregoing) any Covered Customer
(as defined below) to (A) cease being, or not become, a client or customer of any Covered Party with respect to the Business or (B) reduce
the amount of business of such Covered Customer with any Covered Party, or otherwise alter such business relationship in a manner adverse
to any Covered Party, in either case, with respect to or relating to the Business; (ii) interfere with or disrupt (or attempt to interfere
with or disrupt) the contractual relationship between any Covered Party and any Covered Customer; (iii) divert any business with any
Covered Customer relating to the Business from a Covered Party; (iv) solicit for business, provide services to, engage in or do business
with, any Covered Customer for products or services that are part of the Business; or (v) interfere with or disrupt (or attempt to interfere
with or disrupt), any Person that was a vendor, supplier, distributor, agent, or other service provider of a Covered Party at the time
of such interference or disruption. For purposes of this Agreement, a “Covered Customer” shall mean (x) any
Person who is or was an actual customer or client (or prospective customer or client with whom a Covered Party actively marketed or made
or has taken specific action to make a proposal) of a Covered Party, as of the Closing Date, at any time during the Restricted Period,
or as of the relevant time of determination.
3.
Representations and Warranties. The Subject Party hereby represents and warrants, to and for the benefit of the Covered Parties as
of the date of this Agreement and as of the Closing Date, that: (a) the Subject Party has full power and capacity to execute and deliver,
and to perform all of the Subject Party’s obligations under, this Agreement; and (b) neither the execution and delivery of this
Agreement nor the performance of the Subject Party’s obligations hereunder will result directly or indirectly in a violation or
breach of any agreement or obligation by which the Subject Party is a party or otherwise bound. By entering into this Agreement, the
Subject Party certifies and acknowledges that the Subject Party has carefully read all of the provisions of this Agreement, and that
the Subject Party voluntarily and knowingly enters into this Agreement.
4.
Remedies. The covenants and undertakings contained in this Agreement relate to matters which are of a special, unique, and extraordinary
character and a violation of any of the terms of this Agreement may cause irreparable injury, the amount of which may be impossible to
estimate or determine and which cannot be adequately compensated. In the event of any breach or threatened breach of any covenant or
obligation contained in this Agreement, the adversely affected party or parties will be entitled to seek the following remedies (in addition
to, and not in lieu of, any other remedy at law or in equity or pursuant to the Merger Agreement or the other Ancillary Documents that
may be available, including monetary damages), and a court of competent jurisdiction may award: (i) an injunction, restraining order,
or other equitable relief restraining or preventing such breach or threatened breach, without the necessity of posting bond or security,
which each party expressly waives; and (ii) recovery of attorneys’ fees and costs incurred in enforcing the party’s rights
under this Agreement. The Subject Party hereby acknowledges and agrees that in the event of any breach of this Agreement, any value attributed
or allocated to this Agreement (or any other non-competition agreement with the Subject Party) under or in connection with the Merger
Agreement shall not be considered a measure of, or a limit on, the damages of the Covered Parties.
5.
Survival of Obligations. The expiration of the Restricted Period will not relieve the Subject Party of any obligation or liability
arising from any breach by the Subject Party of this Agreement during the Restricted Period. The Subject Party further agrees that the
time periods during which the covenants contained in this Agreement will be effective will be computed by excluding from such computation
any time during which the Subject Party is in violation of any provision of such Sections.
6.
Miscellaneous.
(a)
Notices. All notices, consents, waivers, and other communications hereunder shall be in writing and shall be deemed to have been
duly given when delivered (i) in person, (ii) by facsimile or other electronic means, with affirmative confirmation of receipt, (iii)
one Business Day after being sent, if sent by reputable, nationally recognized overnight courier service or (iv) three (3) Business Days
after being mailed, if sent by registered or certified mail, pre-paid and return receipt requested, in each case to the applicable party
at the following addresses (or at such other address for a party as shall be specified by like notice):
If
to the Purchaser after the Closing, to: |
|
with
copies to (which shall not constitute notice): |
|
|
|
Tevogen
Bio Holdings Inc. |
|
Hogan
Lovells US LLP |
15
Independence Boulevard, Suite #410 |
|
100
International Drive, Suite 2000 |
Warren,
New Jersey 07059 |
|
Baltimore,
Maryland 21202 |
Email:
Ryan.Saadi@Tevogen.com |
|
Attn:
William Intner and Richard Aftanas |
|
|
Telephone
No.: (410) 659-2778; (212) 918-3267 |
|
|
Email:
William.Intner@hoganlovells.com; |
|
|
Richard.Aftanas@hoganlovells.com |
If
to the Subject Party, to: the address set forth below the Subject Party’s name on the signature page to this Agreement |
(b)
Integration and Non-Exclusivity. This Agreement, the Merger Agreement, and the other Ancillary Documents contain the entire agreement
between the Subject Party and the Covered Parties concerning the subject matter hereof. Notwithstanding the foregoing, the rights and
remedies of the Covered Parties under this Agreement are not exclusive of or limited by any other rights or remedies which they may have,
whether at law, in equity, by contract or otherwise, all of which will be cumulative (and not alternative). Without limiting the generality
of the foregoing, the rights, remedies, obligations, and liabilities of the parties under this Agreement are in addition to their respective
rights, remedies, obligations, and liabilities (i) under the laws of unfair competition, misappropriation of trade secrets, or other
requirements of statutory or common law, or any applicable rules and regulations and (ii) otherwise conferred by contract, including
the Merger Agreement and any other written agreement between the Subject Party or its Affiliates and any of the Covered Parties. Nothing
in the Merger Agreement will limit any of the obligations, liabilities, rights, or remedies of the Subject Party or the Covered Parties
under this Agreement, nor will any breach of the Merger Agreement or any other agreement between the Subject Party or its Affiliates
and any of the Covered Parties limit or otherwise affect any right or remedy under this Agreement. If any covenant set forth in any other
agreement between the Subject Party or its Affiliates and any of the Covered Parties conflicts or is inconsistent with the terms and
conditions of this Agreement, the more restrictive terms will control as to the Subject Party or its Affiliate, as applicable.
(c)
Severability; Reformation. Each provision of this Agreement is separable from every other provision of this Agreement. If any
provision of this Agreement is found or held to be invalid, illegal, or unenforceable, in whole or in part, by a court of competent jurisdiction,
then (i) such provision will be deemed amended to conform to applicable laws so as to be valid, legal, and enforceable to the fullest
possible extent, (ii) the invalidity, illegality, or unenforceability of such provision will not affect the validity, legality, or enforceability
of such provision under any other circumstances or in any other jurisdiction, and (iii) the invalidity, illegality, or unenforceability
of such provision will not affect the validity, legality, or enforceability of the remainder of such provision or the validity, legality,
or enforceability of any other provision of this Agreement. The Subject Party and the Covered Parties will substitute for any invalid,
illegal, or unenforceable provision a suitable and equitable provision that carries out, so far as may be valid, legal, and enforceable,
the intent and purpose of such invalid, illegal, or unenforceable provision. Without limiting the foregoing, if any court of competent
jurisdiction determines that any part hereof is unenforceable because of the duration, geographic area covered, scope of such provision,
or otherwise, such court will have the power to reduce the duration, geographic area covered, or scope of such provision, as the case
may be, and, in its reduced form, such provision will then be enforceable. The Subject Party will, at a Covered Party’s request,
join such Covered Party in requesting that such court take such action.
(d)
Amendment; Waiver. This Agreement may not be amended or modified in any respect, except by a written agreement executed by the
Subject Party, the Purchaser, and a majority of the disinterested independent directors of the Purchaser’s board of directors (or
their respective permitted successors or assigns). No waiver will be effective unless it is expressly set forth in a written instrument
executed by the waiving party (and if such waiving party is a Covered Party, by a majority of the disinterested independent directors
of the Purchaser’s board of directors) and any such waiver will have no effect except in the specific instance in which it is given.
Any delay or omission by a party in exercising its rights under this Agreement, or failure to insist upon strict compliance with any
term, covenant, or condition of this Agreement will not be deemed a waiver of such term, covenant, condition, or right, nor will any
waiver or relinquishment of any right or power under this Agreement at any time or times be deemed a waiver or relinquishment of such
right or power at any other time or times.
(e)
Governing Law; Jurisdiction. This Agreement shall be governed by, construed and enforced in accordance with the Laws of the State
of Delaware without regard to the conflict of laws principles thereof. All Actions arising out of or relating to this Agreement shall
be heard and determined exclusively in any state or federal court located in Delaware (or in any appellate courts thereof) (the “Specified
Courts”). Each party hereto hereby (a) submits to the exclusive jurisdiction of any Specified Court for the purpose of
any Action arising out of or relating to this Agreement brought by any party hereto, (b) irrevocably waives, and agrees not to assert
by way of motion, defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that
the venue of the Action is improper, or that this Agreement or the transactions contemplated hereby may not be enforced in or by any
Specified Court and (c) waives any bond, surety or other security that might be required of any other party with respect thereto. Each
party agrees that a final judgment in any Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment
or in any other manner provided by Law or in equity. Each party irrevocably consents to the service of the summons and complaint and
any other process in any other action or proceeding relating to the transactions contemplated by this Agreement, on behalf of itself,
or its property, by personal delivery of copies of such process to such party at the applicable address set forth in Section 6(a). Nothing
in this Section 6(e) shall affect the right of any party to serve legal process in any other manner permitted by Law.
(f)
WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT
MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (B) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS SECTION 6(f). ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 6(f) WITH ANY COURT AS WRITTEN EVIDENCE
OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY.
(g)
Successors and Assigns; Third Party Beneficiaries. This Agreement will be binding upon, and will inure to the benefit of the parties,
and their respective successors and assigns. No Covered Party may assign any or all of its rights under this Agreement, at any time,
in whole or in part, to any Person without first obtaining the consent or approval of the Subject Party (which consent shall not be unreasonably
withheld, conditioned or delayed). The Subject Party agrees that the obligations of the Subject Party under this Agreement are specific
to each of them and will not be assigned by the Subject Party.
(h)
Disinterested Director Majority Authorized to Act on Behalf of Covered Parties. The parties acknowledge and agree that the majority
of the disinterested independent directors of the Purchaser’s board of directors is authorized and shall have the sole right to
act on behalf of Purchaser and the other Covered Parties under this Agreement, including the right to enforce the Purchaser’s rights
and remedies under this Agreement. Without limiting the foregoing, in the event that the Subject Party or Affiliate thereof serves as
a director, officer, employee, or other authorized agent of a Covered Party, the Subject Party shall have no authority, express or implied,
to act or make any determination on behalf of a Covered Party in connection with this Agreement or any dispute or Action with respect
hereto.
(i)
Construction. The Subject Party acknowledges that the Subject Party has been represented by counsel, or had the opportunity to
be represented by counsel of the Subject Party’s choice. Any rule of construction to the effect that ambiguities are to be resolved
against the drafting party will not be applied in the construction or interpretation of this Agreement. Neither the drafting history
nor the negotiating history of this Agreement will be used or referred to in connection with the construction or interpretation of this
Agreement. The headings and subheadings contained in this Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement. In this Agreement: (i) the words “include,” “includes” and “including”
when used herein shall be deemed in each case to be followed by the words “without limitation”; (ii) the definitions contained
herein are applicable to the singular as well as the plural forms of such terms; (iii) whenever required by the context, any pronoun
shall include the corresponding masculine, feminine, or neuter forms, and the singular form of nouns, pronouns, and verbs shall include
the plural and vice versa; (iv) the words “herein,” “hereto,” and “hereby” and other words of similar
import shall be deemed in each case to refer to this Agreement as a whole and not to any particular Section or other subdivision of this
Agreement; (v) the word “if” and other words of similar import when used herein shall be deemed in each case to be followed
by the phrase “and only if”; (vi) the term “or” means “and/or”; and (vii) any agreement or instrument
defined or referred to herein or in any agreement or instrument that is referred to herein means such agreement or instrument as from
time to time amended, modified, or supplemented, including by waiver or consent and references to all attachments thereto and instruments
incorporated therein.
(j)
Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.
A photocopy, faxed, scanned, and/or emailed copy of this Agreement or any signature page to this Agreement, shall have the same validity
and enforceability as an originally signed copy.
(k)
Effectiveness. This Agreement shall be binding upon the Subject Party upon the Subject Party’s execution and delivery of
this Agreement, but this Agreement shall only become effective upon the consummation of the Transactions. In the event that the Merger
Agreement is validly terminated in accordance with its terms prior to the consummation of the Transactions, this Agreement shall automatically
terminate and become null and void, and the parties shall have no obligations hereunder.
[Remainder
of Page Intentionally Left Blank; Signature Pages Follows]
IN
WITNESS WHEREOF, the undersigned has duly executed and delivered this Non-Competition and Non-Solicitation Agreement as of the date
first written above.
|
The
Subject Party: |
|
|
|
|
Dr.
Ryan Saadi |
|
|
|
|
By: |
/s/
Ryan Saadi |
|
Name:
|
Ryan
Saadi |
|
Title: |
Chief
Executive Officer |
Acknowledged
and accepted as of the date first written above:
The
Purchaser: |
|
|
|
|
SEMPER
PARATUS ACQUISITION CORPORATION |
|
|
|
|
By: |
|
|
Name: |
|
|
Title:
|
|
|
Exhibit 10.7
ASSIGNMENT
AND ASSUMPTION AGREEMENT
THIS
ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment and Assumption Agreement”) is made and entered into as of
February 14, 2024, by and between Tevogen Bio Holdings Inc., a Delaware corporation (formerly known as Semper Paratus Acquisition Corporation,
a Cayman Islands exempted company), including any successor entity thereto (“Purchaser”), and Tevogen Bio Inc (the
“Company”). Purchaser and the Company are each referred to herein individually as a “Party” and
collectively, as the “Parties.”
WHEREAS,
on June 28, 2023, (i) Semper Paratus Acquisition Corporation, (ii) Semper Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary
of the Purchaser (“Merger Sub”), (iii) SSVK Associates, LLC, a Delaware limited liability company, (iv) Dr. Ryan Saadi
(the “Seller Representative”), and (v) the Company entered into that certain Merger Agreement (as amended from time
to time in accordance with the terms thereof, the “Merger Agreement”), pursuant to which the parties thereto are effecting
the merger of Merger Sub with and into the Company, with the Company continuing as the surviving entity and a wholly owned subsidiary
of the Purchaser (the “Merger”);
WHEREAS,
in partial consideration therefore, the Merger Agreement requires that Purchaser assume all obligations of the Company under the Company’s
convertible notes listed on Schedule A of this Assignment and Assumption Agreement (the “Convertible Notes”);
and
WHEREAS,
pursuant to the Merger Agreement, Purchaser agreed to execute and deliver to the Company at the Closing this written assumption of the
Convertible Notes.
NOW
THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, and intending to be legally bound hereby, the Parties hereby agree as follows:
1.
Defined Terms. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger
Agreement.
2.
Assignment and Assumption. The Company hereby assigns, transfers and conveys to Purchaser all right, title, benefit, privileges
and interest of the Company in and to, and all of the burdens, obligations and liabilities of the Convertible Notes, and Purchaser hereby
accepts such assignment and hereby assumes and agrees to pay, perform, satisfy or discharge in accordance with their terms, to the extent
not heretofore paid, performed, satisfied or discharged, such Convertible Notes. Other than the Convertible Notes, the Purchaser does
not assume any other Liabilities, and the Parties hereto agree that all such other Liabilities shall remain the sole responsibility of,
and will be satisfied by, the Company.
3.
Non-Assigned Assets. To the extent that any of the Convertible Notes are not assignable without the Consent of another Person,
this Assignment and Assumption Agreement shall not constitute an assignment or an attempted assignment of such Convertible Note if such
assignment or attempted assignment would constitute a breach thereof and such consent is not obtained as of the date hereof; provided,
however, to the extent consent of such other Person is obtained with respect to such Convertible Note after the date hereof, this Assignment
and Assumption Agreement shall constitute an assignment of such Convertible Note in accordance with the terms and subject to the conditions
set forth in the Merger Agreement.
4.
No Additional Representations. Except as otherwise set forth in this Assignment and Assumption Agreement, neither Purchaser nor
the Company is making any additional representations, warranties or covenants in this Assignment and Assumption Agreement other than
those contained in the Merger Agreement.
5.
Further Assurances. Each of the Parties hereto covenants and agrees, at its own expense, to execute and deliver, at the request
of any other Party hereto, all such further instruments of transfer and assignments and to take such other action as such other Party
may reasonably request to more effectively consummate the assignments and assumptions contemplated by this Assignment and Assumption
Agreement.
6.
No Third Party Beneficiaries. Nothing in this instrument, expressed or implied, is intended or shall be construed to confer upon
or give to any Person, other than Purchaser and the Company and their respective successors and assigns, any remedy or claim under or
by reason of this instrument or any agreement, term, covenant or condition hereof, and all of the agreements, terms, covenants and conditions
contained in this instrument shall be for the sole and exclusive benefit of Purchaser and the Company and their respective successors
and assigns.
7.
Modification. This Assignment and Assumption Agreement may not be modified except by a writing executed by all the Parties hereto.
8.
Assignment. No Party may assign any of its rights under this Assignment and Assumption Agreement without the prior consent of
the other Party which will not be unreasonably withheld. Subject to the preceding sentence, the terms of this Assignment and Assumption
Agreement shall be binding upon, inure to the benefit of, and be enforceable by each of the Parties hereto and each of their respective
successors and permitted assigns.
9.
Governing Law. THIS ASSIGNMENT AND ASSUMPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE
STATE OF DELAWARE WITHOUT GIVING EFFECT TO CONFLICT OF LAWS PRINCIPLES.
10.
Execution in Counterparts. This Assignment and Assumption Agreement may be executed in one or more counterparts, each of which
shall be deemed an original and all of which, taken together, shall constitute one and the same instrument. Original signatures hereto
may be delivered by facsimile or by electronic transmission in .PDF or TIF format which shall be deemed originals.
IN
WITNESS WHEREOF, the Parties have executed and delivered this Assignment and Assumption Agreement as of the date first written above.
|
PURCHASER: |
|
|
|
|
Tevogen Bio Holdings Inc., a Delaware corporation |
|
|
|
|
By: |
|
|
Name:
|
|
|
Title: |
|
|
COMPANY: |
|
|
|
|
Tevogen Bio Inc, a Delaware corporation |
|
|
|
|
By:
|
/s/
Ryan Saadi |
|
Name:
|
Ryan
Saadi |
|
Title:
|
Chief
Executive Officer |
Schedule
A
Convertible
Notes
1. |
$10,000,000
Convertible Promissory Note, dated January 22, 2021 by and between Company and HMP Partners, LLC, as amended by that certain letter
agreement dated September 12, 2023 (“Note 1”). |
2. |
$2,500,000
Convertible Promissory Note, dated October 18, 2021 by and between Company and HBP Investors LLC, as amended by that certain letter
agreement dated September 12, 2023 (“Note 2”). |
3. |
$5,000,000
Convertible Promissory Note, dated March 14, 2022 by and between Company and HMP Partners, LLC, as amended by that certain letter
agreement dated September 12, 2023 (“Note 3”). |
4. |
$2,500,000
Convertible Promissory Note, dated December 23, 2022 by and between Company and The Patel Family, LLP, as amended by that certain
letter agreement dated September 12, 2023 (“Note 4”). |
5. |
$2,500,000
Convertible Promissory Note, dated February 3, 2023 by and between Company and The Patel Family, LLP, as amended by that certain
letter agreement dated September 12, 2023 (“Note 5”). |
6. |
$1,150,000
Convertible Promissory Note, dated September 25, 2023, by and between Company and HMP Partners, LLC (“Note 6”). |
7. |
$350,000
Convertible Promissory Note, dated October 8, 2023, by and between Company and HMP Partners, LLC (“Note 7”). |
Exhibit
10.8
TEVOGEN
BIO HOLDINGS INC.
2024
OMNIBUS INCENTIVE PLAN
TABLE
OF CONTENTS
|
|
Page |
1. |
PURPOSE |
1 |
2. |
DEFINITIONS |
1 |
3. |
ADMINISTRATION OF THE PLAN |
9 |
|
3.1 |
Committee. |
9 |
|
|
3.1.1 |
Powers and Authorities. |
9 |
|
|
3.1.2 |
Composition of the Committee. |
9 |
|
|
3.1.3 |
Other Committees. |
10 |
|
|
3.1.4 |
Delegation by the Committee. |
10 |
|
3.2 |
Board. |
10 |
|
3.3 |
Terms of Awards. |
10 |
|
|
3.3.1 |
Committee Authority. |
10 |
|
|
3.3.2 |
Forfeiture; Recoupment. |
11 |
|
3.4 |
No Repricing Without Stockholder Approval. |
12 |
|
3.5 |
Deferral Arrangement. |
12 |
|
3.6 |
Registration; Share Certificates. |
12 |
4. |
STOCK SUBJECT TO THE PLAN |
12 |
|
4.1 |
Number of Shares of Stock Available for Awards. |
12 |
|
4.2 |
Adjustments in Authorized Shares of Stock. |
13 |
|
4.3 |
Share Usage. |
13 |
5. |
TERM; AMENDMENT AND TERMINATION |
14 |
|
5.1 |
Term. |
14 |
|
5.2 |
Amendment, Suspension, and Termination. |
14 |
6. |
AWARD ELIGIBILITY AND LIMITATIONS |
14 |
|
6.1 |
Eligible Grantees. |
14 |
|
6.2 |
Stand-Alone, Additional, Tandem, and Substitute Awards. |
14 |
7. |
AWARD AGREEMENT |
15 |
8. |
TERMS AND CONDITIONS OF OPTIONS |
15 |
|
8.1 |
Option Price. |
15 |
|
8.2 |
Vesting and Exercisability. |
15 |
|
8.3 |
Term. |
15 |
|
8.4 |
Termination of Service. |
16 |
|
8.5 |
Limitations on Exercise of Option. |
16 |
|
8.6 |
Method of Exercise. |
16 |
|
8.7 |
Rights of Holders of Options. |
16 |
|
8.8 |
Delivery of Stock. |
16 |
|
8.9 |
Transferability of Options. |
16 |
|
8.10 |
Family Transfers. |
17 |
|
8.11 |
Limitations on Incentive Stock Options. |
17 |
|
8.12 |
Notice of Disqualifying Disposition. |
17 |
9. |
TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS |
17 |
|
9.1 |
Right to Payment and SAR Price. |
17 |
|
9.2 |
Other Terms. |
18 |
|
9.3 |
Term. |
18 |
|
9.4 |
Rights of Holders of SARs. |
18 |
|
9.5 |
Transferability of SARs. |
18 |
|
9.6 |
Family Transfers. |
18 |
10. |
TERMS AND CONDITIONS OF RESTRICTED STOCK, RESTRICTED STOCK UNITS, AND DEFERRED STOCK UNITS |
19 |
|
10.1 |
Grant of Restricted Stock, Restricted Stock Units, and Deferred Stock Units. |
19 |
|
10.2 |
Restrictions. |
19 |
|
10.3 |
Registration; Restricted Stock Certificates. |
19 |
|
10.4 |
Rights of Holders of Restricted Stock. |
20 |
|
10.5 |
Rights of Holders of Restricted Stock Units and Deferred Stock Units. |
20 |
|
|
10.5.1 |
Voting and Dividend Rights. |
20 |
|
|
10.5.2 |
Creditor’s Rights. |
20 |
|
10.6 |
Termination of Service. |
20 |
|
10.7 |
Purchase of Restricted Stock and Shares of Stock Subject to Restricted Stock Units and Deferred Stock Units. |
21 |
|
10.8 |
Delivery of Shares of Stock. |
21 |
11. |
TERMS AND CONDITIONS OF UNRESTRICTED STOCK AWARDS AND OTHER EQUITY-BASED AWARDS |
21 |
|
11.1 |
Unrestricted Stock Awards. |
21 |
|
11.2 |
Other Equity-Based Awards. |
22 |
12. |
TERMS AND CONDITIONS OF DIVIDEND EQUIVALENT RIGHTS |
22 |
|
12.1 |
Dividend Equivalent Rights. |
22 |
|
12.2 |
Termination of Service. |
22 |
13. |
TERMS AND CONDITIONS OF PERFORMANCE AWARDS |
22 |
|
13.1 |
Grant of Performance Awards. |
22 |
|
13.2 |
Value of Performance Awards. |
22 |
|
13.3 |
Earning of Performance Awards. |
23 |
|
13.4 |
Form and Timing of Payment of Performance Awards. |
23 |
|
13.5 |
Performance Conditions. |
23 |
|
13.6 |
Performance Measures. |
23 |
14. |
FORMS OF PAYMENT |
24 |
|
14.1 |
General Rule. |
24 |
|
14.2 |
Surrender of Shares of Stock. |
24 |
|
14.3 |
|
Cashless Exercise. |
24 |
|
14.4 |
|
Other Forms of Payment. |
24 |
15. |
REQUIREMENTS OF LAW |
25 |
|
15.1 |
|
General. |
25 |
|
15.2 |
|
Rule 16b-3. |
25 |
16. |
EFFECT OF CHANGES IN CAPITALIZATION |
26 |
|
16.1 |
|
Changes in Stock. |
26 |
|
16.2 |
|
Transaction in Which the Company is the Surviving Entity Which Does not Constitute a Change in Control. |
26 |
|
16.3 |
|
Change in Control in which Awards are not Assumed. |
27 |
|
16.4 |
|
Change in Control in which Awards are Assumed. |
28 |
|
16.5 |
|
Adjustments. |
28 |
|
16.6 |
|
No Limitations on Company. |
28 |
17.a |
PARACHUTE LIMITATIONS |
29 |
18. |
GENERAL PROVISIONS |
29 |
|
18.1 |
|
Disclaimer of Rights. |
29 |
|
18.2 |
|
Nonexclusivity of the Plan. |
30 |
|
18.3 |
|
Withholding Taxes. |
30 |
|
18.4 |
|
Captions. |
31 |
|
18.5 |
|
Construction. |
31 |
|
18.6 |
|
Other Provisions. |
31 |
|
18.7 |
|
Number and Gender. |
31 |
|
18.8 |
|
Severability. |
31 |
|
18.9 |
|
Governing Law. |
31 |
|
18.10 |
|
Foreign Jurisdictions. |
31 |
|
18.11 |
|
Section 409A of the Code. |
32 |
|
18.12 |
|
Limitation on Liability. |
32 |
TEVOGEN
BIO HOLDINGS INC.
2024
OMNIBUS INCENTIVE PLAN
1.
PURPOSE
The
Plan is intended to (a) provide eligible individuals with an incentive to contribute to the success of the Company and to operate and
manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability and that
will benefit its stockholders and other important stakeholders, including its employees and customers, and (b) provide a means of recruiting,
rewarding, and retaining key personnel. To this end, the Plan provides for the grant of Awards of Options, Stock Appreciation Rights,
Restricted Stock, Restricted Stock Units, Deferred Stock Units, Unrestricted Stock, Dividend Equivalent Rights, Other Equity-Based Awards,
and cash bonus awards. Any of these Awards may, but need not, be made as performance incentives to reward the holders of such Awards
for the achievement of performance goals in accordance with the terms of the Plan. Options granted under the Plan may be Nonqualified
Stock Options or Incentive Stock Options.
2.
DEFINITIONS
For
purposes of interpreting the Plan documents, including the Plan and Award Agreements, the following capitalized terms shall have the
meanings specified below, unless the context clearly indicates otherwise:
2.1
“Affiliate” shall mean any Person that controls, is controlled by, or is under common control with the Company within
the meaning of Rule 405 of Regulation C under the Securities Act, including any Subsidiary. For purposes of making a grant of Options
or Stock Appreciation Rights, an entity shall not be considered an Affiliate unless the Company holds a Controlling Interest in such
entity. The preceding sentence does not, however, apply for purposes of determining whether Service is uninterrupted for purposes of
vesting, exercisability, or expiration of Options and Stock Appreciation Rights.
2.2
“Applicable Laws” shall mean the legal requirements relating to the Plan and the Awards under (a) applicable provisions
of the Code, the Securities Act, the Exchange Act, any rules or regulations thereunder, and any other laws, rules, regulations, and government
orders of any jurisdiction applicable to the Company or its Affiliates, (b) applicable provisions of the corporate, securities, tax,
and other laws, rules, regulations, and government orders of any jurisdiction applicable to Awards granted to residents thereof, and
(c) the rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.
2.3
“Award” shall mean a grant under the Plan of an Option, a Stock Appreciation Right, Restricted Stock, a Restricted
Stock Unit, a Deferred Stock Unit, Unrestricted Stock, a Dividend Equivalent Right, a Performance Share or other Performance Award, an
Other Equity-Based Award, or cash.
2.4
“Award Agreement” shall mean the written agreement, in such written, electronic, or other form as determined by the
Committee, between the Company and a Grantee that evidences and sets forth the terms and conditions of an Award.
2.5
“Beneficial Owner” shall have the meaning set forth in Rule 13d-3 under the Exchange Act.
2.6
“Benefit Arrangement” shall mean any formal or informal plan or other arrangement for the direct or indirect provision
of compensation to a Grantee (including groups or classes of Grantees or beneficiaries of which the Grantee is a member), whether or
not such compensation is deferred, is in cash, or is in the form of a benefit to or for the Grantee.
2.7
“Board” shall mean the Board of Directors of the Company.
2.8
“Capital Stock” shall mean, with respect to any Person, any and all shares, interests, participations, or other equivalents
(however designated, whether voting or non-voting) in equity of such Person, whether outstanding on the Effective Date or issued thereafter,
including, without limitation, all shares of Stock.
2.9
“Cause” shall have the meaning set forth in an applicable agreement between a Grantee and the Company or an Affiliate,
and in the absence of any such agreement, shall mean, with respect to any Grantee and as determined by the Committee, (a) gross negligence
or willful misconduct in connection with the performance of duties; (b) conviction of, or pleading guilty or nolo contendere to, a criminal
offense (other than minor traffic offenses); (c) engagement in material dishonesty which is injurious to the Company or an Affiliate;
(d) engagement in misconduct or gross neglect that causes material harm to the Company or an Affiliate; (e) material violation of the
Company’s or an Affiliate’s written policies relating to sexual harassment; or (f) material breach of any term of any employment,
consulting or other services, confidentiality, intellectual property, or non-competition agreements, if any, between such Grantee and
the Company or an Affiliate. Any determination by the Committee regarding whether an event constituting Cause shall have occurred shall
be final, binding, and conclusive.
2.10
“Change in Control” shall mean, subject to Section 18.11, the occurrence of any of the following:
(a)
A transaction or a series of related transactions whereby any Person or Group (other than any Permitted Holder, the Company, or any Affiliate)
becomes the Beneficial Owner of fifty percent (50%) or more of the total voting power of the Voting Stock of the Company, on a Fully
Diluted Basis;
(b)
Individuals who, as of the Effective Date, constitute the Board (the “Incumbent Board”) (together with any new directors
whose election by such Incumbent Board or whose nomination by such Incumbent Board for election by the stockholders of the Company was
approved by a vote of at least a majority of the members of such Incumbent Board then in office who either were members of such Incumbent
Board or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the members
of such Board then in office;
(c)
The Company consolidates with, or merges with or into, any Person, or any Person consolidates with, or merges with or into, the Company
(regardless of whether the Company is the surviving Person), other than any such transaction in which the Prior Stockholders, including
any Permitted Holder, own directly or indirectly at least a majority of the voting power of the Voting Stock of the surviving Person
in such merger or consolidation immediately after such transaction;
(d)
The consummation of any direct or indirect sale, lease, transfer, conveyance, or other disposition (other than by way of reorganization,
merger, or consolidation), in one transaction or a series of related transactions, of all or substantially all of the assets of the Company
and its Subsidiaries, taken as a whole, to any Person or Group (other than any Permitted Holder, the Company, or any Affiliate), except
any such transaction or series of transactions in which the Prior Stockholders, including any Permitted Holder, own directly or indirectly
at least a majority of the voting power of the Voting Stock of such Person or Group immediately after such transaction or series of transactions;
or
(e)
The consummation of a plan or proposal for the liquidation, winding up, or dissolution of the Company.
Notwithstanding
the foregoing, the transactions contemplated by that certain Agreement and Plan of Merger, entered into June 28, 2023, by and among Semper
Paratus Acquisition Corporation, Semper Merger Sub Inc., SSVK Associates, LLC, Ryan Saadi, and Tevogen Bio Inc. shall not, individually
or collectively, constitute a Change in Control.
The
Board shall have full and final authority, in its sole discretion, to determine conclusively whether a Change in Control has occurred
pursuant to the above definition, the date of the occurrence of such Change in Control, and any incidental matters relating thereto.
2.11
“Code” shall mean the Internal Revenue Code of 1986, as amended, as now in effect or as hereafter amended, and any
successor thereto. References in the Plan to any Code Section shall be deemed to include, as applicable, regulations and guidance promulgated
under such Code Section.
2.12
“Committee” shall mean a committee of, and designated from time to time by resolution of, the Board, which shall be
constituted as provided in Section 3.1.2 and Section 3.1.3 (or, if no Committee has been so designated, the Board).
2.13
“Company” shall mean Tevogen Bio Holdings Inc., a Delaware corporation, and any successor thereto.
2.14
“Controlling Interest” shall have the meaning set forth in Treasury Regulation Section 1.414(c)-2(b)(2)(i); provided
that (a) except as specified in clause (b) below, an interest of “at least 50 percent” shall be used instead of an interest
of “at least 80 percent” in each case where “at least 80 percent” appears in Treasury Regulation Section 1.414(c)-2(b)(2)(i),
and (b) where a grant of Options or Stock Appreciation Rights is based upon a legitimate business criterion, an interest of “at
least 20 percent” shall be used instead of an interest of “at least 80 percent” in each case where “at least
80 percent” appears in Treasury Regulation Section 1.414(c)-2(b)(2)(i).
2.15
“Deferred Stock Unit” shall mean a Restricted Stock Unit, the terms of which provide for delivery of the underlying
shares of Stock, cash, or a combination thereof subsequent to the date of vesting, at a time or times consistent with the requirements
of Code Section 409A.
2.16
“Disability” shall mean the inability of a Grantee to perform each of the essential duties of such Grantee’s
position by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can
be expected to last for a continuous period of not less than twelve (12) months; provided that, with respect to rules regarding the expiration
of an Incentive Stock Option following termination of a Grantee’s Service, Disability shall mean the inability of such Grantee
to engage in any substantial gainful activity by reason of a medically determinable physical or mental impairment which can be expected
to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months.
2.17
“Disqualified Individual” shall have the meaning set forth in Code Section 280G(c).
2.18
“Dividend Equivalent Right” shall mean a right, granted to a Grantee pursuant to Article 12, entitling the Grantee
thereof to receive, or to receive credits for the future payment of, cash, Stock, other Awards, or other property equal in value to dividend
payments or distributions, or other periodic payments, declared or paid with respect to a number of shares of Stock specified in such
Dividend Equivalent Right (or other Award to which such Dividend Equivalent Right relates) as if such shares of Stock had been issued
to and held by the Grantee of such Dividend Equivalent Right as of the record date of the declaration thereof.
2.19
“Effective Date” shall mean the date the Plan is adopted by the Board, subject to approval of the Plan by the Company’s
stockholders in accordance with Section 5.1.
2.20
“Employee” shall mean, as of any date of determination, an employee (including an officer) of the Company or an Affiliate.
2.21
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, as now in effect or as hereafter amended,
and any successor thereto.
2.22
“Fair Market Value” shall mean the fair market value of a share of Stock for purposes of the Plan, which shall be,
as of any date of determination:
(a)
If on such date the shares of Stock are listed on a Stock Exchange, or are publicly traded on another Securities Market, the Fair Market
Value of a share of Stock shall be the closing price of the Stock as reported on such Stock Exchange or such Securities Market (provided
that, if there is more than one such Stock Exchange or Securities Market, the Committee shall designate the appropriate Stock Exchange
or Securities Market for purposes of the Fair Market Value determination). If there is no such reported closing price on such date, the
Fair Market Value of a share of Stock shall be the closing price of the Stock on the next preceding day on which any sale of Stock shall
have been reported on such Stock Exchange or such Securities Market.
(b)
If on such date the shares of Stock are not listed on a Stock Exchange or publicly traded on a Securities Market, the Fair Market Value
of a share of Stock shall be the value of the Stock as determined by the Committee by the reasonable application of a reasonable valuation
method, in a manner consistent with Code Section 409A.
Notwithstanding
this Section 2.22 or Section 18.3, for purposes of determining taxable income and the amount of the related tax withholding obligation
pursuant to Section 18.3, the Fair Market Value shall be determined by the Committee in good faith using any reasonable method it deems
appropriate, to be applied consistently with respect to Grantees; provided that the Committee shall determine the Fair Market Value of
shares of Stock for tax withholding obligations due in connection with sales, by or on behalf of a Grantee, of such shares of Stock subject
to an Award to pay the Option Price, SAR Price, and/or any tax withholding obligation on the same date on which such shares may first
be sold pursuant to the terms of the applicable Award Agreement (including broker-assisted cashless exercises of Options and Stock Appreciation
Rights, as described in Section 14.3, and sell-to-cover transactions) in any manner consistent with applicable provisions of the Code,
including, without limitation, by using the sale price of such shares on such date (or if sales of such shares are effectuated at more
than one sale price, the weighted average sale price of such shares on such date) as the Fair Market Value of such shares, so long as
such Grantee has provided the Company, or its designee or agent, with advance written notice of such sale.
2.23
“Family Member” shall mean, with respect to any Grantee as of any date of determination, (a) a Person who is a spouse,
former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, niece, nephew, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother, sister, brother-in-law, or sister-in-law, including adoptive relationships, of such Grantee, (b) any Person
sharing such Grantee’s household (other than a tenant or employee), (c) a trust in which any one or more of the Persons specified
in clauses (a) and (b) above (and such Grantee) own more than fifty percent (50%) of the beneficial interest, (d) a foundation in which
any one or more of the Persons specified in clauses (a) and (b) above (and such Grantee) control the management of assets, and (e) any
other entity in which one or more of the Persons specified in clauses (a) and (b) above (and such Grantee) own more than fifty percent
(50%) of the voting interests.
2.24
“Fully Diluted Basis” shall mean, as of any date of determination, the sum of (x) the number of shares of Voting Stock
outstanding as of such date of determination plus (y) the number of shares of Voting Stock issuable upon the exercise, conversion, or
exchange of all then-outstanding warrants, options, convertible Capital Stock or indebtedness, exchangeable Capital Stock or indebtedness,
or other rights exercisable for or convertible or exchangeable into, directly or indirectly, shares of Voting Stock, whether at the time
of issue or upon the passage of time or upon the occurrence of some future event, and whether or not in-the-money as of such date of
determination.
2.25
“Grant Date” shall mean, as determined by the Committee, the latest to occur of (a) the date as of which the Committee
approves the Award, (b) the date on which the recipient of an Award first becomes eligible to receive an Award under Article 6 hereof,
or (c) such date later than the dates specified in clauses (a) and (b) specified by the Committee in the corporate action approving the
Award.
2.26
“Grantee” shall mean a Person who receives or holds an Award under the Plan.
2.27
“Group” shall have the meaning set forth in Sections 13(d) and 14(d)(2) of the Exchange Act.
2.28
“Incentive Stock Option” shall mean an “incentive stock option” within the meaning of Code Section 422.
2.29
“Non-Employee Director” shall have the meaning set forth in Rule 16b-3 under the Exchange Act.
2.30
“Nonqualified Stock Option” shall mean an Option that is not an Incentive Stock Option.
2.31
“Officer” shall have the meaning set forth in Rule 16a-1(f) under the Exchange Act.
2.32
“Option” shall mean an option to purchase one or more shares of Stock at a specified Option Price awarded to a Grantee
pursuant to Article 8.
2.33
“Option Price” shall mean the per share exercise price for shares of Stock subject to an Option.
2.34
“Other Agreement” shall mean any agreement, contract, or understanding heretofore or hereafter entered into by a Grantee
with the Company or an Affiliate, except an agreement, contract, or understanding that expressly addresses Code Section 280G and/or Code
Section 4999.
2.35
“Other Equity-Based Award” shall mean an Award representing a right or other interest that may be denominated or payable
in, valued in whole or in part by reference to, or otherwise based on or related to Stock, other than an Option, a Stock Appreciation
Right, Restricted Stock, a Restricted Stock Unit, a Deferred Stock Unit, Unrestricted Stock, a Dividend Equivalent Right, or a Performance
Share or other Performance Award.
2.36
“Parachute Payment” shall mean a “parachute payment” within the meaning of Code Section 280G(b)(2), or
the corresponding provision of any subsequently enacted tax statute, as amended from time to time.
2.37
“Performance Award” shall mean an Award of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock
Units, Deferred Stock Units, Performance Shares, Other Equity-Based Awards, or cash made subject to the achievement of Performance Measures
(as provided in Article 13) over a Performance Period specified by the Committee.
2.38
“Performance Measures” shall mean performance criteria on which performance goals under Performance Awards are based.
2.39
“Performance Period” shall mean the period of time, up to ten (10) years, during or over which the Performance Measures
under Performance Awards must be met in order to determine the degree of payout and/or vesting with respect to any such Performance Awards.
2.40
“Performance Shares” shall mean a Performance Award representing a right or other interest that may be denominated
or payable in, valued in whole or in part by reference to, or otherwise based on or related to Stock, made subject to the achievement
of Performance Measures (as provided in Article 13) over a Performance Period of up to ten (10) years.
2.41
“Permitted Holder” shall mean each of (a) Ryan Saadi and his siblings, his and their respective spouses and descendants
(including stepchildren and adopted children) and the spouses of such descendants (including stepchildren and adopted children) (collectively,
the “Principal Family Group”); (b) any trust, estate, partnership, corporation, company, limited liability company
or unincorporated association or organization (each an “Entity” and collectively “Entities”) controlled
by (to be interpreted consistent with the definition of “Affiliate” provided herein) one or more members of the Principal
Family Group; (c) any Entity over which one or more members of the Principal Family Group, directly or indirectly, have rights that legally
enable them to make or veto significant management decisions with respect to such Entity, whether pursuant to the constituent documents
of such Entity, by contract, through representation on a board of directors or other governing body of such Entity or in any other manner
(such rights hereinafter referred to as “Veto Power”); (d) the estate of any member of the Principal Family Group;
(e) any trust created (in whole or in part) by any one or more members of the Principal Family Group; (f) any individual or Entity who
receives an interest in any estate or trust listed in clauses (d) or (e), to the extent of such interest; (g) any trust or estate, substantially
all the beneficiaries of which (other than charitable organizations or foundations) consist of one or more members of the Principal Family
Group; (h) any organization described in Section 501(c) of the Code, over which any one or more members of the Principal Family Group
and the trusts and estates listed in clauses (d), (e) and (g) have direct or indirect Veto Power, or to which they are substantial contributors
(as such term is defined in Section 507 of the Code); (i) any organization described in Section 501(c) of the Code of which a member
of the Principal Family Group is an officer, director or trustee; or (j) any Entity, directly or indirectly (1) owned or controlled by
(to be interpreted consistent with the definition of “Affiliate” provided herein), or (2) a majority of the economic
interests in which are owned by, or are for or accrue to the benefit of, in either case, any Person or Persons identified in clauses
(a) through (b) above.
2.42
“Person” shall mean an individual, a corporation, a partnership, a limited liability company, an association, a trust,
or any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof; provided
that, for purposes of Section 2.10(a) and Section 2.10(d), Person shall have the meaning set forth in Sections 13(d) and 14(d)(2) of
the Exchange Act.
2.43
“Plan” shall mean this Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, as amended and/or restated from time
to time.
2.44
“Prior Stockholders” shall mean the holders of equity securities that represented one hundred percent (100%) of the
Voting Stock of the Company immediately prior to a reorganization, merger, or consolidation involving the Company or any sale or other
disposition of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole (or other equity securities
into which the Stock or such other equity securities are converted as part of such reorganization, merger, or consolidation transaction).
2.45
“Restricted Period” shall mean a period of time established by the Committee during which an Award of Restricted Stock,
Restricted Stock Units, or Deferred Stock Units is subject to restrictions.
2.46
“Restricted Stock” shall mean shares of Stock awarded to a Grantee pursuant to Article 10.
2.47
“Restricted Stock Unit” shall mean a bookkeeping entry representing the equivalent of one (1) share of Stock awarded
to a Grantee pursuant to Article 10 that may be settled, subject to the terms and conditions of the applicable Award Agreement, in shares
of Stock, cash, or a combination thereof.
2.48
“SAR Price” shall mean the per share exercise price of a SAR.
2.49
“Securities Act” shall mean the Securities Act of 1933, as amended, as now in effect or as hereafter amended, and
any successor thereto.
2.50
“Securities Market” shall mean an established securities market.
2.51
“Separation from Service” shall have the meaning set forth in Code Section 409A.
2.52
“Service” shall mean service qualifying a Grantee as a Service Provider to the Company or an Affiliate. Unless otherwise
provided in the applicable Award Agreement, a Grantee’s change in position or duties shall not result in interrupted or terminated
Service, so long as such Grantee continues to be a Service Provider to the Company or an Affiliate. Subject to the preceding sentence,
any determination by the Committee whether a termination of Service shall have occurred for purposes of the Plan shall be final, binding,
and conclusive. If a Service Provider’s employment or other Service relationship is with an Affiliate and the applicable entity
ceases to be an Affiliate, a termination of Service shall be deemed to have occurred when such entity ceases to be an Affiliate unless
the Service Provider transfers his or her employment or other Service relationship to the Company or any other Affiliate.
2.53
“Service Provider” shall mean (a) an Employee or director of the Company or an Affiliate, or (b) a consultant or adviser
to the Company or an Affiliate (i) who is a natural person, (ii) who is currently providing bona fide services to the Company or an Affiliate,
and (iii) whose services are not in connection with the Company’s sale of securities in a capital-raising transaction and do not
directly or indirectly promote or maintain a market for the Company’s Capital Stock.
2.54
“Service Recipient Stock” shall have the meaning set forth in Code Section 409A.
2.55
“Share Limit” shall have the meaning set forth in Section 4.1.
2.56
“Short-Term Deferral Period” shall have the meaning set forth in Code Section 409A.
2.57
“Stock” shall mean the common stock, par value $0.0001 per share, of the Company, or any security into which shares
of Stock may be changed or for which shares of Stock may be exchanged as provided in Section 16.1.
2.58
“Stock Appreciation Right” or “SAR” shall mean a right granted to a Grantee pursuant to Article
9.
2.59
“Stock Exchange” shall mean the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market, or another established national or regional stock exchange.
2.60
“Subsidiary” shall mean any corporation (other than the Company) or non-corporate entity with respect to which the
Company owns, directly or indirectly, fifty percent (50%) or more of the total combined voting power of all classes of Voting Stock.
In addition, any other entity may be designated by the Committee as a Subsidiary, provided that (a) such entity could be considered as
a subsidiary according to generally accepted accounting principles in the United States of America and (b) in the case of an Award of
Options or Stock Appreciation Rights, such Award would be considered to be granted in respect of Service Recipient Stock under Code Section
409A.
2.61
“Substitute Award” shall mean an Award granted upon assumption of, or in substitution for, outstanding awards previously
granted under a compensatory plan of the Company, an Affiliate, or a business entity acquired or to be acquired by the Company or an
Affiliate or with which the Company or an Affiliate has combined or will combine.
2.62
“Ten Percent Stockholder” shall mean a natural Person who owns more than ten percent (10%) of the total combined voting
power of all classes of Voting Stock of the Company, the Company’s parent (if any), or any of the Company’s Subsidiaries.
In determining stock ownership, the attribution rules of Code Section 424(d) shall be applied.
2.63
“Unrestricted Stock” shall mean Stock that is free of any restrictions.
2.64
“Voting Stock” shall mean, with respect to any Person, Capital Stock of any class or kind ordinarily having the power
to vote for the election of directors, managers, or other voting members of the governing body of such Person. Without limiting the generality
of the foregoing, the Stock shall be Voting Stock of the Company.
3.
ADMINISTRATION OF THE PLAN
3.1
Committee.
3.1.1
Powers and Authorities.
The
Committee shall administer the Plan and shall have such powers and authorities related to the administration of the Plan as are consistent
with the Company’s certificate of incorporation and bylaws and Applicable Laws. Without limiting the generality of the foregoing,
the Committee shall have full power and authority to take all actions and to make all determinations required or provided for under the
Plan, any Award, or any Award Agreement and shall have full power and authority to take all such other actions and to make all such other
determinations not inconsistent with the specific terms and provisions of the Plan which the Committee deems to be necessary or appropriate
to the administration of the Plan, any Award, or any Award Agreement. All such actions and determinations shall be made by (a) the affirmative
vote of a majority of the members of the Committee present at a meeting at which a quorum is present, or (b) the unanimous consent of
the members of the Committee executed in writing or evidenced by electronic transmission in accordance with the Company’s certificate
of incorporation and bylaws and Applicable Laws. Unless otherwise expressly determined by the Board, the Committee shall have the authority
to interpret and construe all provisions of the Plan, any Award, and any Award Agreement, and any such interpretation or construction,
and any other determination contemplated to be made under the Plan or any Award Agreement, by the Committee shall be final, binding,
and conclusive on all Persons, whether or not expressly provided for in any provision of the Plan, such Award, or such Award Agreement.
In
the event that the Plan, any Award, or any Award Agreement provides for any action to be taken by the Board or any determination to be
made by the Board, such action may be taken or such determination may be made by the Committee constituted in accordance with this Section
3.1 if the Board has delegated the power and authority to do so to such Committee.
3.1.2
Composition of the Committee.
The
Committee shall be a committee composed of not fewer than two (2) directors of the Company designated by the Board to administer the
Plan.
Each
member of the Committee shall (a) be a Non-Employee Director and (b) satisfy the composition requirements of any Stock Exchange on which
the Stock is listed. Any action taken by the Committee shall be valid and effective whether or not members of the Committee at the time
of such action are later determined not to have satisfied the requirements for membership set forth in this Section 3.1.2 or otherwise
provided in any charter of the Committee. Without limiting the generality of the foregoing, the Committee may be the Compensation Committee
of the Board or a subcommittee thereof.
3.1.3
Other Committees.
The
Board also may appoint one or more committees of the Board, each composed of one or more directors of the Company, which (a) may administer
the Plan with respect to Grantees who are not Officers or directors of the Company, (b) may grant Awards under the Plan to such Grantees,
and (c) may determine all terms of such Awards subject, if applicable, to the requirements of Rule 16b-3 under the Exchange Act and the
rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.
3.1.4
Delegation by the Committee.
If
and to the extent permitted by Applicable Laws, the Committee, by resolution, may delegate some or all of its authority with respect
to the Plan and Awards to the Chief Executive Officer of the Company and/or any other officer of the Company designated by the Committee,
provided that the Committee may not delegate its authority hereunder (a) to make Awards to directors of the Company, (b) to make Awards
to Employees who are (i) Officers or (ii) officers of the Company who are delegated authority by the Committee pursuant to this Section
3.1.4, or (c) to interpret the Plan, any Award, or any Award Agreement. Any delegation hereunder will be subject to the restrictions
and limits that the Committee specifies at the time of such delegation or thereafter. Nothing in the Plan will be construed as obligating
the Committee to delegate authority to any officer of the Company, and the Committee may at any time rescind the authority delegated
to an officer of the Company appointed hereunder and delegate authority to one or more other officers of the Company. At all times, an
officer of the Company delegated authority pursuant to this Section 3.1.4 will serve in such capacity at the pleasure of the Committee.
Any action undertaken by any such officer of the Company in accordance with the Committee’s delegation of authority will have the
same force and effect as if undertaken directly by the Committee, and any reference in the Plan to the “Committee” will,
to the extent consistent with the terms and limitations of such delegation, be deemed to include a reference to each such officer.
3.2
Board.
The
Board, from time to time, may exercise any or all of the powers and authorities related to the administration and implementation of the
Plan, as set forth in Section 3.1 and other applicable provisions of the Plan, as the Board shall determine, consistent with the Company’s
certificate of incorporation and bylaws and Applicable Laws.
3.3
Terms of Awards.
3.3.1
Committee Authority.
Subject
to the other terms and conditions of the Plan, the Committee shall have full and final authority to:
(a)
designate Grantees;
(b)
determine the type or types of Awards to be made to a Grantee;
(c)
determine the number of shares of Stock to be subject to an Award or to which an Award relates;
(d)
establish the terms and conditions of each Award (including the Option Price of any Option, the SAR Price for any Stock Appreciation
Right, and the purchase price for applicable Awards, the nature and duration of any restriction or condition (or provision for lapse
thereof) relating to the vesting, exercise, transfer, or forfeiture of an Award or the shares of Stock subject thereto, the treatment
of an Award in the event of a Change in Control (subject to applicable agreements), and any terms or conditions that may be necessary
to qualify Options as Incentive Stock Options);
(e)
prescribe the form of each Award Agreement evidencing an Award;
(f)
subject to the limitation on repricing in Section 3.4, amend, modify, or supplement the terms of any outstanding Award, which authority
shall include the authority, in order to effectuate the purposes of the Plan but without amending the Plan, to make Awards or to modify
outstanding Awards made to eligible natural Persons who are foreign nationals or are natural Persons who are employed outside the United
States to reflect differences in local law, tax policy, or custom; provided that, notwithstanding the foregoing, no amendment, modification,
or supplement of the terms of any outstanding Award shall, without the consent of the Grantee thereof, impair such Grantee’s rights
under such Award; and
(g)
make Substitute Awards.
3.3.2
Forfeiture; Recoupment.
The
Committee may reserve the right in an Award Agreement to cause a forfeiture of the gain realized by a Grantee with respect to an Award
thereunder on account of actions taken by, or failed to be taken by, such Grantee in violation or breach of, or in conflict with, any
(a) employment agreement, (b) non-competition agreement, (c) agreement prohibiting solicitation of Employees or clients of the Company
or an Affiliate, (d) confidentiality obligation with respect to the Company or an Affiliate, (e) policy or procedure of the Company or
an Affiliate, (f) other agreement, or (g) other obligation of such Grantee to the Company or an Affiliate, as and to the extent specified
in such Award Agreement. If the Grantee of an outstanding Award is an Employee of the Company or an Affiliate and such Grantee’s
Service is terminated for Cause, the Committee may annul such Grantee’s outstanding Award as of the date of the Grantee’s
termination of Service for Cause.
Any
Award granted pursuant to the Plan shall be subject to mandatory repayment by the Grantee to the Company (x) to the extent set forth
in the Plan or an Award Agreement or (y) to the extent the Grantee is, or in the future becomes, subject to (1) any Company or Affiliate
“clawback” or recoupment policy that is adopted to comply with the requirements of any Applicable Laws, or (2) any Applicable
Laws which impose mandatory recoupment, under circumstances set forth in such Applicable Laws.
3.4
No Repricing Without Stockholder Approval.
Except
in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, distribution (whether
in the form of cash, shares of Stock, other securities, or other property), stock split, extraordinary dividend, recapitalization, Change
in Control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of shares of Stock, or other
securities or similar transaction), the Company may not: (a) amend the terms of outstanding Options or SARs to reduce the Option Price
or SAR Price, as applicable, of such outstanding Options or SARs; (b) cancel outstanding Options or SARs in exchange for, or in substitution
of, Options or SARs with an Option Price or SAR Price, as applicable, that is less than the Option Price or SAR Price, as applicable,
of the original Options or SARs; or (c) cancel outstanding Options or SARs with an Option Price or SAR Price, as applicable, above the
current Fair Market Value in exchange for cash or other securities, in each case, unless such action (i) is subject to and approved by
the Company’s stockholders or (ii) would not be deemed to be a repricing under the rules of any Stock Exchange or Securities Market
on which the Stock is listed or publicly traded.
3.5
Deferral Arrangement.
The
Committee may permit or require the deferral of any payment pursuant to any Award into a deferred compensation arrangement, subject to
such rules and procedures as it may establish, which may include provisions for the payment or crediting of interest or Dividend Equivalent
Rights and, in connection therewith, provisions for converting such credits into Deferred Stock Units and for restricting deferrals to
comply with hardship distribution rules affecting tax-qualified retirement plans subject to Code Section 401(k)(2)(B)(IV), provided that
no Dividend Equivalent Rights may be granted in connection with, or related to, an Award of Options or SARs. Any such deferrals shall
be made in a manner that complies with Code Section 409A, including, if applicable, with respect to when a Separation from Service occurs.
3.6
Registration; Share Certificates.
Notwithstanding
any provision of the Plan to the contrary, the ownership of the shares of Stock issued under the Plan may be evidenced in such a manner
as the Committee, in its sole discretion, deems appropriate, including by book-entry or direct registration (including transaction advices)
or the issuance of one or more share certificates.
4.
STOCK SUBJECT TO THE PLAN
4.1
Number of Shares of Stock Available for Awards.
Subject
to such additional shares of Stock as shall be available for issuance under the Plan pursuant to Section 4.2 and Section 4.3(c), and
subject to adjustment pursuant to Article 16, the maximum number of shares of Stock reserved for issuance under the Plan shall be equal
to the sum of (a) 40,000,000 shares of Stock (the “Initial Share Limit”) plus (b) an annual increase as of the first
business day of each calendar year, for a period of not more than ten (10) years and starting with the 2025 calendar year, in an amount
equal to the lesser of (i) a number of shares of Stock equal to 5.0% of the total number of shares of Stock outstanding as of the last
day of the immediately preceding calendar year, or (ii) such lesser number of shares of Stock as determined by the Committee (collectively,
the “Share Limit”). Such shares of Stock may be authorized and unissued shares of Stock, treasury shares of Stock,
or any combination of the foregoing, as may be determined from time to time by the Board or by the Committee. Any of the shares of Stock
reserved and available for issuance under the Plan may be used for any type of Award under the Plan, and a number of shares of Stock
up to the Initial Share Limit shall be available for issuance pursuant to Incentive Stock Options.
4.2
Adjustments in Authorized Shares of Stock.
In
connection with mergers, reorganizations, separations, or other transactions to which Code Section 424(a) applies, the Committee shall
have the right to cause the Company to assume awards previously granted under a compensatory plan of another business entity that is
a party to such transaction and to grant Substitute Awards under the Plan for such awards. The Share Limit pursuant to Section 4.1 shall
be increased by the number of shares of Stock subject to any such assumed awards and Substitute Awards. Shares available for issuance
under a stockholder-approved plan of a business entity that is a party to such transaction (as appropriately adjusted, if necessary,
to reflect such transaction) may be used for Awards under the Plan and shall not reduce the number of shares of Stock otherwise available
for issuance under the Plan, subject to applicable rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly
traded.
4.3
Share Usage.
(a)
Shares of Stock covered by an Award shall be counted as used as of the Grant Date for purposes of calculating the number of shares of
Stock available for issuance under Section 4.1.
(b)
Any shares of Stock that are subject to Awards, including shares of Stock acquired through dividend reinvestment pursuant to Article
10, will be counted against the Share Limit set forth in Section 4.1 as one (1) share of Stock for every one (1) share of Stock subject
to an Award. The number of shares of Stock subject to an Award of SARs will be counted against the Share Limit set forth in Section 4.1
as one (1) share of Stock for every one (1) share of Stock subject to such Award regardless of the number of shares of Stock actually
issued to settle such SARs upon the exercise of the SARs. At least the target number of shares of Stock issuable under a Performance
Award grant shall be counted against the Share Limit set forth in Section 4.1 as of the Grant Date, but such number shall be adjusted
to equal the actual number of shares of Stock issued upon settlement of the Performance Award to the extent different from such target
number of shares of Stock.
(c)
If any shares of Stock covered by an Award granted under the Plan are not purchased or are forfeited or expire or if an Award otherwise
terminates without delivery of any Stock subject thereto or is settled in cash in lieu of shares, then the number of shares of Stock
counted against the Share Limit with respect to such Award shall, to the extent of any such forfeiture, termination, expiration, or settlement,
again be available for making Awards under the Plan.
(d)
The number of shares of Stock available for issuance under the Plan will not be increased by the number of shares of Stock (i) tendered,
withheld, or subject to an Award granted under the Plan surrendered in connection with the purchase of shares of Stock upon exercise
of an Option, (ii) that were not issued upon the net settlement or net exercise of a Stock-settled SAR granted under the Plan, (iii)
deducted or delivered from payment of an Award granted under the Plan in connection with the Company’s tax withholding obligations
as provided in Section 18.3, or (iv) purchased by the Company with proceeds from Option exercises.
5.
TERM; AMENDMENT AND TERMINATION
5.1
Term.
The
Plan shall become effective as of the Effective Date, subject to approval of the Plan by the Company’s stockholders within twelve
(12) months of the Effective Date. Upon approval of the Plan by the Company’s stockholders, all Awards made under the Plan on or
after the Effective Date shall be fully effective as if the stockholders of the Company had approved the Plan on the Effective Date.
If the Stockholders do not approve the Plan within twelve (12) months of the Effective Date, any Awards made under the Plan on or after
the Effective Date shall not be exercisable, settleable, or deliverable, except to the extent such Awards could have otherwise been made
under the Plan. The Plan shall terminate on the first to occur of (a) 11:59PM ET on the day before the tenth (10th) anniversary of the
Effective Date, (b) the date determined in accordance with Section 5.2, and (c) the date determined in accordance with Section 16.3.
Upon such termination of the Plan, all outstanding Awards shall continue to have full force and effect in accordance with the provisions
of the terminated Plan and the applicable Award Agreement (or other documents evidencing such Awards).
5.2
Amendment, Suspension, and Termination.
The
Board may, at any time and from time to time, amend, suspend, or terminate the Plan; provided that, with respect to Awards theretofore
granted under the Plan, no amendment, suspension, or termination of the Plan shall, without the consent of any Grantee affected thereby,
impair the rights or obligations under any such Award. The effectiveness of any amendment to the Plan shall be conditioned upon approval
of such amendment by the Company’s stockholders to the extent provided by the Board or required by Applicable Laws; provided that
no amendment shall be made to the no-repricing provisions of Section 3.4, the Option pricing provisions of Section 8.1, or the SAR pricing
provisions of Section 9.1 without the approval of the Company’s stockholders.
6.
AWARD ELIGIBILITY AND LIMITATIONS
6.1
Eligible Grantees.
Subject
to this Article 6, Awards may be made under the Plan to (a) any Service Provider, as the Committee shall determine and designate from
time to time, and (b) any other individual whose participation in the Plan is determined to be in the best interests of the Company by
the Committee.
6.2
Stand-Alone, Additional, Tandem, and Substitute Awards.
Subject
to Section 3.4, Awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in
tandem with, or in substitution or exchange for, (a) any other Award, (b) any award granted under another plan of the Company, an Affiliate,
or any business entity that has been a party to a transaction with the Company or an Affiliate, or (c) any other right of a Grantee to
receive payment from the Company or an Affiliate. Such additional, tandem, exchange, or Substitute Awards may be granted at any time.
If an Award is granted in substitution or exchange for another Award, or for an award granted under another plan of the Company, an Affiliate,
or any business entity that has been a party to a transaction with the Company or an Affiliate, the Committee shall require the surrender
of such other Award or award under such other plan in consideration for the grant of such exchange or Substitute Award. In addition,
Awards may be granted in lieu of cash compensation, including in lieu of cash payments under other plans of the Company or an Affiliate.
Notwithstanding Section 8.1 and Section 9.1, but subject to Section 3.4, the Option Price of an Option or the SAR Price of a SAR that
is a Substitute Award may be less than one hundred percent (100%) of the Fair Market Value of a share of Stock on the original Grant
Date; provided that such Option Price or SAR Price is determined in accordance with the principles of Code Section 424 for any Incentive
Stock Option and consistent with Code Section 409A for any other Option or SAR.
7.
AWARD AGREEMENT
Each
Award granted pursuant to the Plan shall be evidenced by an Award Agreement, which shall be in such form or forms as the Committee shall
from time to time determine. Award Agreements utilized under the Plan from time to time or at the same time need not contain similar
provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing an Award of Options shall specify whether
such Options are intended to be Nonqualified Stock Options or Incentive Stock Options, and, in the absence of such specification, such
Options shall be deemed to constitute Nonqualified Stock Options. In the event of any inconsistency between the Plan and an Award Agreement,
the provisions of the Plan shall control.
8.
TERMS AND CONDITIONS OF OPTIONS
8.1
Option Price.
The
Option Price of each Option shall be fixed by the Committee and stated in the Award Agreement evidencing such Option. Except in the case
of Substitute Awards, the Option Price of each Option shall be at least the Fair Market Value of one (1) share of Stock on the Grant
Date; provided that, in the event that a Grantee is a Ten Percent Stockholder, the Option Price of an Option granted to such Grantee
that is intended to be an Incentive Stock Option shall be not less than one hundred ten percent (110%) of the Fair Market Value of one
(1) share of Stock on the Grant Date. In no case shall the Option Price of any Option be less than the par value of one (1) share of
Stock.
8.2
Vesting and Exercisability.
Subject
to Sections 8.3 and 16.3, each Option granted under the Plan shall become vested and/or exercisable at such times and under such conditions
as shall be determined by the Committee and stated in the Award Agreement, in another agreement with the Grantee, or otherwise in writing;
provided that no Option shall be granted to Grantees who are entitled to overtime under Applicable Laws that will vest or be exercisable
within a six (6)-month period starting on the Grant Date.
8.3
Term.
Each
Option granted under the Plan shall terminate, and all rights to purchase shares of Stock thereunder shall cease, on the tenth (10th)
anniversary of the Grant Date of such Option, or under such circumstances and on such date prior thereto as is set forth in the Plan
or as may be fixed by the Committee and stated in the Award Agreement relating to such Option; provided that, in the event that the Grantee
is a Ten Percent Stockholder, an Option granted to such Grantee that is intended to be an Incentive Stock Option shall not be exercisable
after the fifth (5th) anniversary of the Grant Date of such Option; and provided, further, that, to the extent deemed necessary or appropriate
by the Committee to reflect differences in local law, tax policy, or custom with respect to any Option granted to a Grantee who is a
foreign national or is a natural Person who is employed outside the United States, such Option may terminate, and all rights to purchase
shares of Stock thereunder may cease, upon the expiration of a period longer than ten (10) years from the Grant Date of such Option as
the Committee shall determine.
8.4
Termination of Service.
Each
Award Agreement with respect to the grant of an Option shall set forth the extent to which the Grantee thereof, if at all, shall have
the right to exercise such Option following termination of such Grantee’s Service. Such provisions shall be determined in the sole
discretion of the Committee, need not be uniform among all Options issued pursuant to the Plan, and may reflect distinctions based on
the reasons for termination of Service.
8.5
Limitations on Exercise of Option.
Notwithstanding
any provision of the Plan to the contrary, in no event may any Option be exercised, in whole or in part, after the occurrence of an event
referred to in Article 16 which results in the termination of such Option.
8.6
Method of Exercise.
Subject
to the terms of Article 14 and Section 18.3, an Option that is exercisable may be exercised by the Grantee’s delivery to the Company
or its designee or agent of notice of exercise on any business day, at the Company’s principal office or the office of such designee
or agent, on the form specified by the Company and in accordance with any additional procedures specified by the Committee. Such notice
shall specify the number of shares of Stock with respect to which such Option is being exercised and shall be accompanied by payment
in full of the Option Price of the shares of Stock for which such Option is being exercised, plus the amount (if any) of federal and/or
other taxes which the Company may, in its judgment, be required to withhold with respect to the exercise of such Option.
8.7
Rights of Holders of Options.
Unless
otherwise stated in the applicable Award Agreement, a Grantee or other Person holding or exercising an Option shall have none of the
rights of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to
the shares of Stock subject to such Option, to direct the voting of the shares of Stock subject to such Option, or to receive notice
of any meeting of the Company’s stockholders) until the shares of Stock subject thereto are fully paid and issued to such Grantee
or other Person. Except as provided in Article 16, no adjustment shall be made for dividends, distributions, or other rights with respect
to any shares of Stock subject to an Option for which the record date is prior to the date of issuance of such shares of Stock.
8.8
Delivery of Stock.
Promptly
after the exercise of an Option by a Grantee and the payment in full of the Option Price with respect thereto, such Grantee shall be
entitled to receive such evidence of such Grantee’s ownership of the shares of Stock subject to such Option as shall be consistent
with Section 3.6.
8.9
Transferability of Options.
Except
as provided in Section 8.10, during the lifetime of a Grantee of an Option, only such Grantee (or, in the event of such Grantee’s
legal incapacity or incompetency, such Grantee’s guardian or legal representative) may exercise such Option. Except as provided
in Section 8.10, no Option shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of
descent and distribution.
8.10
Family Transfers.
If
authorized in the applicable Award Agreement and by the Committee, in its sole discretion, a Grantee may transfer, not for value, all
or part of an Option which is not an Incentive Stock Option to any Family Member. For the purpose of this Section 8.10, a transfer “not
for value” is a transfer which is (a) a gift, (b) a transfer under a domestic relations order in settlement of marital property
rights, or (c) unless Applicable Laws do not permit such transfer, a transfer to an entity in which more than fifty percent (50%) of
the voting interests are owned by Family Members (and/or the Grantee) in exchange for an interest in such entity. Following a transfer
under this Section 8.10, any such Option shall continue to be subject to the same terms and conditions as were applicable thereto immediately
prior to such transfer. Subsequent transfers of transferred Options shall be prohibited except to Family Members of the original Grantee
in accordance with this Section 8.10 or by will or the laws of descent and distribution. The provisions of Section 8.4 relating to termination
of Service shall continue to be applied with respect to the original Grantee of the Option, following which such Option shall be exercisable
by the transferee only to the extent, and for the periods specified, in Section 8.4.
8.11
Limitations on Incentive Stock Options.
An
Option shall constitute an Incentive Stock Option only (a) if the Grantee of such Option is an Employee of the Company or any corporate
Subsidiary, (b) to the extent specifically provided in the related Award Agreement, and (c) to the extent that the aggregate Fair Market
Value (determined at the time such Option is granted) of the shares of Stock with respect to which all Incentive Stock Options held by
such Grantee become exercisable for the first time during any calendar year (under the Plan and all other plans of the Company and its
Affiliates) does not exceed one hundred thousand dollars ($100,000). Except to the extent provided in the regulations under Code Section
422, this limitation shall be applied by taking Options into account in the order in which they were granted.
8.12
Notice of Disqualifying Disposition.
If
any Grantee shall make any disposition of shares of Stock issued pursuant to the exercise of an Incentive Stock Option under the circumstances
provided in Code Section 421(b) (relating to certain disqualifying dispositions), such Grantee shall notify the Company of such disposition
immediately but in no event later than ten (10) days thereafter.
9.
TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS
9.1
Right to Payment and SAR Price.
A
SAR shall confer on the Grantee to whom it is granted a right to receive, upon exercise thereof, the excess of (a) the Fair Market Value
of one (1) share of Stock on the date of exercise, over (b) the SAR Price as determined by the Committee. The Award Agreement for a SAR
shall specify the SAR Price, which shall be no less than the Fair Market Value of one (1) share of Stock on the Grant Date of such SAR.
SARs may be granted in tandem with all or part of an Option granted under the Plan or at any subsequent time during the term of such
Option, in combination with all or any part of any other Award, or without regard to any Option or other Award; provided that a SAR that
is granted in tandem with all or part of an Option will have the same term, and expire at the same time, as the related Option; provided,
further, that a SAR that is granted subsequent to the Grant Date of a related Option must have a SAR Price that is no less than the Fair
Market Value of one (1) share of Stock on the Grant Date of such SAR.
9.2
Other Terms.
The
Committee shall determine, on the Grant Date or thereafter, the time or times at which, and the circumstances under which, a SAR may
be exercised in whole or in part (including based on achievement of performance goals and/or future Service requirements); the time or
times at which SARs shall cease to be or become exercisable following termination of Service or upon other conditions; the method of
exercise, method of settlement, form of consideration payable in settlement, method by or forms in which shares of Stock shall be delivered
or deemed to be delivered to Grantees, whether or not a SAR shall be granted in tandem or in combination with any other Award; and any
and all other terms and conditions of any SAR; provided that no SARs shall be granted to Grantees who are entitled to overtime under
Applicable Laws that will vest or be exercisable within a six (6)-month period starting on the Grant Date.
9.3
Term.
Each
SAR granted under the Plan shall terminate, and all rights thereunder shall cease, on the tenth (10th) anniversary of the Grant Date
of such SAR or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Committee
and stated in the Award Agreement relating to such SAR.
9.4
Rights of Holders of SARs.
Unless
otherwise stated in the applicable Award Agreement, a Grantee or other Person holding or exercising a SAR shall have none of the rights
of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to the shares
of Stock underlying such SAR, to direct the voting of the shares of Stock underlying such SAR, or to receive notice of any meeting of
the Company’s stockholders) until the shares of Stock underlying such SAR, if any, are issued to such Grantee or other Person.
Except as provided in Article 16, no adjustment shall be made for dividends, distributions, or other rights with respect to any shares
of Stock underlying a SAR for which the record date is prior to the date of issuance of such shares of Stock, if any.
9.5
Transferability of SARs.
Except
as provided in Section 9.6, during the lifetime of a Grantee of a SAR, only the Grantee (or, in the event of such Grantee’s legal
incapacity or incompetency, such Grantee’s guardian or legal representative) may exercise such SAR. Except as provided in Section
9.6, no SAR shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution.
9.6
Family Transfers.
If
authorized in the applicable Award Agreement and by the Committee, in its sole discretion, a Grantee may transfer, not for value, all
or part of a SAR to any Family Member. For the purpose of this Section 9.6, a transfer “not for value” is a transfer which
is (a) a gift, (b) a transfer under a domestic relations order in settlement of marital property rights, or (c) unless Applicable Laws
do not permit such transfer, a transfer to an entity in which more than fifty percent (50%) of the voting interests are owned by Family
Members (and/or the Grantee) in exchange for an interest in such entity. Following a transfer under this Section 9.6, any such SAR shall
continue to be subject to the same terms and conditions as were in effect immediately prior to such transfer. Subsequent transfers of
transferred SARs shall be prohibited except to Family Members of the original Grantee in accordance with this Section 9.6 or by will
or the laws of descent and distribution.
10.
TERMS AND CONDITIONS OF RESTRICTED STOCK, RESTRICTED STOCK UNITS, AND DEFERRED STOCK UNITS
10.1
Grant of Restricted Stock, Restricted Stock Units, and Deferred Stock Units.
Awards
of Restricted Stock, Restricted Stock Units, and Deferred Stock Units may be made for consideration or for no consideration, other than
the par value of the shares of Stock, which shall be deemed paid by past Service or, if so provided in the related Award Agreement or
a separate agreement, the promise by the Grantee to perform future Service to the Company or an Affiliate.
10.2
Restrictions.
At
the time a grant of Restricted Stock, Restricted Stock Units, or Deferred Stock Units is made, the Committee may, in its sole discretion,
(a) establish a Restricted Period applicable to such Restricted Stock, Restricted Stock Units, or Deferred Stock Units and (b) prescribe
restrictions in addition to or other than the expiration of the Restricted Period, including the achievement of corporate or individual
performance goals, which may be applicable to all or any portion of such Restricted Stock, Restricted Stock Units, or Deferred Stock
Units as provided in Article 13. Awards of Restricted Stock, Restricted Stock Units, and Deferred Stock Units may not be sold, transferred,
assigned, pledged, or otherwise encumbered or disposed of during the Restricted Period or prior to the satisfaction of any other restrictions
prescribed by the Committee with respect to such Awards.
10.3
Registration; Restricted Stock Certificates.
Pursuant
to Section 3.6, to the extent that ownership of Restricted Stock is evidenced by a book-entry registration or direct registration (including
transaction advices), such registration shall be notated to evidence the restrictions imposed on such Award of Restricted Stock under
the Plan and the applicable Award Agreement. Subject to Section 3.6 and the immediately following sentence, the Company may issue, in
the name of each Grantee to whom Restricted Stock has been granted, certificates representing the total number of shares of Restricted
Stock granted to the Grantee, as soon as reasonably practicable after the Grant Date of such Restricted Stock. The Committee may provide
in an Award Agreement with respect to an Award of Restricted Stock that either (a) the Secretary of the Company shall hold such certificates
for such Grantee’s benefit until such time as such shares of Restricted Stock are forfeited to the Company or the restrictions
applicable thereto lapse and such Grantee shall deliver a stock power to the Company with respect to each certificate, or (b) such certificates
shall be delivered to such Grantee, provided that such certificates shall bear legends that comply with Applicable Laws and make appropriate
reference to the restrictions imposed on such Award of Restricted Stock under the Plan and such Award Agreement.
10.4
Rights of Holders of Restricted Stock.
Unless
the Committee provides otherwise in an Award Agreement and subject to the restrictions set forth in the Plan, any applicable Company
program, and the applicable Award Agreement, holders of Restricted Stock shall have the right to vote such shares of Restricted Stock
and the right to receive any dividend payments or distributions declared or paid with respect to such shares of Restricted Stock. The
Committee may provide in an Award Agreement evidencing a grant of Restricted Stock that (a) any cash dividend payments or distributions
paid on Restricted Stock shall be reinvested in shares of Stock, which may or may not be subject to the same vesting conditions and restrictions
as applicable to such underlying shares of Restricted Stock or (b) any dividend payments or distributions declared or paid on shares
of Restricted Stock shall only be made or paid upon satisfaction of the vesting conditions and restrictions applicable to such shares
of Restricted Stock. Dividend payments or distributions declared or paid on shares of Restricted Stock which vest or are earned based
upon the achievement of performance goals shall not vest unless such performance goals for such shares of Restricted Stock are achieved,
and if such performance goals are not achieved, the Grantee of such shares of Restricted Stock shall promptly forfeit and, to the extent
already paid or distributed, repay to the Company such dividend payments or distributions. All stock dividend payments or distributions,
if any, received by a Grantee with respect to shares of Restricted Stock as a result of any stock split, stock dividend, combination
of stock, or other similar transaction shall be subject to the same vesting conditions and restrictions as applicable to such underlying
shares of Restricted Stock.
10.5
Rights of Holders of Restricted Stock Units and Deferred Stock Units.
10.5.1
Voting and Dividend Rights.
Holders
of Restricted Stock Units and Deferred Stock Units shall have no rights as stockholders of the Company (for example, the right to receive
dividend payments or distributions attributable to the shares of Stock underlying such Restricted Stock Units and Deferred Stock Units,
to direct the voting of the shares of Stock underlying such Restricted Stock Units and Deferred Stock Units, or to receive notice of
any meeting of the Company’s stockholders). The Committee may provide in an Award Agreement evidencing a grant of Restricted Stock
Units or Deferred Stock Units that the holder of such Restricted Stock Units or Deferred Stock Units, as applicable, shall be entitled
to receive Dividend Equivalent Rights, in accordance with Article 12.
10.5.2
Creditor’s Rights.
A
holder of Restricted Stock Units or Deferred Stock Units shall have no rights other than those of a general unsecured creditor of the
Company. Restricted Stock Units and Deferred Stock Units represent unfunded and unsecured obligations of the Company, subject to the
terms and conditions of the applicable Award Agreement.
10.6
Termination of Service.
Unless
the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award
Agreement is issued, but prior to termination of Grantee’s Service, upon the termination of such Grantee’s Service, any Restricted
Stock, Restricted Stock Units, or Deferred Stock Units held by such Grantee that have not vested, or with respect to which all applicable
restrictions and conditions have not lapsed, shall immediately be deemed forfeited. Upon forfeiture of such Restricted Stock, Restricted
Stock Units, or Deferred Stock Units, the Grantee thereof shall have no further rights with respect thereto, including any right to vote
such Restricted Stock or any right to receive dividends or Dividend Equivalent Rights, as applicable, with respect to such Restricted
Stock, Restricted Stock Units, or Deferred Stock Units.
10.7
Purchase of Restricted Stock and Shares of Stock Subject to Restricted Stock Units and Deferred Stock Units.
The
Grantee of an Award of Restricted Stock, vested Restricted Stock Units, or vested Deferred Stock Units shall be required, to the extent
required by Applicable Laws, to purchase such Restricted Stock or the shares of Stock subject to such vested Restricted Stock Units or
Deferred Stock Units from the Company at a purchase price equal to the greater of (x) the aggregate par value of the shares of Stock
represented by such Restricted Stock or such vested Restricted Stock Units or Deferred Stock Units or (y) the purchase price, if any,
specified in the Award Agreement relating to such Restricted Stock or such vested Restricted Stock Units or Deferred Stock Units. Such
purchase price shall be payable in a form provided in Article 14 or, in the sole discretion of the Committee, in consideration for Service
rendered or to be rendered by the Grantee to the Company or an Affiliate.
10.8
Delivery of Shares of Stock.
Upon
the expiration or termination of any Restricted Period and the satisfaction of any other conditions prescribed by the Committee, including,
without limitation, any performance goals or delayed delivery period, the restrictions applicable to Restricted Stock, Restricted Stock
Units, or Deferred Stock Units settled in shares of Stock shall lapse, and, unless otherwise provided in the applicable Award Agreement,
a book-entry or direct registration (including transaction advices) or a certificate evidencing ownership of such shares of Stock shall,
consistent with Section 3.6, be issued, free of all such restrictions, to the Grantee thereof or such Grantee’s beneficiary or
estate, as the case may be. Neither the Grantee, nor the Grantee’s beneficiary or estate, shall have any further rights with regard
to a Restricted Stock Unit or Deferred Stock Unit once the shares of Stock represented by such Restricted Stock Unit or Deferred Stock
Unit have been delivered in accordance with this Section 10.8.
11.
TERMS AND CONDITIONS OF UNRESTRICTED STOCK AWARDS AND OTHER EQUITY-BASED AWARDS
11.1
Unrestricted Stock Awards.
The
Committee may, in its sole discretion, grant (or sell at the par value of a share of Stock or at such other higher purchase price as
shall be determined by the Committee) an Award to any Grantee pursuant to which such Grantee may receive shares of Unrestricted Stock
under the Plan. Awards of Unrestricted Stock may be granted or sold to any Grantee as provided in the immediately preceding sentence
in respect of Service rendered or, if so provided in the related Award Agreement or a separate agreement, to be rendered by the Grantee
to the Company or an Affiliate or other valid consideration, in lieu of or in addition to any cash compensation due to such Grantee.
11.2
Other Equity-Based Awards.
The
Committee may, in its sole discretion, grant Awards in the form of Other Equity-Based Awards, as deemed by the Committee to be consistent
with the purposes of the Plan. Awards granted pursuant to this Section 11.2 may be granted with vesting, value, and/or payment contingent
upon the achievement of one or more performance goals. The Committee shall determine the terms and conditions of Other Equity-Based Awards
on the Grant Date or thereafter. Unless the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee,
or otherwise in writing after such Award Agreement is issued, but prior to termination of Grantee’s Service, upon the termination
of a Grantee’s Service, any Other Equity-Based Awards held by such Grantee that have not vested, or with respect to which all applicable
restrictions and conditions have not lapsed, shall immediately be deemed forfeited. Upon forfeiture of any Other Equity-Based Award,
the Grantee thereof shall have no further rights with respect to such Other Equity-Based Award.
12.
TERMS AND CONDITIONS OF DIVIDEND EQUIVALENT RIGHTS
12.1
Dividend Equivalent Rights.
A
Dividend Equivalent Right may be granted hereunder, provided that no Dividend Equivalent Rights may be granted in connection with, or
related to, an Award of Options or SARs. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement
therefor. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently (with or without being subject
to forfeiture or a repayment obligation) or may be deemed to be reinvested in additional shares of Stock or Awards, which may thereafter
accrue additional Dividend Equivalent Rights (with or without being subject to forfeiture or a repayment obligation). Any such reinvestment
shall be at the Fair Market Value thereof on the date of such reinvestment. Dividend Equivalent Rights may be settled in cash, shares
of Stock, or a combination thereof, in a single installment or in multiple installments, all as determined in the sole discretion of
the Committee. A Dividend Equivalent Right granted as a component of another Award may (a) provide that such Dividend Equivalent Right
shall be settled upon exercise, settlement, or payment of, or lapse of restrictions on, such other Award and that such Dividend Equivalent
Right shall expire or be forfeited or annulled under the same conditions as such other Award or (b) contain terms and conditions which
are different from the terms and conditions of such other Award, provided that Dividend Equivalent Rights credited pursuant to a Dividend
Equivalent Right granted as a component of another Award which vests or is earned based upon the achievement of performance goals shall
not vest unless such performance goals for such underlying Award are achieved, and if such performance goals are not achieved, the Grantee
of such Dividend Equivalent Rights shall promptly forfeit and, to the extent already paid or distributed, repay to the Company payments
or distributions made in connection with such Dividend Equivalent Rights.
12.2
Termination of Service.
Unless
the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award
Agreement is issued, a Grantee’s rights in all Dividend Equivalent Rights shall automatically terminate upon such Grantee’s
termination of Service for any reason.
13.
TERMS AND CONDITIONS OF PERFORMANCE AWARDS
13.1
Grant of Performance Awards.
Subject
to the terms and provisions of the Plan, the Committee, at any time and from time to time, may grant Performance Awards in such amounts
and upon such terms as the Committee shall determine.
13.2
Value of Performance Awards.
Each
grant of a Performance Award shall have an initial cash value or an actual or target number of shares of Stock that is established by
the Committee as of the Grant Date. The Committee shall set performance goals in its discretion which, depending on the extent to which
they are achieved, shall determine the amount of cash or value and/or number of shares of Stock that will be paid out to the Grantee
thereof.
13.3
Earning of Performance Awards.
Subject
to the terms of the Plan, after the applicable Performance Period has ended, the Grantee of a Performance Award shall be entitled to
receive a payout of the value earned under such Performance Award by such Grantee over such Performance Period, to be determined based
on the extent to which the corresponding performance goals have been achieved.
13.4
Form and Timing of Payment of Performance Awards.
Payment
of the value earned under a Performance Award shall be made, as determined by the Committee, in the form, at the time, and in the manner
described in the applicable Award Agreement. Subject to the terms of the Plan, the Committee, in its sole discretion, (a) may pay the
value earned under Performance Awards in the form of cash, shares of Stock, other Awards, or a combination thereof, including shares
of Stock and/or Awards that are subject to any restrictions deemed appropriate by the Committee, and (b) shall pay the value earned under
Performance Awards at the close of the applicable Performance Period, or as soon as reasonably practicable after the Committee has determined
that the performance goal or goals relating thereto have been achieved; provided that, unless specifically provided in the Award
Agreement for such Performance Awards, such payment shall occur no later than the fifteenth (15th) day of the third (3rd) month following
the end of the calendar year in which such Performance Period ends. Any shares of Stock paid out under a Performance Award may be granted
subject to any restrictions deemed appropriate by the Committee. The determination of the Committee with respect to the form of payout
of such Awards shall be set forth in the Award Agreement for the Performance Award.
13.5
Performance Conditions.
The
right of a Grantee to exercise or receive a grant or settlement of any Performance Award, and the timing thereof, may be subject to the
achievement of such Performance Measures as may be specified by the Committee. The Committee may use such business criteria and other
measures of performance as it may deem appropriate in establishing any performance conditions.
13.6
Performance Measures.
Performance
under any Performance Measures (a) may be used to measure the performance of (i) the Company, its Subsidiaries, and other Affiliates
as a whole, (ii) the Company, any Subsidiary, and/or any other Affiliate or any combination thereof, or (iii) any one or more business
units or operating segments of the Company, any Subsidiary, and/or any other Affiliate, in each case as the Committee, in its sole discretion,
deems appropriate and (b) may be compared to the performance of one or more other companies or one or more published or special indices
designated or approved by the Committee for such comparison, as the Committee, in its sole discretion, deems appropriate. In addition,
the Committee, in its sole discretion, may select a Performance Measure for comparison to performance under one or more stock market
indices designated or approved by the Committee. The Committee shall also have the authority to provide for accelerated vesting of any
Performance Award based on the achievement of performance goals pursuant to any Performance Measures. For the avoidance of doubt, nothing
herein is intended to prevent the Committee from granting Awards subject to subjective performance conditions (including individual performance
conditions).
14.
FORMS OF PAYMENT
14.1
General Rule.
Payment
of the Option Price for the shares of Stock purchased pursuant to the exercise of an Option or the purchase price, if any, for Restricted
Stock, vested Restricted Stock Units, and/or vested Deferred Stock Units shall be made in cash or in cash equivalents acceptable to the
Company.
14.2
Surrender of Shares of Stock.
To
the extent that the applicable Award Agreement so provides, payment of the Option Price for shares of Stock purchased pursuant to the
exercise of an Option or the purchase price, if any, for Restricted Stock, vested Restricted Stock Units, and/or vested Deferred Stock
Units may be made all or in part through the tender or attestation to the Company of shares of Stock, which shall be valued, for purposes
of determining the extent to which such Option Price or purchase price has been paid thereby, at their Fair Market Value on the date
of such tender or attestation.
14.3
Cashless Exercise.
To
the extent permitted by Applicable Laws and to the extent the Award Agreement so provides, payment of the Option Price for shares of
Stock purchased pursuant to the exercise of an Option may be made all or in part by delivery (on a form acceptable to the Committee)
of an irrevocable direction to a licensed securities broker acceptable to the Company to sell shares of Stock and to deliver all or part
of the proceeds of such sale to the Company in payment of such Option Price and/or any withholding taxes described in Section 18.3.
14.4
Other Forms of Payment.
To
the extent that the applicable Award Agreement so provides and/or unless otherwise specified in an Award Agreement, payment of the Option
Price for shares of Stock purchased pursuant to exercise of an Option or the purchase price, if any, for Restricted Stock, vested Restricted
Stock Units, and/or vested Deferred Stock Units may be made in any other form that is consistent with Applicable Laws, including (a)
with respect to Restricted Stock, vested Restricted Stock Units, and/or vested Deferred Stock Units only, Service rendered or to be rendered
by the Grantee thereof to the Company or an Affiliate and (b) with the consent of the Company, by withholding the number of shares of
Stock that would otherwise vest or be issuable in an amount equal in value to the Option Price or purchase price and/or the required
tax withholding amount.
15.
REQUIREMENTS OF LAW
15.1
General.
The
Company shall not be required to offer, sell, or issue any shares of Stock under any Award, whether pursuant to the exercise of an Option,
a SAR, or otherwise, if the offer, sale, or issuance of such shares of Stock would constitute a violation by the Grantee, the Company,
an Affiliate, or any other Person of any provision of the Company’s certificate of incorporation or bylaws or of Applicable Laws,
including any federal or state securities laws or regulations. If at any time the Company shall determine, in its discretion, that the
listing, registration, or qualification of any shares of Stock subject to an Award upon any Stock Exchange or Securities Market or under
any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the offering, sale, issuance, or
purchase of shares of Stock in connection with any Award, no shares of Stock may be offered, sold, or issued to the Grantee or any other
Person under such Award, whether pursuant to the exercise of an Option, a SAR, or otherwise, unless such listing, registration, or qualification
shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby shall in no way
affect the date of termination of such Award. Without limiting the generality of the foregoing, upon the exercise of any Option or any
SAR that may be settled in shares of Stock or the delivery of any shares of Stock underlying an Award, unless a registration statement
under the Securities Act is in effect with respect to the shares of Stock subject to such Award, the Company shall not be required to
offer, sell, or issue such shares of Stock unless the Committee shall have received evidence satisfactory to it that the Grantee or any
other Person exercising such Option or SAR or accepting delivery of such shares may acquire such shares of Stock pursuant to an exemption
from registration under the Securities Act. Any determination by the Committee in connection with the foregoing shall be final, binding,
and conclusive. The Company may register, but shall in no event be obligated to register, any shares of Stock or other securities issuable
pursuant to the Plan pursuant to the Securities Act. The Company shall not be obligated to take any affirmative action in order to cause
the exercise of an Option or a SAR or the issuance of shares of Stock or other securities issuable pursuant to the Plan or any Award
to comply with any Applicable Laws. As to any jurisdiction that expressly imposes the requirement that an Option or SAR that may be settled
in shares of Stock shall not be exercisable until the shares of Stock subject to such Option or SAR are registered under the securities
laws thereof or are exempt from such registration, the exercise of such Option or SAR under circumstances in which the laws of such jurisdiction
apply shall be deemed to be conditioned upon the effectiveness of such registration or the availability of such an exemption.
15.2
Rule 16b-3.
During
any time when the Company has any class of common equity securities registered under Section 12 of the Exchange Act, it is the intention
of the Company that Awards pursuant to the Plan and the exercise of Options and SARs granted hereunder that would otherwise be subject
to Section 16(b) of the Exchange Act shall qualify for the exemption provided by Rule 16b-3 under the Exchange Act. To the extent that
any provision of the Plan or action by the Committee does not comply with the requirements of such Rule 16b-3, such provision or action
shall be deemed inoperative with respect to such Awards to the extent permitted by Applicable Laws and deemed advisable by the Committee
and shall not affect the validity of the Plan. In the event that such Rule 16b-3 is revised or replaced, the Committee may exercise its
discretion to modify the Plan in any respect necessary or advisable in its judgment to satisfy the requirements of, or to permit the
Company to avail itself of the benefits of, the revised exemption or its replacement.
16.
EFFECT OF CHANGES IN CAPITALIZATION
16.1
Changes in Stock.
If
the number of outstanding shares of Stock is increased or decreased or the shares of Stock are changed into or exchanged for a different
number of shares or kind of Capital Stock or other securities of the Company on account of any recapitalization, reclassification, stock
split, reverse stock split, spin-off, combination of stock, exchange of stock, stock dividend or other distribution payable in capital
stock, or other increase or decrease in shares of Stock effected without receipt of consideration by the Company occurring after the
Effective Date, the number and kinds of shares of Capital Stock for which grants of Options and other Awards may be made under the Plan,
including the Initial Share Limit and the Share Limit, each as set forth in Section 4.1, which includes the number and kinds of issued
shares of Capital Stock by which the Plan reserve may be increased annually, shall be adjusted proportionately and accordingly by the
Committee. In addition, the number and kind of shares of Capital Stock for which Awards are outstanding shall be adjusted proportionately
and accordingly by the Committee so that the proportionate interest of the Grantee therein immediately following such event shall, to
the extent practicable, be the same as immediately before such event. Any such adjustment in outstanding Options or SARs shall not change
the aggregate Option Price or SAR Price payable with respect to shares that are subject to the unexercised portion of such outstanding
Options or SARs, as applicable, but shall include a corresponding proportionate adjustment in the per share Option Price or SAR Price,
as the case may be. The conversion of any convertible securities of the Company shall not be treated as an increase in shares effected
without receipt of consideration. Notwithstanding the foregoing, in the event of any distribution to the Company’s stockholders
of securities of any other entity or other assets (including an extraordinary dividend, but excluding a non-extraordinary dividend, declared
and paid by the Company) without receipt of consideration by the Company, the Board or the Committee constituted pursuant to Section
3.1.2 shall, in such manner as the Board or the Committee deems appropriate, adjust (a) the number and kind of shares of Capital Stock
subject to outstanding Awards and/or (b) the aggregate and per share Option Price of outstanding Options and the aggregate and per share
SAR Price of outstanding SARs as required to reflect such distribution.
16.2
Transaction in Which the Company is the Surviving Entity Which Does not Constitute a Change in Control.
Subject
to Section 16.3, if the Company shall be the surviving entity in any reorganization, merger, or consolidation of the Company with one
or more other entities which does not constitute a Change in Control, any Award theretofore granted pursuant to the Plan shall pertain
to and apply to the Capital Stock to which a holder of the number of shares of Stock subject to such Award would have been entitled immediately
following such reorganization, merger, or consolidation, with a corresponding proportionate adjustment of the per share Option Price
or SAR Price of any outstanding Option or SAR so that the aggregate Option Price or SAR Price thereafter shall be the same as the aggregate
Option Price or SAR Price of the shares of Stock remaining subject to the Option or SAR as in effect immediately prior to such reorganization,
merger, or consolidation. Subject to any contrary language in an Award Agreement, in another agreement with the Grantee, or as otherwise
set forth in writing, any restrictions applicable to such Award shall apply as well to any replacement shares of Capital Stock subject
to such Award received by the Grantee as a result of such reorganization, merger, or consolidation. In the event of any reorganization,
merger, or consolidation of the Company referred to in this Section 16.2, Performance Awards shall be adjusted (including any adjustment
to the Performance Measures or other performance goals applicable to such Awards deemed appropriate by the Committee) so as to apply
to the Capital Stock that a holder of the number of shares of Stock subject to the Performance Awards would have been entitled to receive
immediately following such reorganization, merger, or consolidation.
16.3
Change in Control in which Awards are not Assumed.
Except
as otherwise provided in the applicable Award Agreement, in another agreement with the Grantee, or as otherwise set forth in writing,
upon the occurrence of a Change in Control in which outstanding Awards are not being assumed or continued, the following provisions shall
apply to such Awards, to the extent not assumed or continued:
(a)
Immediately prior to the occurrence of such Change in Control, in each case with the exception of Performance Awards, all outstanding
shares of Restricted Stock and all Restricted Stock Units, Deferred Stock Units, and Dividend Equivalent Rights shall be deemed to have
vested, and all shares of Stock and/or cash subject to such Awards shall be delivered; and either or both of the following two (2)
actions shall be taken:
(i)
At least fifteen (15) days prior to the scheduled consummation of such Change in Control, all Options and SARs outstanding hereunder
shall become immediately exercisable and shall remain exercisable for a period of fifteen (15) days. Any exercise of an Option or SAR
during this fifteen (15)-day period shall be conditioned upon the consummation of the applicable Change in Control and shall be effective
only immediately before the consummation thereof, and upon consummation of such Change in Control, the Plan and all outstanding but unexercised
Options and SARs shall terminate, with or without consideration (including, without limitation, consideration in accordance with clause
(ii) below) as determined by the Committee in its sole discretion. The Committee shall send notice of an event that shall result in such
a termination to all Persons who hold Options and SARs not later than the time at which the Company gives notice thereof to its stockholders;
and/or
(ii)
The Committee may elect, in its sole discretion, to cancel any outstanding Awards of Options, SARs, Restricted Stock, Restricted Stock
Units, Deferred Stock Units, and/or Dividend Equivalent Rights and pay or deliver, or cause to be paid or delivered, to the holder thereof
an amount in cash or Capital Stock having a value (as determined by the Committee acting in good faith), in the case of Restricted Stock,
Restricted Stock Units, Deferred Stock Units, and Dividend Equivalent Rights (for shares of Stock subject thereto), equal to the formula
or fixed price per share paid to holders of shares of Stock pursuant to such Change in Control and, in the case of Options or SARs, equal
to the product of the number of shares of Stock subject to such Options or SARs multiplied by the amount, if any, by which (x) the formula
or fixed price per share paid to holders of shares of Stock pursuant to such transaction exceeds (y) the Option Price or SAR Price applicable
to such Options or SARs.
(b)
For Performance Awards, if less than half of the Performance Period has lapsed, such Awards shall be treated as though the target performance
thereunder has been achieved. If at least half of the Performance Period has lapsed, such Performance Awards shall be earned, as of immediately
prior to but contingent on the occurrence of such Change in Control, based on the greater of (i) deemed achievement of target performance
or (ii) determination of actual performance as of a date reasonably proximate to the date of consummation of the Change in Control as
determined by the Committee, in its sole discretion. After application of this Section 16.3(b), if any Awards arise from application
of this Article 16, such Awards shall be settled under the applicable provision of Section 16.3(a).
(c)
Other Equity-Based Awards shall be governed by the terms of the applicable Award Agreement.
16.4
Change in Control in which Awards are Assumed.
Except
as otherwise provided in the applicable Award Agreement, in another agreement with the Grantee, or as otherwise set forth in writing,
upon the occurrence of a Change in Control in which outstanding Awards are being assumed or continued, the following provisions shall
apply to such Award, to the extent assumed or continued:
The
Plan and the Options, SARs, Restricted Stock, Restricted Stock Units, Deferred Stock Units, Dividend Equivalent Rights, and Other Equity-Based
Awards granted under the Plan shall continue in the manner and under the terms so provided in the event of any Change in Control to the
extent that provision is made in writing in connection with such Change in Control for the assumption or continuation of such Options,
SARs, Restricted Stock, Restricted Stock Units, Deferred Stock Units, Dividend Equivalent Rights, and Other Equity-Based Awards, or for
the substitution for such Options, SARs, Restricted Stock, Restricted Stock Units, Deferred Stock Units, Dividend Equivalent Rights,
and Other Equity-Based Awards of new stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock
units, dividend equivalent rights, and other equity-based awards relating to the Capital Stock of a successor entity, or a parent or
subsidiary thereof, with appropriate adjustments as to the number of shares (disregarding any consideration that is not common stock)
and exercise prices of options and stock appreciation rights.
16.5
Adjustments.
Adjustments
under this Article 16 related to shares of Stock or other Capital Stock of the Company shall be made by the Committee, whose determination
in that respect shall be final, binding, and conclusive. No fractional shares or other securities shall be issued pursuant to any such
adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case by rounding downward to the nearest
whole share. The Committee may provide in the applicable Award Agreement as of the Grant Date, in another agreement with the Grantee,
or otherwise in writing at any time thereafter with the consent of the Grantee, for different provisions to apply to an Award in place
of those provided in Sections 16.1, 16.2, 16.3, and 16.4. This Article 16 shall not limit the Committee’s ability to provide for
alternative treatment of Awards outstanding under the Plan in the event of a change in control event involving the Company that is not
a Change in Control.
16.6
No Limitations on Company.
The
making of Awards pursuant to the Plan shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications,
reorganizations, or changes of its capital or business structure or to merge, consolidate, dissolve, or liquidate, or to sell or transfer
all or any part of its business or assets (including all or any part of the business or assets of any Subsidiary or other Affiliate)
or to engage in any other transaction or activity.
17.
PARACHUTE LIMITATIONS
If
any Grantee is a Disqualified Individual, then, notwithstanding any other provision of the Plan or of any Other Agreement to the contrary
and notwithstanding any Benefit Arrangement, any right of such Grantee to any exercise, vesting, payment, or benefit under the Plan shall
be reduced or eliminated:
(a)
to the extent that such right to exercise, vesting, payment, or benefit, taking into account all other rights, payments, or benefits
to or for the Grantee under the Plan, all Other Agreements, and all Benefit Arrangements, would cause any exercise, vesting, payment,
or benefit to such Grantee under the Plan to be considered a Parachute Payment; and
(b)
if, as a result of receiving such Parachute Payment, the aggregate after-tax amounts received by the Grantee from the Company under the
Plan, all Other Agreements, and all Benefit Arrangements would be less than the maximum after-tax amount that could be received by the
Grantee without causing any such payment or benefit to be considered a Parachute Payment.
Except
as required by Code Section 409A or to the extent that Code Section 409A permits discretion, the Committee shall have the right, in the
Committee’s sole discretion, to designate those rights, payments, or benefits under the Plan, all Other Agreements, and all Benefit
Arrangements that should be reduced or eliminated so as to avoid having such rights, payments, or benefits be considered a Parachute
Payment; provided, that, to the extent any payment or benefit constitutes deferred compensation under Code Section 409A, in order to
comply with Code Section 409A, except as otherwise provided in an applicable agreement between a Grantee and the Company or an Affiliate,
the Company shall instead accomplish such reduction by first reducing or eliminating any cash payments (with the payments to be made
furthest in the future being reduced first), then by reducing or eliminating any accelerated vesting of Performance Awards, then by reducing
or eliminating any accelerated vesting of Options or SARs, then by reducing or eliminating any accelerated vesting of Restricted Stock,
Restricted Stock Units, or Deferred Stock Units, then by reducing or eliminating any other remaining Parachute Payments.
18.
GENERAL PROVISIONS
18.1
Disclaimer of Rights.
No
provision in the Plan, any Award, or any Award Agreement shall be construed (a) to confer upon any individual the right to remain in
the Service of the Company or an Affiliate, (b) to interfere in any way with any contractual or other right or authority of the Company
or an Affiliate either to increase or decrease the compensation or other payments to any Person at any time, or (c) to terminate any
Service or other relationship between any Person and the Company or an Affiliate. In addition, notwithstanding any provision of the Plan
to the contrary, unless otherwise stated in the applicable Award Agreement, in another agreement with the Grantee, or otherwise in writing,
no Award granted under the Plan shall be affected by any change of duties or position of the Grantee thereof, so long as such Grantee
continues to provide Service. The obligation of the Company to pay any benefits pursuant to the Plan shall be interpreted as a contractual
obligation to pay only those amounts provided herein, in the manner and under the conditions prescribed herein. The Plan and Awards shall
in no way be interpreted to require the Company to transfer any amounts to a third-party trustee or otherwise to hold any amounts in
trust or escrow for payment to any Grantee or beneficiary under the terms of the Plan.
18.2
Nonexclusivity of the Plan.
Neither
the adoption of the Plan nor the submission of the Plan to the stockholders of the Company for approval shall be construed as creating
any limitations upon the right and authority of the Board or the Committee to adopt such other incentive compensation arrangements (which
arrangements may be applicable either generally to a class or classes of individuals or specifically to a particular individual or particular
individuals) as the Board or the Committee in their discretion determine desirable.
18.3
Withholding Taxes.
The
Company or an Affiliate, as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Grantee any
federal, state, or local taxes of any kind required by Applicable Laws to be withheld with respect to the vesting of or other lapse of
restrictions applicable to an Award or upon the issuance of any shares of Stock upon the exercise of an Option or pursuant to any other
Award. At the time of such vesting, lapse of restrictions, or exercise, the Grantee shall pay in cash to the Company or an Affiliate,
as the case may be, any amount that the Company or such Affiliate may reasonably determine to be necessary to satisfy such withholding
obligation; provided that if there is a same-day sale of shares of Stock subject to an Award, the Grantee shall pay such withholding
obligation on the day on which such same-day sale is completed. Subject to the prior approval of the Company or an Affiliate, which may
be withheld by the Company or such Affiliate, as the case may be, in its sole discretion, the Grantee may elect to satisfy such withholding
obligation, in whole or in part, (a) by causing the Company or such Affiliate to withhold shares of Stock otherwise issuable to the Grantee
or (b) by delivering to the Company or such Affiliate shares of Stock already owned by the Grantee. The shares of Stock so withheld or
delivered shall have an aggregate Fair Market Value equal to such withholding obligation. The Fair Market Value of the shares of Stock
used to satisfy such withholding obligation shall be determined by the Company or such Affiliate as of the date on which the amount of
tax to be withheld is to be determined. A Grantee who has made an election pursuant to this Section 18.3 may satisfy such Grantee’s
withholding obligation only with shares of Stock that are not subject to any repurchase, forfeiture, unfulfilled vesting, or other similar
requirements. The maximum number of shares of Stock that may be withheld from any Award to satisfy any federal, state, or local tax withholding
requirements upon the exercise, vesting, or lapse of restrictions applicable to any Award or payment of shares of Stock pursuant to such
Award, as applicable, may not exceed such number of shares of Stock having a Fair Market Value equal to the minimum statutory amount
required by the Company or the applicable Affiliate to be withheld and paid to any such federal, state, or local taxing authority with
respect to such exercise, vesting, lapse of restrictions, or payment of shares of Stock; provided, however, that for so long as Accounting
Standards Update 2016-09 or a similar rule remains in effect, the Board or the Committee has full discretion to choose, or to allow a
Grantee to elect, to withhold a number of Shares having an aggregate Fair Market Value that is greater than the applicable minimum statutory
required withholding obligation (but such withholding may in no event be in excess of the maximum required statutory withholding amount(s)
in such Grantee’s relevant tax jurisdiction).
18.4
Captions.
The
use of captions in the Plan or any Award Agreement is for convenience of reference only and shall not affect the meaning of any provision
of the Plan or such Award Agreement.
18.5
Construction.
Unless
the context otherwise requires, all references in the Plan to “including” shall mean “including without limitation.”
18.6
Other Provisions.
Each
Award granted under the Plan may contain such other terms and conditions not inconsistent with the Plan as may be determined by the Committee,
in its sole discretion.
18.7
Number and Gender.
With
respect to words used in the Plan, the singular form shall include the plural form, and the masculine gender shall include the feminine
gender, as the context requires.
18.8
Severability.
If
any provision of the Plan or any Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction,
the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall
remain enforceable in any other jurisdiction.
18.9
Governing Law.
The
Plan and the instruments evidencing the Awards hereunder shall be governed by, and construed and interpreted in accordance with, the
laws of the State of Delaware, other than any conflicts or choice of law rule or principle that might otherwise refer construction or
interpretation of the Plan and the instruments evidencing the Awards granted hereunder to the substantive laws of any other jurisdiction.
18.10
Foreign Jurisdictions.
To
the extent the Committee determines that the material terms set by the Committee imposed by the Plan preclude the achievement of the
material purposes of the Plan in jurisdictions outside the United States, the Committee will have the authority and discretion to modify
those terms and provide for such additional terms and conditions as the Committee determines to be necessary, appropriate, or desirable
to accommodate differences in local law, policy, or custom or to facilitate administration of the Plan. The Committee may adopt or approve
sub-plans, appendices, or supplements to, or amendments, restatements, or alternative versions of the Plan as in effect for any other
purposes. The special terms and any sub-plans, appendices, supplements, amendments, restatements, or alternative versions, however, shall
not include any provisions that are inconsistent with the terms of the Plan as in effect, unless the Plan could have been amended to
eliminate such inconsistency without further approval by the Company’s stockholders.
18.11
Section 409A of the Code.
The
Plan is intended to comply with Code Section 409A to the extent subject thereto, and, accordingly, to the maximum extent permitted, the
Plan will be interpreted and administered to be in compliance with Code Section 409A. Any payments described in the Plan that are due
within the Short-Term Deferral Period will not be treated as deferred compensation unless Applicable Laws require otherwise. Any grant
of an Option or SAR pursuant to the Plan is intended to comply with the “stock rights” exemption from Code Section 409A.
Notwithstanding any provision of the Plan to the contrary, to the extent required to avoid accelerated taxation and tax penalties under
Code Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during
the six (6)-month period immediately following the Grantee’s Separation from Service will instead be paid on the first payroll
date after the six (6)-month anniversary of the Grantee’s Separation from Service (or the Grantee’s death, if earlier).
Furthermore,
notwithstanding anything in the Plan to the contrary, in the case of an Award that is characterized as deferred compensation under Code
Section 409A, and pursuant to which settlement and delivery of the cash or shares of Stock subject to the Award is triggered based on
a Change in Control, in no event will a Change in Control be deemed to have occurred for purposes of such settlement and delivery of
cash or shares of Stock if the transaction is not also a “change in the ownership or effective control of” the Company or
“a change in the ownership of a substantial portion of the assets of” the Company as determined under Treasury Regulation
Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder). If an Award characterized as deferred compensation
under Code Section 409A is not settled and delivered on account of the provision of the preceding sentence, the settlement and delivery
shall occur on the next succeeding settlement and delivery triggering event that is a permissible triggering event under Code Section
409A. No provision of this paragraph shall in any way affect the determination of a Change in Control for purposes of vesting in an Award
that is characterized as deferred compensation under Code Section 409A. Notwithstanding the foregoing, neither the Company nor the Committee
will have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Grantee under Code Section
409A, and neither the Company or an Affiliate nor the Board or the Committee will have any liability to any Grantee for such tax or penalty.
18.12
Limitation on Liability.
No
member of the Board or the Committee shall be liable for any action or determination made in good faith with respect to the Plan, any
Award, or any Award Agreement. Notwithstanding any provision of the Plan to the contrary, neither the Company, an Affiliate, the Board,
the Committee, nor any person acting on behalf of the Company, an Affiliate, the Board, or the Committee will be liable to any Grantee
or to the estate or beneficiary of any Grantee or to any other holder of an Award under the Plan by reason of any acceleration of income,
or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements
of Code Section 422 or Code Section 409A or by reason of Code Section 4999, or otherwise asserted with respect to the Award; provided,
that this Section 18.12 shall not affect any of the rights or obligations set forth in an applicable agreement between the Grantee and
the Company or an Affiliate.
[Remainder
of Page Intentionally Left Blank]
Exhibit
10.9
Grant No.__________
TEVOGEN
BIO INC.
2024
OMNIBUS INCENTIVE PLAN
RESTRICTED
Stock Unit Agreement
COVER
SHEET
Tevogen
Bio Inc., a Delaware corporation (the “Company”), hereby grants restricted stock units (the “RSUs”)
relating to shares of the Company’s non-voting common stock, par value $0.01 per share (the “Stock”), to the
Grantee named below, subject to the vesting and other conditions set forth below. Additional terms and conditions of the RSUs are set
forth in this cover sheet and in the attached Restricted Stock Unit Agreement (together, the “Agreement”) and in the
Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (as it has been or may be amended and/or restated from time to time, the “Plan”).
|
Name
of Grantee: |
|
|
|
|
|
Grant
Date: |
|
|
|
|
|
Number
of Shares of Stock Covered by the RSUs: |
|
|
|
|
|
Vesting
Commencement Date: |
|
|
|
|
|
Vesting
Schedule: |
|
By
your electronic acknowledgement of this Agreement, you agree to all of the terms and conditions described in the Agreement and in the
Plan (a copy of which has been made available to you and will be provided on request). You acknowledge that you have carefully reviewed
the Plan and agree that the Plan shall control in the event any provision of this Agreement should appear to be inconsistent with the
Plan. You must accept your award no later than 5 pm Eastern Time, five (5) business days prior to the vesting date or your entire award
will be cancelled.
Grantee: |
|
|
Date: |
|
|
(Signature) |
|
|
|
|
|
|
|
|
Company: |
|
|
Date: |
|
|
(Signature) |
|
|
|
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
Attachment
This
is not a stock certificate or a negotiable instrument.
TEVOGEN
BIO INC.
2024
OMNIBUS INCENTIVE PLAN
RESTRICTED
Stock Unit Agreement
Restricted
Stock Units |
This
Agreement evidences an award of RSUs in the number set forth on the cover sheet and subject to the terms and conditions set forth
in the Agreement and the Plan. |
|
|
Transferability |
Your
RSUs may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, whether by operation of law or otherwise,
nor may the RSUs be made subject to execution, attachment, or similar process. If you attempt to do any of these things, you will
immediately and automatically forfeit your RSUs. |
|
|
Vesting |
Your
RSUs shall vest in accordance with the vesting schedule set forth on the cover sheet of this
Agreement.
To
the extent that vesting could result in any fractional shares, resulting fractional shares will be rounded to the nearest whole share
and shall be rounded up or down as necessary as of the last applicable vesting date; provided, in all cases, you cannot vest in more
than the number of shares of Stock covered by your RSUs, as set forth on the cover sheet of this Agreement. |
|
|
Leaves
of Absence |
For
purposes of this Agreement, your Service does not terminate when you go on a bona fide
leave of absence that was approved by your employer in writing if the terms of the leave
provide for continued Service crediting, or when continued Service crediting is required
by Applicable Laws. Your Service terminates in any event when the approved leave ends unless
you immediately return to active employee work.
Your
employer may determine, in its discretion, which leaves count for this purpose and when your Service terminates for all purposes
under the Plan in accordance with the provisions of the Plan. Notwithstanding the foregoing, the Company may determine, in its discretion,
that a leave counts for this purpose even if your employer does not agree. |
|
|
Termination
of Service and Forfeiture |
Upon
termination of your Service for Cause at any time prior to the applicable Vesting Date, all
RSUs covered by this Agreement shall immediately and automatically be forfeited upon such
termination of Service, notwithstanding that the Service Condition may have been satisfied
with respect to all or a portion of the RSUs or the Liquidity Event Condition may have been
satisfied with respect to such RSUs.
Upon
termination of your Service for any reason other than Cause, all RSUs for which the Service Condition has not been satisfied shall
immediately and automatically be forfeited upon such termination of Service.
You
will immediately and automatically forfeit to the Company all of your unvested RSUs in the event that the Liquidity Event Condition
has not been satisfied by the seventh (7th) anniversary of the Grant Date. |
Delivery |
Delivery
of the shares of Stock represented by your vested RSUs shall be made within thirty (30) days
following the applicable Vesting Date; provided, however, that if the Liquidity Event Condition
is satisfied by an Initial Public Offering, then delivery of the shares of Stock represented
by the portion of your RSUs that become vested prior to the lapse of any lock-up period applicable
to you shall be made as of the first to occur of (i) the date on which such lock-up period
lapses and (ii) a date determined by the Board, which in case of each of (i) and (ii), shall
be no later than the 15th day of the third month following the end of the calendar
year in which the Vesting Date occurs for such RSUs.
In
the event that (i) any shares covered by your RSUs are scheduled to be delivered on a date (the “Original Distribution Date”)
that does not occur: (A) during an open “window period” applicable to you, as determined by the Company in accordance
with the Company’s then-effective policy on trading in Company securities (the “Policy”); (B) on a date
on which you are permitted to sell shares of Stock pursuant to a written plan that meets the requirements of Rule 10b5-1 under the
Exchange Act, as determined by the Company in accordance with the Policy; or (C) on a date when you are otherwise permitted to sell
shares of Stock on the open market, and (ii) the Company elects not to satisfy its tax withholding obligations by withholding shares
from the shares otherwise deliverable, withholding from other compensation otherwise payable to you by the Company or its Affiliates,
or by permitting you to pay your withholding taxes in cash, then such shares will not be delivered on such Original Distribution
Date and will instead be delivered as of the earlier of (1) the first date you are not subject to any such policy or restriction
and (2) the 15th day of the third month following the end of the calendar year in which the Vesting Date occurs for such
RSUs. |
|
|
Evidence
of Issuance |
The
issuance of the shares of Stock with respect to the RSUs shall be evidenced in such a manner as the Company, in its discretion, deems
appropriate, including, without limitation, by (i) book-entry registration or (ii) issuance of one or more share certificates. |
|
|
Withholding
Taxes |
You
agree as a condition of this Agreement that you will make acceptable arrangements to pay any withholding or other taxes that may
be due relating to the RSUs or the issuance of shares of Stock with respect to the RSUs. In the event that the Company or any Affiliate
determines that any federal, state, local, or foreign tax or withholding payment is required relating to the RSUs or the issuance
of shares of Stock with respect to the RSUs, the Company or any Affiliate shall have the right, in the Committee’s discretion,
to (i) require you to tender a cash payment, (ii) deduct the tax or withholding payment from payments of any kind otherwise due to
you, (iii) permit or require you to enter into a “same day sale” commitment with a broker-dealer that is a member of
the Financial Industry Regulatory Authority (a “FINRA Dealer”), whereby you irrevocably elect to sell a portion
of the shares of Stock to be delivered in connection with the RSUs to satisfy withholding obligations and whereby the FINRA Dealer
irrevocably commits to forward the proceeds necessary to satisfy the withholding obligations directly to the Company or any Affiliate,
or (iv) withhold the delivery of vested shares of Stock otherwise deliverable under this Agreement to meet such obligations, provided
that, to the extent required to avoid adverse accounting consequences to the Company, the shares of Stock so withheld will have an
aggregate Fair Market Value not exceeding the minimum amount of tax required to be withheld by Applicable Laws. |
|
You
agree that the Company or any Affiliate shall be entitled to use whatever method it may deem appropriate to recover such taxes. You
further agree that the Company or any Affiliate may, as it reasonably considers necessary, amend or vary this Agreement to facilitate
such recovery of taxes. |
|
|
Market
Stand-off Agreement |
In
connection with any underwritten public offering by the Company of its equity securities
pursuant to an effective registration statement filed under the Securities Act, including
the Company’s Initial Public Offering, you agree not to sell, make any short sale of,
loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or
transfer for value or agree to engage in any of the foregoing transactions with respect to
any shares of Stock issued pursuant to this Agreement without the prior written consent of
the Company or its underwriters, for such period of time after the effective date of such
registration statement as may be requested by the Company or the underwriters (not to exceed
one hundred eighty (180) days in length).
|
|
|
Representations
and Warranties |
You
hereby agree and represent, by accepting the RSUs, that:
i.
you are acquiring the RSUs for investment for your own account and not with a view to, or intention of, or otherwise for resale in
connection with, any distribution to any person or entity;
ii.
neither the offer nor sale of the RSUs hereunder, or the shares of Stock covered by the RSUs, have been registered under the
Securities Act or registered or qualified under any applicable state securities laws and that the RSUs are being offered to you by
reason of and in reliance upon a specific exemption from the registration provisions of the Securities Act and exemptions from
registration or qualification provisions of such applicable state or other jurisdiction’s securities laws which depend upon,
among other things, the bona fide nature of the investment intent as expressed herein and the truth and accuracy of your
representations, warranties, agreements, acknowledgments, and understandings as set forth herein;
iii.
no public market now exists for any of the securities issued by the Company and that there can be no assurance that a public market
will ever exist for the shares of Stock;
iv.
you must, and are able to, bear the economic risk of your investment in the RSUs and the shares of Stock covered by the RSUs for an
indefinite period of time and can afford a complete loss of your investment in the RSUs and the shares of Stock covered by the
RSUs;
v.
you are sophisticated in financial matters and have such knowledge and experience in financial and business matters as to be capable
of evaluating the risks and benefits of your investment in the RSUs and the shares of Stock covered by the RSUs;
vi.
if the Company has notified you that it is relying or may rely on an exemption pursuant to Regulation D of the Securities Act for
the issuance of the RSUs to you, you are an “accredited investor” within the meaning of Regulation D of the Securities
Act; and |
|
vii. the Company has made available to you all documents that you have requested relating to the Company, the RSUS, and the shares of
Stock, and your receipt of the RSUs, and you have had an opportunity to ask questions and receive answers concerning the Company and
the terms and conditions of the offering and sale of the RSUs pursuant to this Agreement and have had full access to such other
information concerning the Company and the shares of Stock as you deemed necessary or desirable. |
|
|
Retention
Rights |
This
Agreement and the RSUs evidenced hereby do not give you the right to expectation of employment or other Service by, or to continue
in the employment or other Service of, the Company or any Affiliate. Unless otherwise specified in a written employment or other
written compensatory agreement between you and the Company or an Affiliate, the Company or any Affiliate, as applicable, reserves
the right to terminate your employment or other Service relationship with the Company or an Affiliate at any time and for any reason. |
|
|
Stockholder
Rights |
You
have no rights as a stockholder with respect to the RSUs unless and until shares of Stock relating to the RSUs have been issued to
you and either a certificate evidencing your Stock has been issued or an appropriate entry has been made on the Company’s books.
No adjustments to your Stock shall be made for dividends, distributions, or other rights on or with respect to the Stock generally
if the applicable record date for any such dividend, distribution, or right occurs before your certificate is issued (or an appropriate
book entry is made), except as described in the Plan. |
|
|
Corporate
Activity |
Your
RSUs shall be subject to the terms of any applicable agreement of merger, liquidation, or reorganization in the event the Company
is subject to such corporate activity. |
|
|
Forfeiture
of Rights |
If
you should take actions in violation or breach of or in conflict with any (a) employment
agreement, (b) non-competition agreement, (c) agreement prohibiting solicitation of employees
or clients of the Company or any Affiliate, (d) confidentiality obligation with respect to
the Company or any Affiliate, (e) Company or Affiliate policy or procedure, (f) other agreement,
or (g) any other material obligation to the Company or any Affiliate, the Company has the
right to cause an immediate forfeiture of your rights to the RSUs under this Agreement, and
you will immediately forfeit the RSUs.
In
addition, if you have vested in shares of Stock pursuant to this Agreement during the two (2)-year period prior to your actions,
you will owe the Company a cash payment (or forfeiture of shares of Stock) in an amount determined as follows: (1) for any shares
of Stock that you have sold prior to receiving notice from the Company, the amount will be the proceeds received from the sale(s),
and (2) for any shares of Stock that you still own, the amount will be the number of shares of Stock owned times the Fair Market
Value of the shares of Stock on the date you receive notice from the Company (provided, that the Company may require you to satisfy
your payment obligations hereunder either by forfeiting and returning to the Company the shares of Stock or any other shares of Stock
or making a cash payment or a combination of these methods as determined by the Company in its sole discretion). |
Clawback |
The
RSUs are subject to mandatory repayment by you to the Company in the circumstances specified in the Plan, including to the extent
you are or in the future become subject to any Company “clawback” or recoupment policy or Applicable Laws that require
the repayment by you to the Company of compensation paid by the Company to you in the event that you fail to comply with, or violate,
the terms or requirements of such policy or Applicable Laws. |
|
|
Applicable
Law |
This
Agreement will be interpreted and enforced under the laws of the State of Delaware, other than any conflicts or choice of law rule
or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. |
|
|
The
Plan |
The
text of the Plan is incorporated into this Agreement by reference.
Certain
capitalized terms used in this Agreement are defined in the Plan and have the meaning set forth in the Plan.
This
Agreement and the Plan constitute the entire understanding between you and the Company regarding the RSUs. Any prior agreements,
commitments, or negotiations concerning the RSUs are superseded, except that any written employment, consulting, confidentiality,
non-competition, non-solicitation, and/or severance agreement between you and the Company or an Affiliate, as applicable, shall supersede
this Agreement with respect to its subject matter. |
|
|
Disclaimer
of Rights |
The
grant of RSUs under this Agreement will in no way be interpreted to require the Company to transfer any amounts to a third-party
trustee or otherwise hold any amounts in trust or escrow for payment to you. You will have no rights under this Agreement or the
Plan other than those of a general unsecured creditor of the Company. RSUs represent unfunded and unsecured obligations of the Company,
subject to the terms and conditions of the Plan and this Agreement. |
|
|
Data
Privacy |
As
a condition of the grant of the RSUs, you consent to the collection, use, and transfer of personal data as described in this paragraph.
You understand that the Company and its Affiliates hold certain personal information about you, including your name, home address
and telephone number, date of birth, social security number or equivalent, salary, nationality, job title, ownership interests or
directorships held in the Company or its Affiliates, and details of all equity awards or other entitlements to shares of Stock awarded,
cancelled, exercised, vested or unvested (“Data”). You further understand that the Company and its Affiliates
will transfer Data amongst themselves as necessary for the purposes of implementation, administration, and management of your participation
in the Plan, and that the Company and any of its Affiliates may each further transfer Data to any third parties assisting the Company
in the implementation, administration, and management of the Plan. You understand that these recipients may be located in the European
Economic Area or elsewhere, such as the United States. You authorize them to receive, possess, use, retain, and transfer such Data
as may be required for the administration of the Plan or the subsequent holding of shares of Stock on your behalf, in electronic
or other form, for the purposes of implementing, administering, and managing your participation in the Plan, including any requisite
transfer to a broker or other third party with whom you may elect to deposit any shares of Stock acquired under the Plan. You understand
that you may, at any time, view such Data or require any necessary amendments to the Data. |
Consent
to Electronic Delivery |
You
agree, by accepting the RSUs, to receive documents related to the RSUs by electronic delivery (including e-mail or reference to a
website or other URL) and, if requested, agree to participate in the Plan through an on-line or electronic system established and
maintained by the Company or another third party designated by the Company, and your consent shall remain in effect throughout your
term of Service and thereafter until you withdraw such consent in writing to the Company. |
|
|
Code
Section 409A |
The
grant of RSUs under this Agreement is intended to comply with the short-term deferral exemption
from Code Section 409A (“Section 409A”)
and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted
and administered to be in compliance with the exemption. Notwithstanding anything to the
contrary in the Plan or this Agreement, none of the Company, its Affiliates, the Board, or
the Committee will have any obligation to take any action to prevent the assessment of any
excise tax or penalty on you under Section 409A, and none of the Company, its Affiliates,
the Board, or the Committee will have any liability to you for such tax or penalty.
To
the extent that the RSUs constitute “deferred compensation” under Section 409A, a termination of Service occurs only
upon an event that would be a Separation from Service within the meaning of Section 409A. If, at the time of your Separation from
Service, (i) you are a “specified employee” within the meaning of Section 409A, and (ii) the Company makes a good faith
determination that an amount payable on account of your Separation from Service constitutes deferred compensation (within the meaning
of Section 409A), the payment of which is required to be delayed pursuant to the six (6)-month delay rule set forth in Section 409A
to avoid taxes or penalties under Section 409A (the “Delay Period”), then the Company will not pay such amount
on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after the Delay Period (or
upon your death, if earlier), without interest. Each installment of RSUs that vest under this Agreement (if there is more than one
installment) will be considered one of a series of separate payments for purposes of Section 409A. |
|
|
Other
Agreements |
You
agree, by accepting the RSUs, that you will execute such document(s) as necessary to become a party to any subscription agreement,
stockholders agreement, investors’ rights agreement, voting agreement or trust, right of first refusal and co-sale agreement,
or other similar agreement as the Company may require as of the Grant Date and from time to time thereafter. |
By
accepting this Agreement, you agree to all of
the
terms and conditions described above and in the Plan.
Exhibit
10.10
INDEMNIFICATION
AGREEMENT
This
Indemnification Agreement (“Agreement”) is made as of ________ __, 20__ by and between Tevogen Bio Holdings Inc.,
a Delaware corporation (the “Company”), and ______________ (“Indemnitee”). This Agreement supersedes
and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
RECITALS
WHEREAS,
the Board of Directors of the Company (the “Board”) believes that highly competent persons have become more reluctant
to serve publicly held corporations as [directors] [officers] or in other capacities unless they are provided with adequate protection
through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service
to and activities on behalf of the corporation;
WHEREAS,
the Board has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing
basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities.
Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other
business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in
the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations
or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things,
matters that traditionally would have been brought only against the Company or business enterprise itself. The By-Laws of the Company
(the “Bylaws”) require indemnification of the officers and directors of the Company. Indemnitee may also be entitled
to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”). The Bylaws and the
DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts
may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;
WHEREAS,
the uncertainties relating to such insurance and to indemnification may increase the difficulty of attracting and retaining such persons;
WHEREAS,
the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests
of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of
such protection in the future;
WHEREAS,
it is reasonable, prudent, and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf
of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from
undue concern that they will not be so indemnified;
WHEREAS,
this Agreement is a supplement to and in furtherance of the Bylaws and any resolutions adopted pursuant thereto, as well as any rights
of Indemnitees under any directors’ and officers’ liability insurance policy, and this Agreement shall not be deemed a substitute
therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and
WHEREAS,
Indemnitee does not regard the protection available under the Bylaws and insurance as adequate in the present circumstances, and may
not be willing to serve or continue to serve as an officer or director without adequate protection, and the Company desires Indemnitee
to serve or continue to serve in such capacity. Indemnitee is willing to serve, continue to serve, and take on additional service for
or on behalf of the Company on the condition that Indemnitee be so indemnified.
NOW,
THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree
as follows:
Section
1. Services to the Company. Indemnitee agrees to serve as a [director] [officer] [employee] [agent] of the Company. Indemnitee
may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by
operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position.
This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.
Indemnitee specifically acknowledges that Indemnitee’s employment with the Company (or any of its subsidiaries or any Enterprise),
if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise
provided in any written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), other
applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company,
by the Certificate of Incorporation of Incorporation of the Company (the “Certificate of Incorporation”), the Bylaws,
and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as an [officer]
[director] [agent] [employee] of the Company, as provided in Section 16 hereof.
Section
2. Definitions. As used in this Agreement:
(a)
References to “agent” shall mean any person who is or was a director, officer, or employee of the Company or a subsidiary
of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a
director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture,
trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of
the Company.
(b)
A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any
of the following events:
i.
Acquisition of Stock by Third Party. Any Person (as defined below) other than Dr. Ryan Saadi or any one or more of his controlled affiliates
is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifty percent
(50%) or more of the combined voting power of the Company’s then outstanding securities unless the change in relative Beneficial
Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares
of securities entitled to vote generally in the election of directors;
ii.
Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this
Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated
by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv))
whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds
of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election
was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;
iii.
Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation
continuing to represent (either by remaining outstanding or by being converted into voting securities of the Surviving Entity) more than
50% of the combined voting power of the voting securities of the Surviving Entity outstanding immediately after such merger or consolidation
and with the power to elect at least a majority of the board of directors or other governing body of such Surviving Entity;
iv.
Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or
disposition by the Company of all or substantially all of the Company’s assets; and
v.
Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A
of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined
below), whether or not the Company is then subject to such reporting requirement.
For
purposes of this Section 2(b), the following terms shall have the following meanings:
(A)
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.
(B)
“Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that
Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company,
and (iii) any entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their
ownership of stock of the Company.
(C)
“Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however,
that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving
a merger of the Company with another entity.
(d)
“Surviving Entity” shall mean the surviving entity in a merger or consolidation or any entity that controls, directly
or indirectly, such surviving entity.
(c)
“Corporate Status” describes the status of a person who is or was a director, trustee, partner, managing member, officer,
employee, agent or fiduciary of the Company or of any other corporation, limited liability company, partnership or joint venture, trust
or other enterprise which such person is or was serving at the request of the Company.
(d)
“Disinterested Director” shall mean a director of the Company who is not and was not a party to the Proceeding in
respect of which indemnification is sought by Indemnitee.
(e)
“Enterprise” shall mean the Company and any other corporation, limited liability company, partnership, joint venture,
trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner,
managing member, employee, agent or fiduciary.
(f)
“Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees and
other costs of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone
charges, postage, delivery service fees,[any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or
deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements, obligations or expenses
of the types customarily incurred in connection with, or as a result of, prosecuting, defending, preparing to prosecute or defend, investigating,
being or preparing to be a deponent or witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses
incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other
costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, (ii) Expenses incurred in connection with
recovery under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether
Indemnitee is ultimately determined to be entitled to such indemnification, advancement or Expenses or insurance recovery, as the case
may be, and (iii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement
or defense of Indemnitee’s rights under this Agreement, the Certificate of Incorporation, the Bylaws or under any directors’
and officers’ liability insurance policies maintained by the Company, by litigation or otherwise. The parties agree that for the
purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement,
all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable in the good faith
judgment of such counsel shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement
by Indemnitee or the amount of judgments or fines against Indemnitee.
(g)
“Independent Counsel” shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation
law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter
material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees
under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.
Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards
of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action
to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent
Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out
of or relating to this Agreement or its engagement pursuant hereto.
(h)
The term “Proceeding” shall include any threatened, pending or completed action, suit, claim, counterclaim, cross
claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual,
threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative,
legislative, regulatory or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or
will be involved as a party, potential party, non-party witness or otherwise by reason of Indemnitee’s Corporate Status, by reason
of any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee’s
part while acting pursuant to Indemnitee’s Corporate Status, in each case whether or not serving in such capacity at the time any
liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement.
If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall
be considered a Proceeding under this paragraph.
(i)
Reference to “other enterprise” shall include employee benefit plans; references to “fines” shall
include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company”
shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by,
such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who
acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries
of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company”
as referred to in this Agreement.
Section
3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this Section
3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the
right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent
permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments
and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement)
actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with such Proceeding or any claim, issue
or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best
interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that Indemnitee’s conduct
was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification
in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation,
the Bylaws, vote of the Company’s stockholders or disinterested directors or applicable law.
Section
4. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions
of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of
the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted
by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with
such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed
to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect
of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless
and only to the extent that the Delaware Court (as hereinafter defined) or any court in which the Proceeding was brought shall determine
upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and
reasonably entitled to indemnification.
Section
5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement,
to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful,
on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall
indemnify Indemnitee against all Expenses actually and reasonably incurred by or on behalf of Indemnitee in connection therewith. If
Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than
all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably
incurred by Indemnitee or on Indemnitee’s behalf in connection with or related to each successfully resolved claim, issue or matter
to the fullest extent permitted by law. For purposes of this Section 5 and without limitation, the termination of any claim, issue or
matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue
or matter.
Section
6. Indemnification For Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the fullest extent permitted
by applicable law and to the extent that Indemnitee is, by reason of Indemnitee’s Corporate Status, a witness, is or was made (or
asked) to respond to discovery requests in any Proceeding, or otherwise asked to participate in any Proceeding to which Indemnitee is
not a party, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s
behalf in connection therewith.
Section
7. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company
for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee
for the portion thereof to which Indemnitee is entitled.
Section
8. Additional Indemnification.
(a)
Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable
law if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the
right of the Company to procure a judgment in its favor) by reason of Indemnitee’s Corporate Status.
(b)
For purposes of Section 8(a), the meaning of the phrase “to the fullest extent permitted by applicable law” shall
include, but not be limited to:
i.
to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement,
or the corresponding provision of any amendment to or replacement of the DGCL, and
ii.
to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement
that increase the extent to which a corporation may indemnify its officers and directors.
Section
9. Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make
any indemnification payment in connection with any claim involving Indemnitee:
(a)
for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except
with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or
(b)
for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within
the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or
common law, (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation
or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange
Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley
Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale
by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act) or (iii) any reimbursement of the Company by Indemnitee
of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of
the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section
10D of the Exchange Act; or
(c)
except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by
Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers,
employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation,
(ii) such payment arises in connection with any mandatory counterclaim or cross claim brought or raised by Indemnitee in any Proceeding
(or any part of any Proceeding), or (iii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested
in the Company under applicable law.
Section
10. Advances of Expenses. Notwithstanding any provision of this Agreement to the contrary (other than Section 14(d)), the Company
shall advance, to the extent not prohibited by law, the Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding
(or any part of any Proceeding) not initiated by Indemnitee or any Proceeding initiated by Indemnitee with the prior approval of the
Board as provided in Section 9(c), and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement
or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall
be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without
regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with
Section 14(d), advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement,
including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall
qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing
that the Indemnitee undertakes to repay the amounts advanced (without interest) by the Company pursuant to this Section 10, if and only
to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking
shall be required other than the execution of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which
indemnity is excluded pursuant to Section 9.
Section
11. Procedure for Notification and Defense of Claim.
(a)
Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement
of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification
to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification
under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and
information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is
entitled to indemnification following the final disposition of such Proceeding. The omission by Indemnitee to notify the Company hereunder
will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and
any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of
the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested
indemnification.
(b)
The Company will be entitled to participate in the Proceeding at its own expense.
(c)
The Company shall not settle any Proceeding (in whole or in part) if such settlement would impose any Expense, judgment, liability, fine,
penalty or limitation on Indemnitee in respect of which Indemnitee is not entitled to be indemnified hereunder without Indemnitee’s
prior written consent, which shall not be unreasonably withheld.
Section
12. Procedure Upon Application for Indemnification.
(a)
Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with
respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred,
by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control
shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a
committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of
the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in
a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders
of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within
ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with
respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance
request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available
to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys’ fees and disbursements)
incurred by or on behalf of Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne
by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies
and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing with respect to any determination
that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has
been denied.
(b)
In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof,
the Independent Counsel shall be selected as provided in this Section 12(b). If a Change in Control shall not have occurred, the Independent
Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising Indemnitee of the identity of
the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee
(unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee
shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee
or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to
the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection
may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel”
as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.
Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and
substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn
or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of submission
by Indemnitee of a written request for indemnification pursuant to Section 11(a) hereof and the final disposition of the Proceeding,
no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court
for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent
Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall
designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel
under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement,
Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards
of professional conduct then prevailing).
(c)
If the Company disputes a portion of the amounts for which indemnification is requested, the undisputed portion shall be paid and only
the disputed portion withheld pending resolution of any such dispute.
Section
13. Presumptions and Effect of Certain Proceedings.
(a)
In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination
shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee
has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest
extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons
or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or Independent
Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper
in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including
by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action
or create a presumption that Indemnitee has not met the applicable standard of conduct.
(b)
Subject to Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether
Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of
the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law,
be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material
fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with
the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however,
that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or
entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining
or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section
13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section
12(a) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination
the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held
within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is
called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose
within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement
to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of this Agreement.
(c)
The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea
of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely
affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which
Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding,
that Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful.
(d)
For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action
is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee
by the directors or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or
on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser, financial
advisor or other expert selected with reasonable care by or on behalf of the Enterprise. The provisions of this Section 13(d) shall not
be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable
standard of conduct set forth in this Agreement.
(e)
The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee
of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.
Section
14. Remedies of Indemnitee.
(a)
Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not
entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement,
(iii) no determination of entitlement to indemnification shall have been made pursuant to Sections 12(a) of this Agreement within ninety
(90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Sections
5, 6 or 7 or the second to last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written
request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten (10) days after
a determination has been made that Indemnitee is entitled to indemnification, or (vi) the Company or any other person takes or threatens
to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed
to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee
shall be entitled to an adjudication by a court of Indemnitee’s entitlement to such indemnification or advancement of Expenses.
Alternatively, Indemnitee, at Indemnitee’s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant
to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication
or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant
to this Section 14(a). The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.
(b)
In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to
indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a
de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In
any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company shall have the burden of proving Indemnitee
is not entitled to indemnification or advancement of Expenses, as the case may be.
(c)
If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the
Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent
(i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement
not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable
law.
(d)
The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration
commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and
shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It
is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other
Expenses associated with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement by litigation or
otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee
hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested
by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited
by law, such Expenses to Indemnitee, which are incurred by or on behalf of Indemnitee in connection with any action brought by Indemnitee
for indemnification or advancement of Expenses from the Company under this Agreement or under any directors’ and officers’
liability insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying
claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to the extent Indemnitee
is successful on such underlying claims or otherwise as permitted by law, whichever is greater.
(e)
Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under
this Agreement shall be required to be made prior to the final disposition of the Proceeding.
Section
15. Non-exclusivity; Survival of Rights; Insurance; Subrogation.
(a)
The rights of indemnification and to receive advancement of Expenses as provided by this Agreement (i) shall not be deemed exclusive
of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws,
any agreement, a vote of stockholders or a resolution of directors, or otherwise and (ii) shall be interpreted independently of, and
without reference to, any other such rights to which Indemnitee may at any time be entitled. No amendment, alteration or repeal of this
Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken
or omitted by Indemnitee in Indemnitee’s Corporate Status prior to such amendment, alteration or repeal. To the extent that a change
in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded
currently under the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the
greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy,
and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter
existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other right or remedy.
(b)
To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees,
or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum
extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of
the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect,
the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance
with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause
such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of
such policies.
(c)
In the event of any payment made by the Company under this Agreement, the Company shall be subrogated to the extent of such payment to
all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights,
including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.
(d)
The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement
is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy,
contract, agreement or otherwise.
(e)
The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company
as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, limited liability company,
partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received
as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust
or other enterprise.
Section
16. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date
that Indemnitee shall have ceased to serve as a [director] [officer] [employee] [agent] of the Company or (b) one (1) year after the
final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of
Expenses hereunder and of any proceeding (including any appeal thereof) commenced by Indemnitee pursuant to Section 14 of this Agreement
relating thereto. The indemnification and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding
upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor
by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue
as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise, and shall
inure to the benefit of Indemnitee and Indemnitee’s spouse, assigns, heirs, devisees, executors and administrators and other legal
representatives. The Company shall require and shall cause any successor (whether direct or indirect by purchase, merger, consolidation
or otherwise) to all or substantially all of the business or assets of the Company to, by written agreement, expressly assume and agree
to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession
had taken place.
Section
17. Severability. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail
to do any act in violation of applicable law. If any provision or provisions of this Agreement shall be held to be invalid, illegal or
unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement
(including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal
or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall
remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary
to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible,
the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision
held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give
effect to the intent manifested thereby.
Section
18. Enforcement.
(a)
The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying
upon this Agreement in serving or continuing to serve as a director or officer of the Company.
(b)
This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof;
provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws, any directors’
and officers’ insurance maintained by the Company and applicable law, and shall not be deemed a substitute therefor, nor to diminish
or abrogate any rights of Indemnitee thereunder.
Section
19. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing
by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provisions of this Agreement nor shall any waiver constitute a continuing waiver.
Section
20. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation,
subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification
or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any
obligation which it may have to the Indemnitee under this Agreement or otherwise.
Section
21. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed
to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have
been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it
is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall
have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:
(a)
If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide
to the Company.
(b)
If to the Company to
Tevogen
Bio Holdings Inc.
15
Independence Boulevard
Warren,
NJ 07059
With
a copy to:
Hogan
Lovells US LLP
100
International Drive
Suite
2000
Baltimore,
MD 21202
Attn:
William Intner
Email:
william.intner@hoganlovells.com
or
to any other address as may have been furnished to Indemnitee by the Company.
Section
22. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement
is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount
incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses,
in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable
in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee
as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and
its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).
Section
23. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by,
and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except
with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby
irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be
brought only in the Court of Chancery of the State of Delaware (the “Delaware Court”), and not in any other state
or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction
of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to
the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably RL&F Service Corp., 920
North King Street, 2nd Floor, Wilmington, New Castle County, Delaware 19801 as its agent in the State of Delaware as such
party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same
legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying
of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any
such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.
Section
24. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be
deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the
party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.
Section
25. Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The
headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect
the construction thereof.
IN
WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.
TEVOGEN BIO HOLDINGS Inc. |
|
INDEMNITEE |
|
|
|
|
|
By: |
|
|
|
Name: |
|
|
Name: |
|
Office: |
|
|
Address: |
|
|
|
|
|
|
|
|
|
|
|
v3.24.0.1
Cover
|
Feb. 14, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 14, 2024
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-41002
|
Entity Registrant Name |
Semper Paratus Acquisition Corp
|
Entity Central Index Key |
0001860871
|
Entity Tax Identification Number |
85-1284695
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
15
Independence Boulevard
|
Entity Address, Address Line Two |
Suite #410
|
Entity Address, City or Town |
Warren
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
07059
|
City Area Code |
(877)
|
Local Phone Number |
838-6436
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
LGST
|
Security Exchange Name |
NASDAQ
|
Warrants, each exercisable for one share of Common Stock for $11.50 per share |
|
Title of 12(b) Security |
Warrants,
each exercisable for one share of Common Stock for $11.50 per share
|
Trading Symbol |
LGSTW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LGSTU_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LGSTU_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Semper Paratus Acquisiti... (NASDAQ:LGSTU)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Semper Paratus Acquisiti... (NASDAQ:LGSTU)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024